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ABSTRACT 
MOLECULAR CHANGES FOLLOWING SKELETAL MUSCLE  
 
DISUSE IN HUMANS 
 
SEPTEMBER 2009 
 
KIMBERLY A. REICH, B.S., INDIANA UNIVERSITY 
M.A.M., CARNEGIE MELLON UNIVERSITY 
M.S., SOUTHERN CONNECTICUT STATE UNIVERSITY 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Priscilla M. Clarkson 
 The purpose of this dissertation was to investigate the molecular events associated 
with the onset of skeletal muscle disuse in humans. Study I examined global gene 
expression changes in vastus lateralis muscle following 48h unloading (UL) and 24h 
reloading (RL) in humans. Results showed that functions related to protein degradation 
and oxidative stress were enriched following UL and that these global gene expression 
patterns were not readily reversed following RL, thus indicating that molecular events 
associated with short-term disuse may persist beyond the duration of the stimulus. In 
contrast to previous work in IM, collagen gene expression increased in this study, 
demonstrating that differences in molecular signaling may exist among disuse models in 
humans.  
 Study II of this dissertation expanded on the findings of Study I to investigate 
global gene expression patterns related to the early stage of multiple disuse models. 
Microarray data collected 48h post-UL in Study I were analyzed within the context of 
data previously collected in our laboratory following 48h immobilization (IM) and spinal 
viii 
 
cord injury (SCI). Results showed that the disuse models shared a small subset of 
commonly differentiated genes. Furthermore, the similarities between IM, SCI, and UL 
extended beyond specific genes to include commonly enriched functions and pathways 
such as protein degradation and oxidative stress, suggesting that these molecular 
mechanisms are involved in the early stages of disuse, regardless of specific stimulus. 
 In Study III, an in vitro model of skeletal muscle was used to test the exploratory 
hypothesis that induction of oxidative stress response gene heme oxygenase-1 (HMOX1) 
would lead to decreases in gene expression associated with proteolysis, namely ubiquitin 
E3 ligases atrogin1 and MuRF1, as well as increased XXT cleavage (a marker of 
metabolic enzyme activity). In this study, C2C12  myotubes were pre-treated with hemin 
(an inducer of HMOX1) and then treated with H2O2 to elicit oxidative stress. Results 
showed that hemin treatment resulted in increased HMOX1 expression and decreased E3 
ligase expression. Furthermore, hemin-treated cells exhibited increased XTT cleavage 
compared to controls. HMOX1 may be a promising gene target to protect against 
oxidative stress that accompanies early stages of disuse.  
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CHAPTER I 
 
DEVELOPMENT OF THE PROBLEM 
 
Introduction 
 
Disuse muscle atrophy occurs in response to immobilization (IM) (25, 36, 65), 
unloading (UL) (1, 5-6), bed rest (7-8, 50), spaceflight (1, 61, 63), and spinal cord injury 
(SCI) (13, 26, 56, 64). Although studies in humans have documented the effects of disuse 
on skeletal muscle structure and function (5-6, 9, 16-18, 23, 26-27, 35, 37, 48, 56), the 
underlying mechanisms regulating these changes are not well understood. Investigations 
of limb immobilization (3, 40), hindlimb suspension (10, 30-32, 57), and denervation (30, 
58) in animals have shown that there is a coordinated alteration in expression of genes 
encoding for proteins that function in the initiation of the muscle atrophy process. 
Futhermore, it has also been proposed that genes with transcription most sensitive to UL 
and reloading (RL) may be key regulators in this atrophy process (10).  
The molecular mechanisms leading to atrophy are likely complex and involve 
alterations in molecular signaling of multiple pathways. The most elucidated molecular 
pathway associated with atrophy in animals is the ubiquitin proteasome pathway (UPP), 
which is the intracellular signaling pathway responsible for the majority of protein 
degradation in the cell (10, 12, 28, 33, 44, 54, 59) and is dependent, in part, on 
AKT/FOXO pathway activity (12, 28). Recent findings by Urso et al. (64-65) confirmed 
decreases in phosphorylation of AKT 48h following SCI as well as after short-term (48h) 
limb IM in humans, although accompanying elevations in UPP protein products (i.e., E3 
ligases Atrogin1, MuRF1) were not found. In addition, alterations have been observed in 
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mRNA levels for FBXO32 (aka Atrogin1) following 2wk IM (36) and 20d of bed rest 
(50), as well as MuRF1 (36) with 2wk IM.  
Other intriguing (potentially interrelated) mechanisms associated with the early 
stages of disuse identified in the animal literature include oxidative stress (43, 53-54, 60), 
decreased abundance of protein chaperones (30, 41, 60), alterations in signaling related to 
growth factors (42, 55, 60), and inflammation (32, 34, 36, 60). Following 48h of 
immobilization, Urso et al. showed that metallothionein gene transcription was 
upregulated (65), and unpublished microarray data from biopsies taken 48h post-SCI in 
humans showed that metallothionein gene transcription was upregulated following that 
disuse stimulus as well. Thus, oxidative stress may be a common component to various 
disuse stimuli in humans. Furthermore, unpublished data from both of these studies 
showed that protein chaperones may also be decreased in agreement with the animal 
literature. Finally, alterations in gene transcription and related protein products for 
extracellular matrix (ECM) components may accompany the early stages of disuse (2-3, 
39, 65). The most abundant ECM component is collagen (4). Following 48h IM, gene 
expression and protein levels for two collagen isoforms (COL3 and COL4) were found to 
be to be decreased (65) in agreement with the animal literature (2-3, 39), yet unpublished 
microarray data from biopsies collected 48h post-SCI showed that transcripts for these 
isoforms may have been increased. These contrary findings suggest that while the 
responses to IM and SCI may share common components as noted above, they may also 
display distinct and unique signaling mechanisms contributing to subsequent muscle 
atrophy.   
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Many conditions of disuse (such as bed rest, and spaceflight) restrict load. When a 
muscle is immobilized, there is no change in muscle length; with UL, the muscle can 
lengthen and shorten but experiences little mechanotransduction (24, 29, 66).  Therefore, 
although data from animal studies suggest similar expression of atrophy-related genes 
with UL and IM (11, 43), it is unknown whether limb UL in humans leads to alterations 
in gene expression and protein products similar to that demonstrated with IM. 
Furthermore, while gene expression and related protein products of individual molecules 
have been investigated following IM and SCI disuse in humans (64-65), the potential 
relationship between these genes was not studied.  
The purpose of this dissertation was to investigate the molecular events associated 
with the onset of skeletal muscle unloading in humans and to explore common signaling 
pathways found in multiple forms of disuse. Previous work in our laboratory by Urso et 
al. (64-65) revealed increases in gene expression related to protein degradation and 
decreases in expression related to ECM remodeling following 48h IM. However, 
molecular signaling following limb UL (without joint movement restriction such as that 
seen with IM) had not yet been investigated at this early timepoint. Furthermore, little 
was known about the effects of resumption of activity following these short-term periods 
of inactivity in humans. While it may be assumed that the effects of short-term disuse 
were quickly reversed, evidence in rats (10) showed that, with low-intensity RL 
following short-term UL, genes upregulated following disuse were more resistant to the 
effects of RL than those that were downregulated. It was unknown if human muscle 
responded in a similar fashion. Therefore, the first specific aim of this dissertation was to 
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study global gene expression changes following short-term UL and RL in human skeletal 
muscle.  
Previous studies in animals (12, 43) indicated that key molecular pathways 
relating to protein degradation may play a central role in multiple forms of disuse, and 
that global gene expression following different forms of disuse shared common patterns 
(43). It was unknown however if gene expression responses following multiple disuse 
stimuli in humans shared common pathways and functions. Because our laboratory had 
previously collected global gene expression data following both 48h IM and 48h SCI, 
(64-65), I was presented with the unique opportunity to investigate the early molecular 
signaling patterns of UL within the context of gene expression following these two 
common forms of disuse in humans. Therefore, the second specific aim of this 
dissertation was to investigate global gene expression patterns related to disuse in 
biopsies collected following 48h post-IM, SCI, and UL.  
Molecular signaling leading to disuse atrophy is likely a complex sequence of 
events involving numerous interrelated pathways and may begin as early as 48h 
following the introduction of a disuse stimulus. Systems biology is an emerging 
discipline that focuses on the relationships between multiple cellular components (22). To 
this end, bioinformatic tools have been developed capable of analyzing complex gene 
expression data. Microarray technology allows us to measure expression levels of 
thousands of genes at once, and software tools such as Database for Annotation, 
Visualization and Integrated Discovery (DAVID) (20) and Ingenuity Pathway Analysis 
(IPA)  (51) use microarray results to identify functional groups and build potential 
signaling networks encompassing many differentially expressed genes (51). Employing 
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high-thoughput technology to interpret gene expression results may lead to a better 
understanding of functions and pathways associated with disuse.  
Studying global gene expression patterns at the early time point of 48h of disuse 
(before any measurable atrophy has occurred) led to the identification of molecules and 
pathways that may provide therapeutic targets to prevent or attenuate disuse-associated 
atrophy. Before findings of such investigations can be translated to intervention studies 
however further experimentation is required. The C2C12 mouse muscle immortal cell line 
is often used as an in vitro model for skeletal muscle because these cells differentiate into 
multinucleated myotubes that exhibit similar phenotypes and gene expression patterns as 
mammalian skeletal muscle cells in vivo. Therefore, an exploratory aim of this 
dissertation was to develop hypotheses based on the findings of the two previous 
dissertation studies and to devise a proof of concept experiment to test these hypotheses 
in vitro.  
Research Plan Development 
 
Although studies in humans have documented the effects of disuse on skeletal 
muscle structure and function (5-6, 9, 16-18, 23, 26-27, 35, 37, 48, 56), the underlying 
mechanisms regulating these changes are not well understood. Investigations of multiple 
forms of disuse in animals have shown that there is a coordinated alteration in expression 
of genes encoding for proteins that function in the initiation of the muscle atrophy 
process (11, 21, 31, 38, 43, 45, 49, 60). Mechanisms identified in these studies have 
included increases in gene expression related to protein degradation and stress response 
as well as decreases in gene expression related to transcription and translation, energy 
metabolism, and ECM proteins (43).  
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Of the few studies that have been undertaken in humans (14, 19, 36, 46, 64-65), 
lower limb studies have primarily involved immobilization of the ankle (19, 36)or knee 
joint (64-65). As with the animal models, these studies have shown alterations in 
expression of components of the ubiquitin proteasome pathway (UPP) such as Atrogin1 
and MuRF1, ECM components such as collagen, and metabolic enzymes such as NADH 
dehydrogenase and pyruvate dehydrogenase. With the exception of one study in our 
laboratory (65) that measured gene expression following 48h of knee IM, these 
investigations have measured time points from 5d – 3wk of IM (15, 19, 36). However, 
measurable proteolysis has been detected as early as 72h post-UL in humans (62), and 
therefore, molecular atrophy triggers (such as alterations in the transcription of key 
genes) likely occur prior to that time point. Furthermore, it has been proposed that key 
regulators of muscle atrophy are likely those most sensitive to the disuse stimulus (10). 
 Study I of this dissertation examined the global gene expression patterns 
following short-term unloading (48h UL) and reloading (24h RL) in human skeletal 
muscle using a human suspension model most analogous to hindlimb unloading in 
rodents, unilateral lower limb suspension (ULLS). Microarray technology was employed 
to identify gene expression changes in up to 60,000 genes represented on the U133 plus 
2.0 gene chip. Cluster analysis was then performed for significantly altered gene 
expression, and each cluster was analyzed using DAVID and IPA to identify functional 
groups and signaling pathways associated with the UL/RL protocol. Target genes were 
further measured via qRT-PCR and protein products were measured via Western blot 
analysis.  
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 The results of Study I indicated that upregulation in molecular signaling related to 
UPP activity and to oxidative stress response were the most abundantly altered functional 
groups and/or canonical pathways following UL, and in general, these gene expression 
patterns persisted following RL. Conversely, downregulated functional groups and 
pathways were involved primarily in mitochondrial metabolism. Key genes related to the 
UPP and oxidative stress response were confirmed via qRT-PCR, and measurement of 
selected protein products (using available tissue) identified which of these differentially 
expressed genes were also altered at the protein level. Finally, contrary to findings from 
previous work in our laboratory (65), results also indicated that genes encoding for 
components of the ECM may be upregulated following 48h UL in humans, rather than 
down-regulated as observed following 48h IM. Study I identified global gene expression 
patterns associated with short-term UL and RL in humans, fulfilling the purpose of the 
first specific aim of this dissertation. 
 Study II of this dissertation expanded upon the findings of Study I by using the  
microarray results collected in that study to explore similarities between global gene 
expression patterns following UL and two other common forms of skeletal muscle disuse 
in humans: IM and SCI. Gene expression changes following 48h UL were analyzed along 
with previously collected microarray data following 48h IM and 48h SCI in our 
laboratory, the results of which are published elsewhere. As with Study I, high-
throughput software was used to identify functional groups and canonical pathways via 
DAVID and IPA, respectively. In addition, IPA was used to identify potential gene 
networks (interrelated groups of genes) common to all three forms of disuse.  
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 The results of Study II revealed that, although only a small group of genes were 
shared by the three datasets, there were key common functional groups and pathways 
associated with all three related to chelation, protein chaperone, protein degradation, and 
stress response. This led me to believe that there is potential to develop therapies in the 
future which may help protect against multiple forms of disuse atrophy by targeting early 
molecular events following disuse. Study II identified global gene expression patterns 
common to 48h IM, UL, and SCI, fulfilling the purpose of the second specific aim of this 
dissertation. 
Global gene expression findings from both Study I and Study II suggested 
oxidative stress as a probable effect (although to varying degrees) of the first 48h 
following disuse, regardless of the disuse stimulus. This supported the findings of  
previous literature (reviewed in (53)) which showed that oxidative stress may, indeed, be 
an upstream contributor to the cascade of events leading to protein degradation associated 
with longer periods of disuse. Evidence of oxidative stress in both Studies I and II of this 
dissertation came in the form of the upregulation of stress response genes including those 
believed to have antioxidant properties. In fact, the gene with the greatest degree of 
upregulation in Study I codes for one such molecule: heme oxygenase-1 (HMOX1). 
Furthermore in Study II, HMOX1 was found to be upregulated in two out of the three 
forms of disuse (SCI and UL).  HMOX1 was consistently shown in the animal literature 
to be increased following various disuse stimuli (21, 31, 47, 52) and it was proposed in 
these studies that, although increases in HMOX1 gene expression were not adequate to 
prevent disuse atrophy, superphysiological expression levels of the gene may help 
attenuate protein degradation, though expression of genes associated with proteolysis 
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were not measured (47). Therefore, a relationship between HMOX1 expression and 
proteolytic gene expression had not been established. 
Study III of this dissertation utilized an in vitro cell model of skeletal muscle to 
investigate the effects of hemin-induced superphysiological HMOX1 gene expression on 
E3 ligase expression and XTT cleavage (a marker for cellular metabolic enzyme activity) 
following an oxidative stress stimulus. Hemin is a substrate of HMOX1 (and an inducer 
of the HMOX1 gene) which is already available as a drug (Panhematin) used to treat the 
blood disorder, porphyra, under a physician’s care in a hospital setting.  The results of 
this study demonstrated that, in C2C12 myotubes, there was a relationship between 
magnitude of HMOX1 induction, XTT cleavage, and E3 ligase gene expression such that 
increased HMOX1 expression was associated with greater XTT cleavage and decreased 
E3 ligase gene expression. The findings of Study III supported the hypothesis generated 
by Studies I and II, that HMOX1 may serve a protective effect against protein 
degradation during oxidative stress, thus fulfilling the exploratory aim of this dissertation. 
Summary 
 
The overall purpose of this dissertation was to investigate the molecular events 
associated with the onset of skeletal muscle unloading in humans and to explore common 
signaling pathways found in multiple forms of disuse. In Study I, I examined the global 
gene expression patterns in human skeletal muscle associated with short-term UL and RL 
and performed selective conformational analysis. In Study II, I expanded upon these 
findings to compare the global gene expression patterns associated with short-term UL to 
those found at the same time point following IM and SCI. The findings of Study I and 
Study II led me to test the hypothesis that induction of the stress response gene HMOX1 
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in an in vitro model of skeletal muscle would lead to a decreases in expression of 
proteolytic genes and increases in XTT cleavage. Results from these three studies serve 
to further elucidate the complex molecular response to periods of disuse in human 
skeletal muscle and help to lay the foundation for potential treatments aimed at 
attenuating atrophy by targeting molecular mechanisms at play in the early stages of 
disuse, before measurable atrophy has occurred. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
Introduction 
Skeletal muscle inactivity (disuse) due to bed rest, limb immobilization, exposure 
to micro-gravity or spinal cord injury result in profound functional and structural 
adaptations such as decreases in muscle size (1, 11, 13, 16, 22, 34, 38-39, 53, 61, 66-67, 
70, 75, 89, 93, 96, 106, 116, 123, 133, 139, 146) and force generating capacity (20, 27-
29, 32, 35, 38, 42, 48, 63, 69, 75, 88-89, 93, 96, 120, 139, 146). These adaptations have 
mainly been attributed to the muscle unloading that occurs because of the reduction in 
weight-bearing activity (1, 12, 17), although the molecular mechanisms underlying these 
changes are not well understood. Recent technological and theoretical advances in the 
area of gene expression (e.g. microarray analysis, qRT-PCR, and other advances in field 
of systems biology) have allowed researchers to begin to describe the complex 
transcriptional events associated with skeletal muscle disuse atrophy, including those 
molecular changes that may precede morphological and functional alterations in muscle 
tissue. 
The purpose of this review will be to describe the current understanding of 
alterations in skeletal muscle related to decreases in muscle size associated with disuse. 
Unlike cachexia-associated atrophy or sarcopenia, disuse atrophy is directly related to 
changes in load or contractile activity without the concomitant contribution of disease or 
age. First, I will address the functional and morphological changes associated with 
skeletal muscle disuse at the whole muscle and microscopic level in various human and 
animal models. I will then present the molecular mechanisms currently proposed as 
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factors that may contribute to the initiation and persistence of protein degradation leading 
to disuse muscle atrophy. 
Functional and Structural Changes in Skeletal Muscle Associated with Disuse 
Experimental models of disuse in humans and animals have been used to examine 
the associated alterations in muscle size and strength. In humans, the most popular disuse 
models are voluntary bed rest (10, 20, 35, 38-39, 42, 48, 88-89, 102), limb 
immobilization (IM) via casting/bracing (32, 63, 120, 139), and unloading via unilateral 
lower limb suspension (ULLS) (24, 36, 59, 107, 109). Data has also been collected from 
individuals who have sustained accidental spinal cord injury (SCI) (22, 29, 136). In 
animals, unloading via hind-limb suspension (HS) is the most popular, though 
immobilization via casting/joint fixation has been used as well (15, 41, 66-67, 106, 116); 
and denervation and spinal cord transaction have been used as models for SCI .  
Bed Rest 
Bed rest has long been used to model profound disuse in humans (10-11, 13, 20, 
35, 38-39, 42, 48, 88-89). In fact, it has served as the primary micro-gravity model to 
simulate musculoskeletal changes during spaceflight (1, 20, 40, 132, 135). In the knee 
extensors (KE), force decrements of 15% were detectable after 14d (20), ~20% after 20 – 
35d (35, 38, 42), and ~29% after 42d (11). After 120d of bed rest, force decrements 
reached 30% (89). These results suggest the rate of performance deficit development may 
be higher in the earlier stages of bed rest compared to later time-points. Gastrocnemius 
and soleus muscles demonstrated a strength deficit of ~25% by 35d (48, 88), showing 
that the rate of decrement development may be greater for these antigravity muscles than 
the KE muscles.  
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Muscle size measurements following bed rest have generally been of the lower 
extremity, and the rate of decreases in muscle size was greatest in the first few weeks (2 – 
3wk). After 7d of bed rest, a 3% decrease in thigh muscle volume was already apparent 
(39), and by 14d, the decrement in KE CSA was 10% (10). After 20d, decrements of 6 – 
11% were reported, and after 30d, the greatest decrements reported were 11% (13). By 
42d, decrements in KE muscle size were 14 – 17% (13, 39), and after ~120d of bedrest, 
15% decreases in muscle size were reported compared to baseline (89).  In the case of the 
calf muscles, the time-course of decrements in muscle size corresponded with the thigh, 
expect at 120d when the decreases in calf muscle were approximately twice those of the 
thigh (89), suggesting that various muscle groups may follow a different atrophy pattern 
in chronic (>3mo) unloading. 
Changes at the microscopic level with bed rest have shown decreases (22) in fiber 
cross-sectional area (CSA). Fiber-size decrements were similar for type I and type II 
fibers at earlier time-points, but diverged at later time-points such that the degree of 
decrease in CSA was different across time, and the pattern of change across fiber-type 
was not the same in all muscle groups. In the soleus, the CSA of type I fibers decreased 
from 7 – 29% after 60d and 35 – 48% after 120 days (103-104, 125). Furthermore, the 
type I fibers showed a continuous decrease in CSA whereas the type II fibers exhibited a 
different pattern such that there was a 34% decrease at 60d, but no further decreases at 
120d (125). The reverse was true of the KEs: type II fiber CSA was decreased by 13% at 
60d and 32% at 120d (125), whereas Type I fiber CSA was decreased by 16% at 60d with 
no further decrease at 120d (125).  
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Immobilization (IM) 
Referred to as “limb immobilization,” this disuse model is, practically speaking, 
actually joint immobilization. By immobilizing bones together that contribute proximally 
and distally to a joint, movement about the joint is constricted, and therefore contraction 
of the muscles that act upon that joint are also largely diminished. Although the joint is 
immobilized, the neuromuscular infrastructure is left largely intact, and there is a small 
degree of neuromuscular activity, as evidenced via electromyography; though it is greatly 
decreased compared to pre-immobilization or control conditions (63).   
Humans 
In humans, the knee or elbow joints are typically immobilized. In the case of the 
lower extremity, a leg cast is used and the knee is fixed in a slightly flexed position, and 
subjects are usually provided with crutches to assist in ambulation. IM can result in 
substantial decreases in strength. For example, KE torque measured via maximum 
voluntary contraction resulted in a 17% decrease in peak torque following 14d of IM 
(32), a 45% decrease following 21d (63), and a 53% decrease after 28d (139). 
Interestingly, after merely 9d of IM, Maximum voluntary contraction was decreased by 
13% (120), suggesting that the molecular events leading to performance decrements may 
exhibit a relatively rapid onset.  
Few studies in healthy subjects have been conducted that measure muscle size, 
but the limited data available suggests that whole muscle size measured via MRI is 
decreased with immobilization and that protein degradation in the muscle exhibits a 
relatively rapid onset (1). 10 – 14d of IM resulted in an ~11% decrease in KE group CSA 
(61, 133). Interestingly, a recent study of 14d of leg immobilization reported only a 4.7% 
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reduction in lean muscle mass via dual energy x-ray absorptiometry (70); the difference 
between these results and those of the previously cited studies may have been due to the 
method of measurement. In the 28d study cited above, subjects demonstrated a 21% 
decrease in KE group cross-sectional area (CSA) (139). On the microscopic level, muscle 
fiber CSA decrements in the biopsies from vastus lateralis (VL) were 8% for type I, 11% 
for type IIa, and 9% for IIb (61). With increased periods of immobilization these 
decrements increased such that at 28d of IM, decrements of 26% for type I, 13% for type 
IIa, and 36% type IIb were demonstrated (139) showing preferential atrophy of type 2A 
fibers. 
The body of literature examining functional losses in upper extremity muscles 
with IM is small, and the documented decrements with regard to muscle size and function 
were less dramatic than in lower limb IM (75, 93, 96, 146). Twenty-eight days of elbow 
joint IM showed an 11% loss in elbow flexor muscle group CSA measured via MRI, and 
force decrements of 35% were reported (146). Shorter durations of IM have produced 
conflicting results, however. Following 21d of wrist joint IM, no significant size 
decrements were reported in the forearm though grip strength was decreased by 19% 
(75). Conversely, 9d of wrist joint IM resulted in 29% reduction in isometric wrist flexion 
strength, but only 4% decrement in forearm CSA (96). On the microscopic level, 6wk of 
elbow joint immobilization resulted in decrements of 25% for type I and 26% for type II 
(93). This suggests that in the upper limb, there may be no difference between rate of 
type I and type II size decrement.  
Immobilization in humans results in decreases in whole muscle size with lower 
extremity IM, showing that protein degradation outpaces protein synthesis. The muscle 
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size changes with upper extremity IM are less definitive, especially in the periods of 
disuse <28d. It is clear that, at the least, the muscle atrophy is less dramatic in the upper 
extremity than that found in the lower extremity. Furthermore, strength losses are 
demonstrated even in the absence of size decrement in the upper extremity, suggesting 
that functional losses can be experienced in the absence of contractile protein loss, 
suggesting that perhaps neuromuscular and/or muscle quality adaptations are responsible 
for the strength deficits. The more dramatic size and strength losses in the lower 
extremity compared to upper extremity with immobilization may be a reflection of the 
relative disuse stimulus. In other words, the weight-bearing sustained by the lower 
extremity during normal ambulation far exceeds that of the upper extremity, and when 
IM is introduced, the relative decrease in load for the lower extremity is far greater for 
the lower extremity compared to upper extremity. Lower limb immobilization in humans 
shows the greatest degree of atrophy in type II fibers compared to type I, while the results 
with regard to fiber type preference in upper extremity immobilization in not conclusive.  
Animals 
 Limb IM in rats and mice results in rapid yet selective decreases in muscle mass. 
Post-IM, muscle mass measurements show much greater decrements than in humans 
depending on the muscle and its relative position during IM. For example, muscle loss in 
the lower leg can reach between 35 – 45% in less than 2wk of IM (15, 66-67, 106, 116) 
and can reach as much as 45% following 4wk of IM in young mice (116). Furthermore, 
the relative position of the muscle (short vs. lengthened) can have a large impact of the 
degree of muscle mass loss. In the shortened position, rat soleus muscle showed 44% 
decrease in muscle mass following 21d of IM compared to control, while the tibialis 
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anterior (which was in the lengthened position during the same experiment) showed no 
significant atrophy compared to control (26). Limb IM in animals results in a fiber-type 
shift from type I to type II. However, unlike with lower limb IM in humans where type II 
fibers show greater relative decreases in CSA, there is preferential atrophy of type I fibers 
in animals (18).  
Limb Suspension 
Limb suspension protocols in animals and humans were originally designed as 
ground-based models for studying unweighting experienced in the microgravity 
environment during spaceflight (1, 132). As with the immobilization models discussed 
earlier, the neuromuscular system remains intact. However, while immobilization 
involves constant fixation of the joint, suspension models allow for movement at the 
joint, yet no weight-bearing activity.  
Humans (Unilateral Lower Limb Suspension) 
  Unilateral lower limb suspension (ULLS) is a model in which one leg does not 
bear weight because the foot is not allowed to touch the ground. To facilitate this 
suspension (without requiring the subject to actively keep the foot off the ground by 
contracting hip and knee flexors) one of two methods is used: an older protocol involving 
a strap that suspends one lower limb (8), and a newer protocol involving the use of a 
platform shoe on the contralateral limb to prevent weightbearing (24, 35, 59, 107-108). 
The difference between the three methods is that the strap keeps the knee in a flexed 
position during ambulation while the use of the platform shoe allows the unloaded leg to 
remain in anatomical position during ambulation.  
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 ULLS results in less dramatic decrements in both muscle strength and size 
compared to immobilization, but similar results compared to those seen with bed rest (1). 
ULLS studies of short duration (10 – 12d) showed KE MVS decreases of ~12 - 17% (8-
9). Data regarding accompanying size decreases at these earlier time points were not 
reported. The earliest time-point for which whole muscle CSA was measured was 16d 
which showed an 8% decrease in KE CSA (2). Longer duration studies (28 – 42d) 
showed strength decrements of ~20% regardless of time-point (8, 24, 36, 107-108), while 
muscle size measurements across studies showed greater size decrements the longer the 
period of ULLS. For example, by 42d of ULLS, the KE exhibited a 16% relative decrease 
in CSA and the gastrocnemius and solecus muscles showed a 17% and 25% decline in 
CSA, respectively (59). Few studies are available that reported changes in fiber size with 
ULLS, but the studies that are available suggest that they may be comparable with that 
seen in bed rest studies (1). 
Animals 
 Hindlimb suspension (HS) is the most popular rodent disuse model. In this model, 
the animal is suspended by ~30º (angle of torso to floor of the cage) so that the weight of 
their body is borne by their forelimbs and tail traction, leaving their hindlimbs 
unweighted, yet free to move at all limb joints (97). As with human ULLS, the greatest 
losses in strength and size were shown in the anti-gravity muscles such as the soleus 
(144). Measurable atrophy is apparent at very early time points in rodents. For example, 
bodyweight of HS rats were less than control at 3d post-HS and reached significance at 
6d (30). By 30d of HS, their bodyweight was 70% of control (114). For this reason, 
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researchers have often preferred this model to study the molecular changes associated 
with disuse. 
To summarize, prolonged periods of disuse in humans result in measurable and 
sometimes dramatic decreases in muscle strength and size (at both the whole muscle and 
single fiber levels). The most striking decrements appear to occur at early time-points 
(within first 2 – 3 weeks), after which muscle loss continues, but the rate of loss 
diminishes. Evidence from animal models shows an even sooner and more rapid decline 
in strength and size than in humans, and findings show that morphological changes begin 
in the first days following the unloading stimulus, suggesting that changes a the 
molecular level may occur almost immediately. Limited evidence in human biopsy 
studies suggests that this may be true for humans, as well. The next section of this 
literature review will outline the molecular changes shown to occur with skeletal muscle 
disuse in animal models as well as findings from the limited number of human studies. 
Spinal Cord Injury 
Spinal cord injury (SCI) directly affects the function of skeletal muscle function 
in that affected neurons no longer effectively carry information to the muscles they 
innervate. Chronic changes in skeletal muscle following both complete and incomplete 
spinal cord injury have long been established including profound muscle atrophy, 
increases in connective tissue abundance, and fiber type shifts from type I to type II (22). 
These changes result from decreased muscle contraction and load stemming from the 
decrease or cessation of activation by affected neurons. 
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Humans 
 The time-course for these changes have been difficult to ascertain because testing 
is rarely conducted prior to 4 – 6 wk post-injury, generally considered to be the point at 
which SCI patients are clinically stable (29). However, it has been suggested that muscle 
remodeling post-SCI is rapid. For example, in a study measuring atrophy in quadricpes 
femoris muscles 6 – 46 wk post-SCI, it was found that while muscle size decreased by 
40% post-SCI in ~10 months, the most dramatic losses were within the first few months 
post-SCI: At 6wk, the muscle was 25% smaller than that of able-bodied controls; by 
10wk, this decrement reached ~30%; and by 24wk, it was ~38%. (34). On the 
microscopic level, it was found that in muscle biopsies collected 4wk post-complete SCI, 
distribution of type I to type II fibers was 50%, whereas by 16wk, type I fibers 
represented less than 10% of total fibers. In addition, CSA of fibers decreased by 40 – 
50% (29, 53). Following incomplete SCI, decreases in CSA compared to able-bodied 
controls showed a decrease of over 30% in thigh CSA (123).  
Animals 
Spinal cord transection (SI) and denervation are animal models for SCI. In SI, a 
lesion is created in the alpha motor neuron impairing communication between the neuron 
and the affected muscle; in denervation communication between the neuron is impaired 
by either crushing a nerve or administering a chemical such tetrodotoxin which prevents 
acetylcholine release. In both models, the fiber-type shift is greater than that seen in 
humans (53). Furthermore, the loss in muscle mass, as evidenced by relative wet-weight 
of affected muscles is more rapid than that seen in humans. For example, 72h post-
denervation decreases of 20% were observed compared to control in mice, and by 14d 
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post-denervation, this decrement increased to 35% (113). Rodents and humans have both 
shown decreases in size and fiber-type shift post-SCI, though the changes are more rapid 
in animals than in humans making the translation of animal research to humans relevant, 
but difficult. 
Molecular Changes with Skeletal Muscle Disuse 
 Little research has been performed in humans to study the effects of skeletal 
muscle disuse on gene expression and related protein products (70, 102, 136-137). In 
fact, to my knowledge, only two study has investigated the early (≤ 48h) effects of disuse 
signaling pathways in skeletal muscle (136-137).  Urso et al. (137) found that 48h of leg 
immobilization resulted in increases in mRNA for components of the ubiquitin 
proteasome pathway (UPP) and increases in metallothionein (MT) expression. Urso et al. 
(136) also found that 48h after SCI, MTs were upregulated. These findings were 
generally in line with animal literature, which suggests that skeletal muscle disuse may 
set off a cascade of events involving increases in the rate of proteolysis (46, 62, 68, 73) 
and that this increase may be triggered, in part, by increases in oxidative stress (68, 111-
112, 128). 
Ubiquitin Proteasome Pathway (UPP) 
 There are several proteolytic mechanisms in skeletal muscle including lysosomal 
proteolysis (44, 79, 131, 141, 143), calpain-mediated proteolysis (51, 84, 111, 126, 128), 
and the proteasome system (7, 14, 16, 47, 65-66, 70, 101, 122, 127-128). While 
lysosomal proteases are activated during disuse (44), evidence suggests that calpain and 
proteasome activity, coordinated within a multi-faceted ubiquitin proteasome pathway, 
are the primary means of protein breakdown in the cell (44, 112). I will, therefore, focus 
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on these two important mechanisms and the pathway within which they function. For an 
illustration of the UPP, see figure 2.1. 
Figure 2.1: Ubiquitin proteasome pathway. Target = protein destined for degradation. 
 
Proteasome Machinery 
 The 20S core and the 26S proteasome are proteolytic machinery responsible for 
the disassembly of proteins into their peptide components (47), and is the primary system 
by which muscle cells decrease protein content leading to atrophy (115). The 26S 
proteasome is comprised of the 20S complex flanked by 2 19S complexes on either side. 
The 19S complex facilitates ATP-dependent protein unfolding into the barrel-shaped 20S 
complex, while the 20S complex consists of 2 outer α-rings which serve as the 
“gatekeepers” of the proteolytic core comprised of 2 β-rings. These 2 β-rings contain 
trypsin-like activities which serve to cleave and degrade the core’s contents, respectively 
(47).  
   Proteasome units are abundant in skeletal muscle and, therefore, it has been a 
subject of debate as to whether increases in mRNA for genes encoding proteins 
contributing to the structure of the proteolytic machinery are necessary precursors for 
increases in proteolysis. Studies have shown that, at least in some cases, genes related to 
the 20S complex are indeed upregulated with disuse (128, 137). A greater body of 
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evidence exists, however, to support the theory that proteolytic activity is regulated in 
greater part by the upregulation of the “escort system” that delivers proteins targeted for 
degradation to the proteasome (16, 46-47, 128). 
Ubiquitination Cascade  
 Although the proteasome is the primary means by which proteins are degraded in 
the cell, it will generally only degrade those proteins that have been tagged for 
proteolysis via ubiquitination. Ubiquitination is achieved through a cascade of events 
involving the small molecule ubiquitin (Ub) and 3 classes of enzymes (E1, E2, and E3). 
This is a multi-step cascade in which ubiquitin is activated by E1 (ubiquitin activating 
enzyme), transferred to E2 (ubiquitin conjugating enzyme) and eventually attached by E3 
(ubiquitin ligase) to a target protein destined for degradation. This ubiquitination cascade 
involves increasing levels of specificity such that there is only one ubiquitin molecule, 
one isoform of E1 per cell type (e.g. muscle), 20 – 40 E2s, yet over 1000 E3s (124). As a 
result, transcription of their encoding mRNAs and translation of specific E3s are believed 
to be important means by which proteolysis of skeletal muscle contractile proteins is 
regulated leading to atrophy (15, 52, 62, 70). 
 The first step of this multi-step process is activation of ubiquitin by E1 through 
ATP-dependent adenylation. E1 adenylates the ubiquitin molecule at its C-terminus, 
forms a high-energy thioester bond between the two molecules, and releases AMP. In the 
next step, E1 adenylates a second molecule of ubiquitin leading to the transfer of a 
ubiquitin molecule to E2’s catalytic site. In the third step, E3 transfers ubiquitin from E2 
to the protein molecule destined for degradation (115). Free E3s have much higher 
affinity for E2’s bond to ubiquitin than to free E2s, and this difference in affinity helps 
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drive the enzymatic cascade (74). Several ubiquitin molecules must be attached to a 
substrate before it is recognized for degradation by the proteasome (145) 
E3 Specificity   
 Two muscle specific ligases have been implicated in disuse atrophy: Atrogin-1 
(FBXO32/MAFbx) and muscle ring finger-1 (MuRF-1) (15). Like the majority of E3s, 
both of these proteins contain RING (Really Interesting New Gene)-finger domains 
which allow the E3 molecule to serve as a scaffold bringing the targeted substrate and the 
E2 molecule together for conjugation (73). Upregulation of the genes that encode 
Atrogin-1 and MuRF-1 (FBX32 and MuRF, respectively), as well as increases in related 
protein levels, are associated with skeletal muscle atrophy (15, 60).  
MuRF-1 is a monomeric RING-finger protein shown to be selectively recruited to 
the M-line of the sarcomere by the A168-A170 region of titin where it binds via a C-
terminal helical domain (98). Evidence has shown MuRF-1 may play a role in 
maintenance of the M-line and thick filament structure, yet overexpression of MuRF-1 
leads to titin protein degradation (95). Furthermore, MuRF-1 has a nuclear component, 
binds with nuclear import proteins as well as a transcriptional regulator (GMEB-1), and 
has been localized not only to the sarcomere in vivo, but to the nuclei in myocytes (95), 
suggesting that it also may play a role in gene transcription.  
Atrogin-1 is also a RING finger E3. However, rather than being a monomeric 
protein, it has multiple subunits and is a member of the Skp1-Cull-F-box group of cullin-
RING ligases known as SCF complexes (52). The core of Atrogin-1 is the cullin subunit, 
one end of which binds the RING component and the E2 enzyme. The other end of the 
cullin subunit binds the F-box protein subunit containing the substrate binding motif. The 
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F-box protein subunit, in turn, binds to the target substrate via an adaptor protein, Skp1 
(52). Atrogin-1 has been shown to be located at the Z-line of the sarcomere (90). 
Therefore, like MuRF-1, it likely targets sarcomeric proteins, although specific protein 
targets have not been identified. Furthermore, it has been suggested that atrophy is not 
only associated with increases in transcription of FBXO32 and subsequent 
translation/aggregation of Atrogin-1 (16), but also with phosphorylation of the complex 
since it has been shown to lead to F-box/substrate binding and Ub conjugation (111).  
Both Atrogin-1 and MuRF-1 have been found to be differentially expressed with 
disuse atrophy. For example, the genes that encode for both of these proteins have been 
shown to be upregulated as early as 24h following the initiation of immobilization and 
unloading in rat muscle (15). Furthermore, Atrogin-1 and MuRF-1 knockout mice 
showed attenuated atrophy following unloading (15), and C2C12  myotubes transfected 
with Atrogin-1 were measurably thinner than controls (15). Taken together, these 
findings suggest that Atrogin-1 and MuRF-1 proteins may be important early regulators 
of skeletal muscle atrophy and that they (or their protein targets) may be excellent 
candidates for early intervention following disuse via drug-mediated modification to 
attenuate atrophy in humans. However, findings from human studies have not yet fully 
supported this hypothesis. While both 20d of bed rest (102) and 2wk of leg 
immobilization (70) led to a significant 1.6-fold increase in Atrogin-1 gene expression 
and a trend for an upregulation in MuRF-1 expression (70), no differential expression 
was found for these two genes following 48h of leg immobilization (137) or 48h after 
SCI (136). Though they may play an important role in disuse atrophy in humans, the 
time-courses for their effects are not clear. 
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Calpains 
The majority of skeletal muscle proteins exist in actomyosin complexes (134). 
Therefore, because the 20S proteolytic core can only degrade monomeric proteins, 
contractile proteins destined for degradation (e.g. actin myosin, and titin) must not only 
be ubiquitinated in order to undergo proteolysis by the proteasome, but must first be 
released from the sarcomere. Recent research suggests that the calpains may be 
responsible for actomyosin disassociation prior to proteolytic degradation by the 20S 
proteolytic core or the 26 proteosome (51, 134), and as such, could play an important role 
in skeletal muscle remodeling following a disuse stimulus.  
Calpains are non-lysosomal, calcium ion (Ca2+)-dependent, cysteine proteases 
(51). There are three members of the family abundant in skeletal muscle, (ubiquitious 
calpains 1 and 2, and the muscle-specific isoform, calpain-3). They are found primarily at 
the Z-disk of the sarcomere where they are transformed from their inactive to active state 
through Ca2+-dependent autolysis. (37). Active calpains cleave proteins into polypeptide 
components, and in this way, may render them vulnerable to ubiquitination and 
subsequent proteolysis. 
Calpain-3 has been of particular interest lately in regards to its potential role in 
sarcomere remodeling since a loss-of-function mutation in CAPN3 results in limb-girdle 
muscular dystrophy type 2A (LGMD2A), which is characterized by progressive atrophy 
and weakness of the proximal limb muscles (117). In addition to a potential role for 
calpain-3 during muscle anabolism, it has been proposed that calpain-3 plays a role in 
muscle catabolism during disuse atrophy (84). Indeed, in a study using CAPN3 knock-out 
(C3KO) mice,  it was shown that following hind-limb unloading, the rate of muscle mass 
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loss was lower in C3KO mice compared to wild-type (WT) (84). Furthermore, this study 
provided evidence to support the theory that proteolytic activity of the 26S proteasome 
may be predicated on caplain-3 cleavage of sarcomeric proteins because C3KO mice did 
not show increases in ubiquitination following hindlimb suspension, while WT mice did 
(84). 
Molecular Changes Influencing UPP Activity 
 The increase in UPP activity is likely influenced by multiple molecular 
mechanisms including (but not limited to) activity of the AKT/FOXO and NFkB 
pathways, oxidative stress, and decreases in protective protein chaperones. Furthermore, 
recent work has shown that extracellular matrix (ECM) remodeling (specifically 
decreases in collagen proteins) is found with skeletal muscle disuse not only in animals 
(3-4, 6, 76) , but in humans (137), although the relationship with the UPP is unclear. 
AKT/FOXO Pathway 
UPP activity is influenced by an upstream regulating signaling cascade involving 
AKT and forkhead box O (FOXO) transcription factors. AKT1 has been identified as the 
“master switch” modulating the balance between protein synthesis and protein 
degradation (16, 46, 62). When phosphorylate (activated), AKT in turn phosphorylates 
downstream targets including FOXO transcription factors and mammalian target of 
rapamyacin (mTOR). Phosphorylation of mTOR results in its activation and a signaling 
cascade favoring protein synthesis. At the same time, phosphorylation of FOXO 
transcription factor sequesters the molecules in the cytosol, rendering them inactive. 
Conversely, when AKT phosphorylation decreases, FOXO transcription factors become 
dephosphorylated, allowing them to translocate to the nucleus where they serve to 
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upregulate transcription of E3 ligases Atrogin-1 and MuRF-1 (99). Figure 2.2 illustrates 
the effects of a decrease in growth factors on the pathway when AKT phosphorylation is 
decreased.  
Figure 2.2: AKT signaling pathway with decreased growth factor conditions. 
 
 As discussed earlier, increased cellular levels of these important enzymes in the 
ubquitination cascade lead to increased proteolytic activity. Evidence shows that in both 
animals (23, 31, 85) and humans (137), levels of phosphorylated AKT decrease with 
immobilization. While this also been demonstrated with unloading in animals (56, 130), 
it has yet to be investigated in humans.  
IGF-1 Signaling 
An important factor contributing to decreases in AKT phosphorylation status with 
disuse are likely decreases in Insulin-like Growth Factor-1 (IGF-1) (87, 119, 128). IGF-1 
is a polypeptide that is secreted by the liver as well as generated in paracrine/autocrine 
fashion in the muscle tissue and preferentially binds to the insulin-like growth factor 
receptor (IGFR) (138). Physical activity has been shown to increase IGF binding at the 
muscle cell membrane leading to increases in protein synthesis (49-50).  IGF exerts its 
effects via a signaling cascade whereby IGF-1 binding leads to phosphorylation of the 
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IGF-1 receptor, AKT, mTOR, and downstream signaling molecules that promote 
hypertrophy (62). Decreases in IGF-1 signaling secondary to muscle disuse result in the 
opposite effect whereby dephosphorylation of the IGF-1 receptor leads to 
dephosphorylation of AKT and an increase in AKT/FOXO pathway activity (Figure 2.2) 
(62). IGF-1 treatment has been used in an in vitro model of hypertrophy where post-
fusion IGF-1 treatment resulted in measurable hypertrophy in C2C12 myotubes compared 
to control (87, 119, 142). It is unknown whether removal of this growth stimulus would 
result in measurable atrophy, through it is an intriguing question worthy of further 
investigation, as it may provide a model system within which to study atrophy-related 
molecular signaling.  
IGF binding proteins 1 – 6 (IGFBP 1 – 6) are carrier proteins that can interact 
with IGF to modify its signaling capability (118). Differential expression of IGFBPs has 
been found with disuse atrophy; IGFBP-5 gene expression has been shown to be 
upregulated in both hind-limb unloading and diaphragm unloading via mechanical 
ventilation (111, 128). It can sequester IGF in the ECM (111), and the results from these 
disuse studies suggest that IGFBP-5 may contribute to disuse atrophy by decreasing IGF 
signaling and subsequently promoting the activity of the AKT/FOXO and UPP pathways. 
In addition to interacting with IGF-1, IGFBPs can regulate cell growth and survival via 
IGF-independent mechanisms. For example, IGFBP-3, 5 and 6 have been identified as 
pro-apoptotic mediators, though the related signaling pathways are poorly understood 
(118), and the potential activity of these pathways during disuse are unknown.  
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Oxidative Stress  
Oxidants are molecules with unpaired electrons in their outer electron shells. 
Common oxidants, known as reactive oxygen species (ROS) are superoxide (O2-), and 
hydroxyl radicals (OH). Molecules in this state are highly reactive and are important in a 
number of normal cellular processes (111). However, when their levels increase 
dramatically in the cell, oxidative stress can result. Oxidative stress is the cellular damage 
to proteins, lipids, and DNA that occurs when the production of reactive oxygen 
outweighs the cells ability to buffer oxidants via reduction/oxidation (redox) reactions 
and/or repair oxidant-induced alterations in cellular components (33). A related reactive 
species called reactive nitrogen species (RNS) can be produced secondary to ROS 
production. These are highly reactive molecules contain nitrogen instead of oxygen. 
Because their production follows that of ROS, their negative cellular effects can still be 
considered the result of oxidative stress. 
It has been documented that oxidative stress increases with disuse atrophy (73, 
111-112, 128), and increased levels of ROS in the cytosol have received growing 
attention in the literature. Theories for how ROS may potentially contribute to increased 
activity of the proteasome pathway include: 1) increases in Ca2+ levels in the cell 
resulting in activation of calpains (83); 2) promotion of Atrogin-1 and MuRF-1 
transcription (112); 3) oxidation of proteins that then undergo degradation in the 20S 
proteolytic core without first requiring ubiquitination (54); and 4) signaling cascades 
leading to increased NFkB pathway activity (112). 
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Oxidative Stress and Calpain Activity 
As previously discussed, calpains likely promote UPP activity by cleaving titin 
and/or nebullin, thereby releasing actin and myosin from the sarcomere, freeing them for 
ubiquitination and then degradation by the proteasome (134). Because calpain activity is 
triggered by Ca2+-mediated autolysis, it follows that increases in calcium levels in the cell 
may lead to increased calpain activity. Evidence from in vitro studies suggests that 
oxidative stress may lead to Ca2+ overload and subsequent calpain activation (83). Plasma 
membrane Ca2+ ATPase facilitates Ca2+ removal from the cell, yet levels of this enzyme 
are reduced by oxidant-generated reactive aldehydes. Therefore, increases in cellular 
levels of ROS may retard Ca2+ removal from the cell, thereby contributing to cellular 
Ca2+ accumulation. The increased calpain activation may, in turn, lead to increased 
proteolysis via the proteasome. 
Oxidative Stress and E3 Ligase Pool 
Oxidative stress has been shown to upregulate Atrogin-1 and MuRF-1 in 
myotubes (91). Therefore, increases in ROS may promote proteolytic activity by 
increasing E3 ligases available to deliver ubiquitinated proteins to the proteosome. 
Indeed, ROS (as evidenced by H2O2) has been shown to activate FOXO transcription 
factor signaling in muscle cells (43), while increased FOXO signaling has been linked to 
increased Atrogin-1 expression and decreased fiber size (122).  These findings provide 
evidence for the theory that ROS initiates FOXO-mediated transcription of E3 ligases 
leading to increased protein degradation via the UPP.  Furthermore, increased ROS may 
also lead to degradation of non-ubiquitinated proteins. Studies indicate that the 
proteolytic core of the proteasome can degrade oxidated proteins without ubiquitination 
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(54). Therefore, it is possible that oxidative stress promotes protein degradation via the 
proteasome either by increasing the size of the pool of E3 ligases, by oxidizing proteins, 
or by both of these mechanisms. 
Oxidative Stress and the NFkB Pathway 
Nuclear Factor kappa B (NFkB) is a family of “stress response” transcription 
factors that are activated by over 150 molecules, and in turn, transcribe over 100 genes  
depending on the cell type and stimulus. Among the many stimuli that may induce NFkB 
activation, is disuse-associated oxidative stress (68, 112). A likely molecular trigger for 
NFkB, in this case, is the intercellular signaling molecule tumor necrosis factor alpha 
(TNF-α). TNF-α is a cytokine that exerts its effects on muscle cells via tumor necrosis 
factor receptors one and two (TNFR1 and TNFR2). It has been established that when 
TNF-α binds to the skeletal muscle membrane via one of these receptors, the NFkB 
pathway is activated (64), and studies have shown that elevations in TNF-α stimulate the 
degradation of NFkB inhibitor proteins and NFkB-DNA binding in the nucleus (91). In 
addition, increased TNF-α levels have been associated with increased ubiquitin 
proteasome activity (55), suggesting a strong relationship between the NFkB and ubiqutin 
proteasome pathways.  
TNF-α has been found to be a potent atrophy stimulus both in vitro (91-92, 129) 
and in vivo (5, 114). Elevated TNF-α levels have been linked to increased NFkB pathway 
activity associated with disease-related muscle wasting (5) and aging-related sarcopenia 
(114). It is not known whether a similar relationship between TNF- α levels and NFkB 
pathway activity may exist with disuse atrophy. In fact, research has shown that increases 
in NFkB pathway activity may be stimulated by another molecular mechanism (64). It 
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was shown that, following 7 days of hind-limb unloading, TNF α levels were not elevated 
even though there was evidence of increases in NFkB transcriptional activity. These 
findings suggest that an alternative activation pathway may exist for NFkB associated 
molecular signaling during disuse atrophy. 
In the inactive state, NFkB is in complex with its inhibitor IKb. In this state, the 
transcription factor is sequestered in the cytosol. When NFkB is cleaved from IKK by the 
enzyme IKb kinase (IKK), it becomes activated and translocates to the nucleus where it 
may transcribe a variety of genes including Atrogin-1 and MuRF-1 (68) . Increased 
oxidative stress in the cell may lead to enhanced NFkB activation because ROS have 
been shown to promote activation of kinases that participate in the NFkB/IKb cleaving 
process (64). As such, this is an additional way in which oxidative stress may increase 
ubiquitin proteasome activity. 
Recently there has been debate regarding the effects of oxidative stress on the 
NFkB pathway (71, 105). Oxidative stress may lead to oxidation of direct and indirect 
activators of NFkB, thereby enhancing NFkB pathway activity, and in turn, UPP activity. 
Conversely, recent evidence has also shown that oxidation of the NFkB molecules, 
themselves, diminishes their DNA-binding activity, suggesting that oxidative stress could 
also inhibit NFkB transcriptional activity (71). Because NFkB activity and interaction 
with subsequent transcriptional targets is a complex mechanism regulated by diverse 
stimuli and may differ between cell types, more research will be necessary to elucidate 
the role of the NFkB pathway during disuse muscle atrophy. 
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Reactive Oxygen and Nitrogen Species Production 
For oxidative stress to occur, oxidant levels must first be increased in the cell. 
Multiple mechanisms exist by which oxidants may be produced during disuse. Examples 
of these mechanisms include NO· production via nitric oxide synthase (NOS) activity and 
O2- production via the xanthine oxidase (XO) pathway (57). Furthermore, increased 
levels of reactive iron can participate in reactions that produce ROS  
Oxidant Production via NOS and XO 
NOS produces NO by catalysing a five-electron oxidation of a guanidino nitrogen 
of L-arginine (L-Arg). Evidence has shown that NOS activity is likely increased during 
limb immobilization, leading to increased NO production (80). There are two NOS 
isoforms in muscle: neuronal NOS (nNOS) and endothelial NOS (eNOS) (77), the latter 
of which is calcium-activated. Therefore, increased cellular Ca2+ levels may promote 
eNOS activity, which would lead to increased production of NO. Also, the production of 
NO via NOS can result in the formation of RNS which can lead to increased lipid 
peroxidation and nitrosylation of proteins causing further cellular damage (72).  
 The role of NOS and NO in disuse atrophy is a subject of debate as it has also 
been shown that NO can function as an anti-inflammatory mediator during disuse (100), 
and that it can inhibit calpain activity, thus potentially attenuating atrophy during 
unloading (78). Whether NO works as a pro-inflammatory mediator (promoting atrophy), 
or an anti-inflammatory mediator (preventing atrophy), is yet to be determined. The 
experiments in which NO was found to attenuate atrophy were studies in which mice 
were genetically altered to over-express NOS (100). Since NOS appears to be tightly 
regulated (21), a hyper-physiological state may not represent a relevant cellular 
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environment. Furthermore, the study in which NO prevented catalytic activity of calpains 
was performed in vitro with ionophore-induced proteolysis which may or may not 
translate to muscle disuse in vivo (78). This is an area where more research is need. 
Caplains can degrade xanthine dehydrogenase to produce XO which in turn can 
catalyze the formation of O2- . O2- is quite benign when compared to other radicals. 
However, it can be used to form more damaging reactive species. For example, O2- and 
NO can react to form peroxynitrite (ONOO-), one of the RNS (57).  
Reactive Iron 
Transition metals, such as reactive iron (Fe2+), can participate in reactions that 
produce hydroxyl radicals (·OH) (57). The production of ROS from reactive iron may be 
a feed-forward process since bound iron, which is not reactive, can be released from the 
iron-binding protein by O2-, thereby becoming reactive. In this way, increases of O2-, a 
free radical, can lead to increases in reactive iron, which in turn, would lead to further 
increases in ROS. Heme-oxygenase-1 (HMOX1) protein activity may also lead to 
increases in cellular levels of reactive iron by releasing iron bound to heme proteins (57). 
Research has shown that HMOX1, the gene encoding for the HMOX1 protein, was 
upregulated with diaphragm unloading via mechanical ventilation (111) and hindlimb 
unloading (128). However, the role of hmox-1 is unclear, in that it may have antioxidant 
properties, as well. Evidence suggests that hmox1-mediated iron release may lead to 
increased ferritin synthesis (140). Ferritin is an abundant iron-binding protein in the cell 
(57), and increases in hmox-1 protein could provide protection against iron-mediated 
oxidative damage associated with disuse because increased ferritin may lead to a decrease 
in reactive iron in the cytosol by binding free iron. Nonetheless, increases in total muscle 
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iron levels have been shown with immobilization (81), and these increases in muscle iron 
were found to be associated with increases in lipid peroxidation. Furthermore, when a 
systemically delivered iron chelator (a chemical sequesteror of iron) was administered, 
atrophy was attenuated (81). Taken together, these findings suggest that immobilization 
leads to increases in muscle iron, and that oxidative stress caused by ROS (produced in 
an iron-dependent reaction) may contribute to the immobilization-associated muscle 
atrophy. 
Oxidative Stress Markers and Disuse  
The theory that muscle disuse increases intracellular oxidative stress is supported 
by findings showing upregulation of oxidative stress markers associated with disuse 
atrophy  (111, 128, 137). In addition to the upregulation of HMOX1 (the antioxidant 
properties of which are a source of debate as discussed above), other oxidative markers 
have also been shown to be upregulated with disuse atrophy. These include iron and 
heavy metal response genes such as ferroxidase (128), the transferrin receptor (128), and 
metallothioneins (MT) (111, 128, 137), as well as the chemoprotective enzyme 
glutathione-s-transferase (111, 128, 137). 
Ferroxidase catalyzes the oxidation of Fe2+ to Fe3+, while transferrin is a carrier of 
Fe3+. The transferrin receptor mediates the endocytosis of Fe3+ into the cell (82) .  
Ferroxidase and transferrin are known to work together in the blood plasma to respond to 
oxidative stress. Transferrin can only bind Fe3+, and therefore ferroxidase activity 
promotes transferrin-iron binding (109). Elevated levels for transferrin and ferroxidase in 
the blood are considered biomarkers for inflammation (19). However, the roles of these 
proteins in the muscle cell are not clear. Furthermore, an increase in transferrin receptor 
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activity may lead to an increase in intracellular iron, though its association with disuse-
related molecular changes is not known. 
Metallothioneins (MTs) 
Members of the MT family of antioxidant molecules have been shown to be 
upregulated with hindlimb unloading (128) and mechanical ventilation-mediated 
diaphragm unloading (111). Furthermore, following 48h of immobilization in humans 
(137) and 48h after SCI (136) a number of (MTs) were found to be upregulated. MTs are 
small cysteine-rich molecules with antioxidant properties. MTs have the capacity to bind 
heavy metals through the thiol group of their cysteine residues, especially zinc ions (Zn+). 
Zn+ is an important component in the activation and binding of some zinc-finger proteins 
that interact with DNA. The zinc-finger is a DNA-binding protein domain comprised of 
two anti-parallel β-strands and an α-helix. The zinc ion is crucial to the functionality of 
the zinc-finger domain because it unfold if it does not bind a zinc ion (25). MTs regulate 
cellular levels of Zn+  by binding and releasing it, and as such, are important for zinc 
signaling.  
MTs are purported to serve as antioxidants by capturing ROS (25). From this 
+reaction, the MT’s cysteine residue is oxidized to cystine, and the metal ions which were 
previously bound to cysteine (usually Zn) are liberated.  Zinc is widely considered to be 
an antioxidant (110). However, while Zn can directly protect the cell from oxidative 
damage to a small degree, the primary way in which it exerts its antioxidant effect is 
through its role in the production of MTs. Once the Zn, previously bound to cysteine is 
liberated, it can translocate to the nucleus where it interacts with the metal response 
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element (MTE) in the MT gene promoter to activate the transcription of MT, so that more 
MT protein can be transcribed and ultimately translated (121).  
Decreases in Protective Chaperone Proteins 
 Chaperones proteins are very important for maintenance of healthy muscle fibers. 
They play a role in protein stabilization during synthesis, refolding of proteins damaged 
by stress, and protecting proteins from degradation. Many protein chaperones are 
categorized as heat shock proteins (HSP) and a number of members of this protein 
superfamily have been shown to be downregulated with disuse atrophy. For example, 
HSP70 was shown to be decreased in rat soleus muscle following 12 – 18h and 24h – 14d 
of hindlimb unloading (128). Furthermore, this decrease in HSP70 protein was associated 
with decreases in protein synthesis rates (86). HSP70 is known for facilitating protein 
translation by associating with nascent polypeptides as they exit the ribosome. It has been 
suggested that decreases in HSP70 during disuse may slow protein synthesis rate, 
contributing to atrophy (128). The role of other heat shock proteins chaperones is 
unknown, but the downregulation of the genes that code for a number of them have been 
found with hindlimb unloading (128), suggesting that a decrease in heat shock proteins 
may contribute to disuse atrophy. 
Extracellular Matrix Integrity 
 The extracellular matrix (ECM) is found in the connective tissue and basement 
membrane (BM) around muscle fibers and is a mixture of water, sugars, and proteins 
(collagens, proteoglycans (PG), noncollagenous glycoproteins, and elastins).  Not only 
does the ECM provide the three-dimensional framework for skeletal muscle organization 
and fiber anchorage, but it is also involved in the regulation of  intracellular signaling and 
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provides storage for signaling molecules such as growth factors, cytokines, chemokines, 
and enzymes (6). The ECM is a highly dynamic structure that is subject to constant 
remodeling (6, 76), and evidence suggests that muscle disuse leads to decreases in ECM 
integrity and that these molecular changes, in turn, lead to alterations in cellular signaling 
(137). 
Collagen 
 Collagen is, perhaps, the most abundant protein in the ECM. The predominant 
collagen isoforms in the connective tissue surrounding muscle fibers are fibrillar 
collagens I and III. They consist of 3 polypeptide alpha chains containing triple-helical 
collagenous (COL) domains as well as noncollagenous (NC) domains. Upon deposition, 
they assemble into polymer scaffolds (enclosing PGs and glycoproteins) designed to 
withstand tensile forces and provide stability to the connective tissue.  The predominant 
collagen isoform in the BM is fibrillar collagen IV. It is a heterotrimeric combination of 6 
individual α-polypeptide chains (6), and while not essential to the formation of the BM, is 
likely required for maintaining ECM integrity under mechanical stress (6, 94).  
The animal literature has shown that disuse atrophy is associated with decreases 
in mRNA expression for genes encoding collagen proteins and decreases in collagen 
protein levels (3-4, 45, 76). These findings were recently corroborated in humans 
following 48h leg immobilization where mRNA levels for the genes encoding for 
collagen III and collagen IV mRNA were decreased post-immobilization, as were related 
protein products (137). Furthermore, evidence suggests that decreases in collagen are 
associated with increases in cellular signaling leading to proteolysis and disuse atrophy 
(45, 58, 106). Since it has already been established that the majority of protein 
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degradation occurs via proteasome activity, these findings provide evidence to support 
the theory that decreases in ECM integrity may lead to increases in signaling cascades 
associated with the UPP. 
Matrix Metalloproteinases (MMPs)  
Collagen degradation is initiated by matrix metalloproteinases (MMPs) which 
cleave ECM components (45). MMPs are zinc-dependent endopeptidases that are first 
secreted in an inactive state that includes a propeptide domain, a catalytic domain, and a 
C-terminal domain. A cysteine residue in the propeptide domain binds to a Zn 2+ ion, 
which is bound to the catalytic domain. In this way, the catalytic domain is prevented 
from binding any other molecules. When the propeptide domain is cleaved, MMPs are 
activated. In an animal model, it was shown that MMP-2 and -9 gene expression is 
upregulated with 14d of rat hindlimb suspension (16). This finding was not confirmed 
following 48h of leg immobilization in humans (137). In fact, MMP28 was significantly 
decrease by 1.9-fold. One possible explanation for these contrasting findings is that the 
time-course for MMPs is such that it is not an early responder to disuse, but takes days or 
weeks to manifest a change in gene expression. Another possibility is that human and rat 
MMP responses differ. The limited in vivo literature on the topic makes it difficult to 
explain those results, but they are of interest because, to date, the study from which they 
were derived is the only human atrophy study to document alterations in MMPs with 
disuse, and is contrary to the previous animal study (45). 
Summary 
Animal models have shown that a decrease in protein synthesis and an increase in 
proteolysis lead to atrophy in skeletal muscle with disuse and that the majority of the 
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protein degradation occurs as a result of increased activity of the UPP. Limited research 
in humans suggests that the degradation mechanism may be similar since gene expression 
for components of the UPP are increased with immobilization. The time-course for these 
changes in humans, however, is unclear. Furthermore, the animal literature suggests that 
factors regulating the rate of proteolysis via the UPP may include IGF-1 signaling, 
oxidative stress, decreases in protective chaperone protein availability, and changes in 
extracellular matrix integrity.  The molecular signaling networks associated with these 
interrelated factors are likely dynamic and complex.  
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CHAPTER III 
GLOBAL GENE EXPRESSION CHANGES WITH SKELETAL MUSCLE 
UNLOADING AND RELOADING IN HUMANS 
Abstract 
 
PURPOSE: Although short-term disuse does not result in measurable muscle 
atrophy, recent studies suggest that molecular changes associated with protein 
degradation may be initiated within days of the onset of a disuse stimulus such as 
immobilization. However, little is known, about molecular changes accompanying disuse 
stimuli that allow free joint movement such as unloading (UL). This study sought to 
examine the global gene expression patterns following 48h UL and 24h reloading (RL) in 
human skeletal muscle. METHODS: Seven sedentary young men underwent 48h UL via 
unilateral lower limb suspension, followed by 24h RL. Biopsy samples of the left vastus 
lateralis were collected at baseline as well as after the UL and RL periods. Global gene 
expression changes were identified using Affymetrix microarrays (U133 Plus 2.0), gene 
clustering was performed using Genespring software, enriched functions within the 
dataset were identified using the Database for Annotations, Visualization and Integrated 
Discovery (DAVID), and significant canonical pathways were identified using Ingenuity 
Pathway Analysis (IPA). Candidate genes were confirmed via qRT-PCR, and relative 
protein levels were measured via Western blot. RESULTS: Of the upregulated genes, the 
most enriched functional group in the dataset was related to protein ubiquitination, as was 
the highest ranked canonical pathway (the protein ubiquitination pathway). Furthermore, 
the oxidative stress response pathway was the second highest ranked canonical pathway. 
Of the downregulated genes, functions related to the mitochondrion and aerobic 
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metabolism were the mostly highly enriched. In general, gene expression patterns 
following UL persisted following RL. qRT-PCR analysis confirmed increases in mRNA 
for UPP-related E3 ligase atrogin1 (but not accompanying increases in protein products) 
and stress response gene HMOX1 (which showed a trend towards increases in protein 
products at 48h UL) as well as extracellular matrix (ECM) component COL4. 
CONCLUSIONS: Short-term skeletal muscle unloading in humans led to increases in 
transcription of protein degradation and stress response genes as well as decreases in 
genes associated with mitochondrial metabolism; the gene expression patterns were not 
readily reversed upon reloading suggesting that molecular responses to short-term periods 
of skeletal muscle inactivity may persist even after activity resumes. 
Introduction 
Disuse muscle atrophy occurs in response to immobilization (IM) (40, 80), 
unloading (UL) (2, 7-8), bed rest (9-10, 61), spaceflight (2, 75, 78), and spinal cord injury 
(SCI) (79). Studies in humans have documented the effects of disuse on skeletal muscle 
structure and function (7-8, 11, 27, 34, 43, 58) such as decreases in muscle size and 
strength as well as increases in rate of muscle fatigue. The underlying mechanisms 
regulating these changes are not well understood, though investigations in IM, UL, and 
denervation (13-14, 31) in animals have shown that there are coordinated alterations in 
expression of genes encoding for proteins that may function in the initiation of the muscle 
atrophy process. Differential gene expression has been detected for molecules related to 
protein degradation and synthesis (13-14, 31), extracellular matrix (ECM) remodeling (4-
5, 30), oxidative stress response (reviewed in (66)), and metabolism (50). Also, it has 
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been proposed that key regulators of muscle atrophy are likely those most sensitive to the 
disuse stimulus (12). 
Recently, studies have been undertaken in humans to investigate the gene 
expression changes in skeletal muscle associated with disuse (17, 25, 40, 80). As with the 
animal models, these studies have shown alterations in expression of components of the 
ubiquitin proteasome pathway (UPP) such as fbox-only protein 32 (FBXO32, aka 
atrogin1) and muscle specific ring finger 1 (MuRF1), ECM components such as collagen, 
and metabolic enzymes such as NADH dehydrogenase and pyruvate dehydrogenase. 
With the exception of one study from our laboratory (80) that measured gene expression 
following 48h of knee IM, these investigations have measured time points from 5d – 3wk 
of IM (17, 25, 40). However, measurable proteolysis has been detected as early as 72h 
post-unloading in humans (76), and therefore, molecular atrophy triggers (such as 
alterations in the transcription of key genes) likely occur prior to that time point in 
humans.  
This study examined the global gene expression patterns following short-term 
unloading (48h UL) and reloading (24h RL) in human skeletal muscle using a human 
suspension model most analogous to hindlimb unloading in rodents, unilateral lower limb 
suspension (ULLS). By learning more about the molecular events accompanying the 
earliest stages of disuse, we sought to uncover information that may aid in future efforts 
to prevent or attenuate disuse atrophy. Furthermore, by also investigating transcription 
immediately following RL, we aimed to discover key genes that were most sensitive to 
disuse stimuli. Microarray technology and high-throughput array analysis provided us 
with the tools to analyze the global expression patterns of thousands of genes within each 
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tissue sample, and these technologies allowed us to gain valuable insight by investigating 
the multifaceted regulation of biological processes associated with disuse.   
Methods 
Subjects 
Seven (n = 7) sedentary young men were recruited from the University of 
Massachusetts community (for demographic data see Table 3.1). Those with bleeding 
problems, known allergies to Lidocaine, orthopedic problems, or use of medications that 
could increase bleeding (such as aspirin) were excluded from the study, as were 
individuals who are taking muscle building supplements or restricting caloric intake. All 
subjects signed an informed consent form approved by the University of Massachusetts 
and Hartford Hospital institutional review boards and completed a medical history 
questionnaire and physical activity questionnaire before being enrolled in the study to 
insure they met the inclusion/exclusion criteria. In addition, each potential subject was 
carefully screened to ensure that he was aware of the inconvenience inherent in the UL 
protocol, understood the potential discomfort from the biopsy procedure, and felt 
confident that he could comply with all study requirements. 
Unloading and Reloading Protocol 
Lower limb UL was achieved using the ULLS model which required that subjects 
wear a shoe with a 10-cm sole (Kintec Footlabs, Surrey, BC) on the right foot. The left 
foot did not have contact with the ground. Therefore, the left lower limb was unloaded 
for the duration of the 48h UL protocol. All ambulatory activity was performed on 
crutches with only the right foot having contact with the ground. Although the UL leg 
was free to move, no load was placed on it, and any physical activity requiring use of the 
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left quadriceps muscles was restricted. Berg et al. (7) and others (3, 20, 33) have used this 
ULLS model up to 6 wk. Compliance during the UL phase of the current study was 
confirmed through the use of activity monitors (Model #7164 Computer Science and 
Applications, Inc., Shalimar FL) worn on both ankles, which showed a 29% - 35% 
reduction in acceleration in the UL leg compared to the loaded leg. Following 48h UL, 
subjects were instructed to ambulate normally for 24h, which constituted the RL 
condition. 
Biopsies 
Three biopsies were taken from the left vastus lateralis of each subject over the 
course of the study. A baseline biopsy was taken 2wk prior to UL. Biopsies were also 
taken immediately following 48h UL and 24h RL. All biopsy procedures were conducted 
at Hartford Hospital and were taken at the same time of day to reduce circadian 
influences. Subjects were fed a standardized meal 3h prior to each biopsy because meal 
patterns alter the activity of certain genes related to muscle atrophy and hypertrophy (22). 
Percutaneous needle muscle biopsies were obtained using a Bergstrom 5-mm 
biopsy needle (Depuy, Warsaw, IN) in a sterile field. First, skin was lightly anesthetized 
with 2% Lidocaine hydrochloride solution. Next, a small (5-6mm) incision was made 
through the skin and muscle fascia, and the biopsy needle was inserted. Up to 150mg of 
tissue was removed and divided into 3 aliquots (up to 50mg each). Biopsy samples were 
immediately snap-frozen in liquid nitrogen upon excision. All samples were stored at  
-80 C until analysis. After each biopsy, subjects were escorted home and contacted 
every 12hr for the next 3d to ensure the biopsy site was healing properly.  
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Expression Profiling 
Affymetrix Human Genome U133 Plus 2.0 microarrays for analysis of over 
47,000 transcripts were used for this study. The procedures including total RNA 
isolation, cDNA synthesis, cRNA labeling, microarray hybridization and image acquiring 
was done as described in our previous publications (18).  Briefly, total RNA isolated with 
TRIzol reagent and purified with RNeasy MinElute Cleanup Kit (Qiagen, Valencia, CA).  
Three microgram of total RNA from each sample were converted into double-stranded 
cDNA then cRNA using one-cycle target labeling and control reagents and protocol 
(Affymetrix, Santa Clara, CA). After purification using GeneChip® Sample Cleanup 
Module (Affymetrix, Santa Clara, CA), biotin-labeled cRNA was then fragmented 
randomly prior to hybridizing to the microarrays. Each array was washed and stained on 
the Affymetrix Fluidics Station 450, and then probe arrays were scanned via the 
GeneChip® Scanner 3000.  The quality control criteria developed at Children’s National 
Medical Center Microarray Center for each array were followed (1, 18). 
Absolute analysis of Affymetrix "raw" data was conducted using Affymetrix 
MAS5.0 and DNA-Chip Analyzer software (dCHIP) (52, 54). The data were then 
imported into the GeneSpring 7.0 (Silicon Genetics, Redwood City, CA) for data filtering 
and statistical analysis. First, genes with 2 “present calls” (~10% of the total arrays) were 
selected for statistical analysis.   Probe sets showing significant (p < 0.05) expression 
changes (using Welch’s t-test) in both MAS5.0 and dCHIP were retained for hierarchical 
clustering, functional and pathway analysis. 
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Functional and Pathway Analysis of Expression Profiles 
First, a two-dimensional cluster map was constructed using Genespring. Cluster 
gene lists were then uploaded into the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) (26), a web-accessible gene database provided by the 
National Institutes of Health (http://david.abcc.ncifcrf.gov). The functional classification 
tool in DAVID provides enrichment analysis and correction for multiple testing. For this 
study, the Benjamini and Hochberg false discovery rates (5% false positive discovery 
rate) was used. In DAVID, the magnitude of enrichment is represented as a fold-change 
such that the percentage of genes in the uploaded dataset belonging to a particular 
functional group is expressed as a ratio of the percentage of genes belonging to that 
functional group in the entire human genome. In the present study, functional groups 
passed filtering if they that not only reached statistical significance after multiple testing 
correction (p<0.05), but that also reached an enrichment level ≥ 1.5-fold as directed by 
Huange et al. (36).  
 Clusters which contained functional groups passing the filtering criteria were then 
uploaded into Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, Redwood City, 
CA) in order to identify canonical pathways that were altered by the 48h UL and 24h RL 
conditions. The significance of the association between the genes in each dataset and the 
canonical pathway was determined by using Fischer’s exact test to calculate a p-value 
determining the probability that the association between the genes in the dataset and the 
canonical pathway was explained by chance alone. Pathways were then ranked according 
to p-value. 
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RNA isolation and cDNA synthesis 
 Total mRNA was isolated using TRIZOL reagent (following manufacturer’s 
instructions) and quantified via spectrophotometry (Nanodrop, Wilmington, DE). Equal 
amounts of total RNA was synthesized into cDNA using a First-Strand cDNA Synthesis 
kit (Fermentas, Hanover, MD). ABgene Absolute qPCR SYBR Green  Master Mix 
(ABggene, Surrey, UK) with ROX dye was used for all PCR protocols. Forward and 
reverse primers (Integrated DNA Technologies, Coralville, IA) were designed using 
NCBI gene sequences with IDT DNA SciTools for all genes of interest (Table 3.2). 
Gene Expression Analysis via qRT-PCR 
Reactions were run in 96-well plates with all cDNA samples from each treatment 
condition run in triplicate for each gene of interest. Thus, each plate allowed me to 
analyze two genes of interest and one reference standard for all subjects at all time points 
as well as no-template controls in triplicate for both the gene of interest and the reference 
standard (Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)). The average Ct 
(comparative threshold) value for triplicate samples was be used for data analysis. Ct 
values were directly related to fluorescence of the respective SYBR-green probe after 40 
cycles of amplification on a MX3000p Real-Time PCR System (Stratagene, La Jolla, 
CA) available in the central Bioinformatics and Genomics Facility at the University of 
Massachusetts. At the end of each reaction, a melting curve analysis was run to identify 
possible primer dimmers. The results of the melting curve analysis were confirmed, and 
appropriate product size determined via 2% agarose gel electrophoresis with ethidium 
bromide staining. 
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Protein Quantification 
Protein was isolated using TRIZOL reagent (Invitrogen, Carlsbad, CA) and 
quantitated through measurement on a FLUostar plate reader (BMG Lab Technologies, 
Chapel Hill, NC) using NANO Orange reagent (. Target proteins were then quantified via 
Western blot analysis. Densitometry calculations of protein bands was used to compare 
changes in the relative amount of protein product between the 48h UL condition and 
baseline. 15ug of protein from each sample was loaded into 4-15% gradient sodium 
dodecyl sulfate (SDS) poly-acrylamide gels (Bio-Rad Laboratories, Hercules, CA) and 
separated by electrophoresis (60-90min@100v). Precision Plus Kaleidoscope Protein 
Standards (Bio-Rad Laboratories) was used as molecular weight markers for each gel.  
Following electrophoresis, proteins were transferred onto a polyvinylidene 
diflouride membrane (Millipore, Inc, Billerica, MA) at 100v for 3h. Membranes were then 
cut horizontally (based on the placement of the molecular weight markers) so that the 
membrane could be probed for both the protein of interest at one position in the lane and 
GAPDH. (In the case of HMOX1, which is of similar molecular weight to GAPDH, the 
membrane was stripped and reprobed). 
Each membrane was then blocked for 2h at room temperature with rocking 
motion in a solution of PBST containing 5% non-fat dry milk (Carnation, Nestle, Wilkes-
Barre, PA) and 0.1% Tween-20. The membrane was then washed (3X5 minutes each in 
1XPBST) and incubated incubated in primary antibody (HMOX1, atrogin1, or GAPDH), 
at the appropriate dilution (HMOX 1:1000, atrogin1  1:500, GAPDH 1:3500) with 
rocking motion overnight at 4 degrees.  The membrane was then washed (5X10 min each 
with 1XPBST) and incubated in the appropriate HRP-labeled secondary antibody for 1.5 
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hr, after which 4X10 washes in 1XPBST followed. Membranes were then treated for 2m 
with enhanced chemiluminescence (ECL) solution (GE Healthcare, Piscataway, NJ) in 
clear plastic sheet holders, and exposed to Kodak film for the appropriate duration. 
Antibodies for GAPDH (rabbit polyclonal) and HMOX1 (rabbit monoclonal) were 
obtained from Abcam (Abcam, Cambridge, MA), as were anti-rabbit, anti-mouse, and 
anti-goat secondary antibodies. The antibody against atrogin1 (goat polyclonal) was 
acquired from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Santa Cruz, CA) 
 Bands from each blot were scanned from the respective film using a Fotodyne 
Transilluminator (Hartland, WI) and quantified via densitometry using ImageJ software 
(NIH). To quantify protein products for each time point, densitometer values for protein 
bands in each condition were normalized to the densitometer value of the GAPDH 
protein band from the same sample. Although this is an arbitrary value (au), the 
calculated ratio identifies differences in protein product. 
Results 
Global Gene Expression 
 There were 1130 transcripts that were differentially expressed in this experiment 
(p < 0.05) with 48h UL and 24h RL conditions normalized to baseline.  To manage the 
large number of transcripts differentially expressed on the genechip, hierarchical 
clustering was performed, and 8 expression clusters were identified (Figure 3.1). In 
Figure 1, conditions (Baseline, 48h UL, 24h RL) are represented in the horizontal 
dimension, and gene trees (clusters) are represented in the vertical dimension. Red color 
intensity represents upregulation (higher mRNA levels), blue color intensity represents 
downregulation (lower mRNA levels), and yellow color intensity represents no change in 
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gene expression. 48h UL and 24h RL conditions were normalized to baseline, and 
therefore, the color intensity for the baseline condition in Figure 1 is yellow. As the 
figure illustrates, a large number of transcripts showed expression changes such that gene 
upregulation following 48h UL persisted following 24h RL, while conversely, a 
considerable number of genes showing downregulation following 48 UL continued to be 
downregulated following 24h RL.  
Functional Groups via DAVID 
Genes within each cluster were grouped by function using DAVID. Of the 8 
clusters identified through hierarchical clustering (Figure 1), only cluster 1 (n=579) and 
cluster 7 (n=241) contained functional groups that reach significance (p<0.05) after 
correcting multiple testing.  The changes in gene expression resulting from the short-term 
48h UL and 24h RL conditions were small compared to those found with 
pathophysiological muscular conditions (18, 67) or longer disuse perturbations (61) to 
muscle; the majority of the gene expression changes in this study ranged from 1.2 – 1.5-
fold up- or downregulated relative to baseline. Although the expression changes were 
modest with the subclinical intervention used in the current study, the majority of the p-
values for these transcripts were p<0.005. Table 3.3 summarizes the noteworthy 
functional groups for these two clusters.  
Genes in cluster 1 (Table 3.3) were upregulated. Over-represented groups were 
related to ubiquitin conjugation, post-translational modification, and mRNA metabolism 
and were enriched 180-330% in this dataset compared to the number of genes related to 
these functions in the human genome. Enrichment values ≥ 150% are generally 
considered biologically relevant (36). Because ubiquitin conjugation has consistently 
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been identified as an important component of disuse atrophy (13), members of the 
ubiquitin conjugation functional group from cluster 1 that met more stringent filtering 
criteria (±1.2-fold, p≤0.01) are listed in Table 3.4a. This functional group contained E2 
conjugating enzymes, E3 ligases (including atrogin1), ubiquitin-specific proteases, and 
other proteolytic mediators, suggesting an increase in the activity of the UPP.  
Interestingly, a number of the ubiquitin conjugation genes that were significantly 
upregulated following 48h UL were also upregulated following 24h RL; furthermore, the 
number of significantly upregulated transcripts almost doubled following 24h RL 
compared to the previous 48h UL (Table 3.4a).  
Genes in cluster 7 (Table 3.3) were downregulated, and functional groups 
identified via DAVID were largely related to mitochondrial function, energy metabolism, 
and catalytic activity. These groups were over-represented in the dataset 150-530% (for 
full list of cluster 7 genes in these functional groups, see Appendix B, Tables B4 – B6). 
Because disuse has been shown to lead to decreases in mitochondrial activity (17), genes 
in cluster 7 associated with the mitochondrion (±1.2-fold, p≤0.01) are listed in Table 
3.4b. These genes include those that encode proteins involved in mitochondrial 
metabolism—especially those related to aerobic metabolism. While the majority of 
upregulated ubiquitin conjugation genes in cluster 1 were upregulated both at 48h UL and 
24h RL, only 5 of the 29 downregulated mitochondrial genes were significantly altered at 
48h UL. The remaining genes in the functional group were not significantly altered until 
the subsequent 24h RL. 
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Canonical Pathways via IPA 
Clusters 1 and 7 were analyzed using IPA, and canonical pathways were 
identified. For cluster 1, 10 canonical pathways reached significance (p<0.05, Table 3.5). 
As expected, the top ranking pathway was the Protein ubiquitination pathway (p=0.0007) 
with 11 participating genes, followed by the NRF2-mediated Oxidative Stress Response 
Pathway (p=0.005) with 9 participating genes. Oxidative stress has been highlighted in 
the literature as a likely contributor to the initiation of muscle atrophy (reviewed in (66)), 
and genes from the dataset found in this canonical pathway included heme oxygenase-1 
(HMOX1), the gene with the most dramatic differential expression in the entire dataset 
(48h UL=15.4-fold, p=0.002; 24h RL=6.5-fold, p=0.007). Other upregulated pathways 
identified by IPA were related to inflammation (IL-8 and IL-10 pathways), vitamin D 
receptor activity (VDR/RXR activation), and glucocorticoid signaling.  
For cluster 7, 12 canonical pathways reached significance (p<0.05, Table 3.5). 
The top three canonical pathways identified in IPA for cluster 7 included the oxidative 
phosphorylation, ubiquinone biosynthesis, and the citrate cycle pathways (Table 5). 
These results were in agreement with the DAVID analysis which identified mRNA 
downregulation related to mitochondrial function and especially to electron transport and 
energy production (Table 3.4b). Consistent with the DAVID functional categories, IPA 
revealed a greater number of transcripts in these pathways reaching significance 
following 24h RL than following the previous 48h UL. 
Protein Synthesis 
Recent literature (76) has proposed that decreased protein synthesis plays an 
important role in the regulation of disuse muscle atrophy. Functional groups associated 
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with protein synthesis did not reach significance via DAVID or IPA. However, global 
screening, using search tools in NetAffx (http://www.affymetrix.com), did reveal that a 
previously identified key protein synthesis mediator, S6 kinase, 70kDa, polypeptide 1 
(S6K1) (28) was, indeed, differentially expressed in the current dataset. S6K1, a 
participant in mTOR-mediated cell growth, was significantly upregulated following 24h 
RL (1.3-fold; p=0.029). However, other genes in this muscle growth pathway, such as 
TORC1 and 4EBP1, were not differentially expressed. 
Gene Expression Confirmation 
Four genes were chosen for expression confirmation via qRT-PCR (Table 3.6). 
Among the transcripts in the dataset, HMOX1 was chosen for analysis because it showed 
the greatest expression changes via microarray following both 48h UL and 24h RL 
conditions (15.4 and 6.51 respectively). E3 ligase atrogin1 was chosen for confirmation 
because it has previously been found to be a key regulator of disuse atrophy in humans 
and in animals; a member of the ubiquitin conjugation functional group in the DAVID 
analysis in this study, atrogin1 was upregulated via microarray across conditions 
(UL=1.4, RL=1.3). Collagen type IV, alpha-3 (COL4A3), a subunit of collagen-IV 
(COL4), was also upregulated via microarray (UL=1.7, RL=1.3), which was surprising 
because the down-regulation of COL4 has been previously proposed as an early trigger of 
disuse atrophy (80). Therefore, COL4A3 was chosen for expression confirmation (Table 
7). Finally, because no probe-sets for E3 ligase MuRF1 existed on the U133 plus 2 Gene 
Chip, qRT-PCR was also performed for this gene, as it has been identified, along with 
atrogin1, as an important atrophy regulator. The qRT-PCR experiments verified that 
mRNA levels for HMOX1, atrogin1, and COL4 were significantly upregulated following 
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UL (Table 3.7) and that HMOX1 expression remained elevated following 24h RL. 
Consistent with previous findings in our laboratory, which showed no differential 
expression for MuRF1 following immobilization (80), there were no significant 
difference in MURF1 mRNA levels following either 48h UL or 24h RL compared to 
baseline (Table 7). 
Protein Quantification 
With limited protein available, protein products for only two of the genes 
confirmed via qRT-PCR were chosen for protein quantification: HMOX1 (Figure 3.2a) 
and atrogin1 (Figure 3.2b). Protein was not available for all subjects at all time points, but 
samples for 4 subjects were available at both baseline and 48h UL. There was a trend 
towards increased protein products for HMOX1 following 48h UL (Figure 3.2a, p=0.09) 
in agreement with the microarray and qRT-PCR data. Relative intensity of protein bands 
for HMOX1 increased for all 4 subjects (Figure 3.2b). There were no significant 
differences in protein products for atrogin1 48h UL relative to baseline 
(mean±S.E.=1.40±0.70, p=0.74). 
Discussion 
The major findings in this study were that: 1) of the upregulated genes, the most 
enriched functional group and highest ranked canonical pathway both were related to the 
UPP; 2) the oxidative stress response pathway was ranked second only to the protein 
ubiquitination pathway; 3) of the downregulated genes, the most enriched functional 
group and the three highest ranked canonical pathways were related to mitochondrial 
function—specifically to aerobic metabolism; and 4) general patterns showed differential 
gene expression in the same direction for both the 48h UL and 24h RL conditions with 
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greater numbers of significant changes following reloading. qRT-PCR confirmed 
upregulation of the UPP-related gene atrogin1 and oxidative stress-related gene HMOX1, 
while Western blotting showed a trend towards an increase in protein products for 
HMOX1. Furthermore, COL4 showed an increase in mRNA levels following 48h UL via 
microarray (which was confirmed through qRT-PCR). 
The Ubiquitin Proteasome Pathway (UPP) 
For cluster 1, which showed increased gene expression following both 48h UL 
and 24h RL (Figure 3.1), the most enriched functional group via DAVID, ubiquitin 
conjugation (Table 3.3) and highest ranked canonical pathway, protein ubiquitination 
(Table 3.5), were both related to the UPP. The UPP is the pathway by which proteins are 
tagged for destruction and then degraded by the proteasome. Increases in gene expression 
related to this pathway have been shown in both animal and human models of skeletal 
muscle atrophy. Differential expression at the very early time point of unloading (48h) in 
the current study is consistent with previous work in our laboratory showing changes in 
expression of UPP-related genes following 48h of immobilization (80) in which range of 
motion at the knee joint, but not load, was restricted. Furthermore, measurable increases 
in proteolysis have been shown as early as 72h post-ULLS (76); therefore, UPP gene 
expression with unloading, as found in the current study, may portend muscle catabolism 
and decreases in muscle size that have been found at later time points. 
The highest ranked pathway identified via IPA was the protein ubiquitination 
pathway with Uubiquitin specific peptidases (USPs) and Proteasome 26S subunit non-
ATPase 11 (PSMD11) mRNA increased following 48h UL (Table 3.5). USPs 
deubiquitinate (and therefore replenish) the ubiquitin pool in the cell and may play a role 
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in increasing ubiquitin availability during catabolic states such as immobilization in 
humans, as evidenced by previous work of Urso et al. (21, 80). PSMD11 is a gene that 
encodes for a subunit of the 26S proteasome, the catalytic complex that performs 
ubiquitin-dependent protein degradation; in previous work in our laboratory, it was found 
to be increased at both the mRNA and protein levels following spinal cord injury in 
humans (79). In the current study, USP-3, 32, and 34 were upregulated (Table 3.4a), as 
was PSMD11 (Table 3.5; FC=1.4, p=0.02), following 48h UL. These findings in the 
current study showed that increases in components necessary for protein degradation 
were in evidence in the first 48h of disuse. 
The high throughput analysis afforded by DAVID allowed us to identify 24 
differentially expressed genes associated with the UPP, 14 of which met the more 
stringent p<0.01 cut-off; these genes included E2 conjugating enzymes that attach 
ubiquitin to proteins, E3 ligases that deliver these proteins to the proteosome, and 
ubiquitin specific peptidases that recycle ubiquitin, among others. 
E3 Ligases 
There were five different E3 ligases that displayed increased mRNA levels via 
microarray in this study (Table 4a). atrogin1 was upregulated following 48h UL and 
subsequent 24h RL via microarray (Table 3.4a), with the 48h UL increase confirmed 
through qRT-PCR (Table 3.7). Atrogin1 has been shown to be located at the Z-line of the 
sarcomere (53), and therefore, likely targets sarcomeric proteins such as contractile 
filaments actin and myosin. It was also recently found to target important growth 
regulators myoD (77) and calcineurin (53). Furthermore, data of Urso et al. (79) 
suggested that atrogin1 may target sarcolemmal proteins such as dystrophin, which 
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anchors and secures myofibular proteins to the cell membrane. atrogin1 has been found to 
be upregulated with disuse atrophy in animals (13) and in humans 5d (17) and 12d (40) 
post-immobilization and as early as 48h post-spinal cord injury (79), so it was not 
surprising to see similar results following 48h UL in the current study.  
However, these findings were in disagreement with previous work in our 
laboratory, which found significant increases in atrogin1 via microarray analysis (1.79-
fold, p = 0.02; unpublished) following 48h immobilization, but no significant differences 
when measured with the more sensitive qRT-PCR (80).  Furthermore, in the current 
study, protein quantification via Western blot revealed no significant differences in 
protein products for atrogin1 following 48h UL. It has been suggested that atrogin1 
expression is controlled at the translational level, and that the level of expression is 
dependent on the magnitude and duration of the disuse stimulus (51). It is also possible 
that the Western blot was not sensitive enough to detect small changes in protein levels. 
In a study by Urso et al. (79), which measured mRNA and protein levels 2d and 5d post-
spinal cord injury, atrogin1 mRNA levels were increased, but protein levels were not. It 
was proposed that because atrogin1 is a key player in the atrophy process, this E3 ligase 
is tightly controlled on the translational level so as to prevent active atrophy following 
transient periods of disuse. The findings from the current study support this assertion. 
MuRF1 not measured via microarray in this study. Because this E3 ligase has 
been identified in animals as an important regulator of the atrophy process, we measured 
mRNA levels via qRT-PCR, but found no significant differences for expression of this 
gene (Table 3.7). This was in agreement with findings of Urso et al. (80) who reported no 
significant differences in MuRF1 gene expression following 48h immobilization in 
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humans. Previous work in mice found MuRF1, along with atrogin1, to be an important 
regulator of atrophy following immobilization and unloading in rat muscle (13, 45), and 
MuRF1 knock-out mice exhibited attenuated rates of atrophy (13).  Although MuRF1 
gene expression was recently shown to be upregulated in humans following 
immobilization (24), significant increases in MuRF1 mRNA were not detected until 10d 
post-immobilization. The lack of increased gene expression of MuRF1 following 48h UL 
in the current study suggests that if MuRF1 is a key regulator of atrophy in humans, its 
increase in gene expression follows a later time-course than atrogin1.  
Additional E3 ligases were identified as members of cluster 1 (Table 3.4a). 
Several of them are of particular interest because of their apparent functions. Activity of 
SMAD-specific E3 Ubiquitin Protein Ligase 2 (SMURF2) has been found to decrease 
bone (42) and also to decrease AKT signaling (62), which could potentially promote 
muscle wasting. Ring Finger Protein 19 (RNF19, aka Dorfin) is an E3 ligase that has 
been shown to be increased in neurodegenerative diseases such as ALS and localized to 
inclusions containing misfolded proteins (6, 35, 60); its activity is facilitated by Vatosin 
Containing Protein (VCP), which was also upregulated in this dataset (Table 3.4a) (38). It 
has been proposed that remodeling of the neuromuscular junction may be an important 
component of disuse muscle atrophy (68). The fact that increases in RNF19 and VCP 
mRNA in the current study reached significance following reloading suggests that 
increased transcription of the E3 ligase and its facilitator may have been induced after the 
disuse stimulus was removed, potentially to aid in the removal of damaged protein.  In 
fact, although the roles of E3 ligases following short term unloading and reloading are 
unclear, what was interesting in the current study was that E3 ligases upregulated 
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following 48h UL largely remained upregulated following subsequent 24h RL (Table 
3.4a).   
E2 Conjugating Enzymes 
Ubiquitin conjugating enzymes (UBEs) in cluster 1 included UBE2D2, UBE2E2, 
and UBE2G1 (Table 3.4a).  Two of these enzymes (UBE2D2 and UBE2E2) were only 
significantly upregulated following 24h RL, while the latter (UBE2G1) was significantly 
upregulated across both time points. UBE2G1 is a UBC7 homologue (82) that has been 
found to be associated with dexamethasone-induced skeletal muscle wasting (19) and 
cardiac cachexia (72) in rats. The two UBEs showing significant upregulation at only the 
24h reloading time point have both been associated with the degradation of apoptosis- 
and catabolism-inducing proteins. UBE2D2 interacts with E3 ligase Mouse Double 
Minute-2 Human Homolog (69) to selectively target p53 for degradation. In healthy 
muscle, p53 is largely inactive; however, following the introduction of stressful stimuli 
including oxidative stress, p53 becomes activated and can induce apoptosis. In fact, 
increases in p53 activity have been found to be associated with apoptosis following 
atrophic stimuli (70-71). UBE2E2 is a UBE about which little is known, although yeast-
two-hybrid experiments have shown that it interacts with RNF8, a ring-finger E3 ligase 
(39).  Increases in UBE2D2 and following reloading may act to reverse proapoptotic and 
procatablic molecular events occurring during the previous 48h unloading. 
Oxidative Stress Response 
 The canonical pathway, NRF2-mediate Oxidative Stress Response, was ranked 
second only to the Protein ubiquitination pathway for cluster 1 in IPA (Table 3.5). 
Increases in molecules with purported antioxidant capabilities in this pathway 
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accompanied both the 48h UL and 24h RL conditions, suggesting that oxidative stress 
accompanied these conditions and that compensatory transcription may have occurred in 
an attempt to offset the effects of this cellular assault. The gene with the greatest increase 
in expression via microarray (confirmed through qRT-PCR (Table 3.7) and also via 
Western blot (Figures 2A, 2B) was HMOX1, a component of this pathway.  
Oxidative stress has been implicated as a potential contributor in the initiation of 
disuse atrophy. Accumulation of reactive oxygen species (ROS) has been proposed to 
initiate a cascade of events leading to the release of actomyosin complexes from 
sarcomeres of skeletal muscle fibers with disuse (66). Cellular increases in ROS are 
accompanied by increases in stress response molecules which have the role of 
neutralizing ROS and other reactive molecules, such as reactive iron, and maintaining 
REDOX balance. Therefore, it is not surprising that increases in stress response proteins 
following atrophy stimuli have often been observed in animals (37, 41, 50, 73). HMOX1 
is one such molecule (29, 37). HMOX1 mRNA has been consistently shown to be 
increased following skeletal disuse in animals (37, 41, 50, 73), and work in our laboratory 
has shown that HMOX1 mRNA increases following spinal cord injury in humans (Urso 
et al., unpublished), HMOX1 may provide a protective mechanism in addition to its 
catalytic activity in heme breakdown. It has been shown HMOX1 to activate AKT (56), 
and therefore may decrease FOXO transcription factor activity. In addition, increases in 
HMOX1 transcription has been shown to lead to increases in ferritin, which functions to 
binding reactive iron (74), and therefore may serve an antioxidant function.  
To provide evidence to support the hypothesis that HMOX1 expression increases 
antioxidant activity, McClung et al. (57) recently restored redox balance during disuse 
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(mechanical ventilation) in mice via treatment with hemin, a potent HMOX1 inducer. In 
the current study, the increase in HMOX1 transcripts across both time points (48h UL 
and 24h RL) was likely a protective strategy in response to oxidative stress associated 
with these conditions. The relationship between HMOX1 expression and proteolysis has 
not been established, however.  
 Additional member genes of the NRF2-mediate oxidative stress response pathway 
that were upregulated in this dataset were heat shock proteins (HSPs) such as HSPB8 and 
DNAJ subfamily B and C (Table 3.7).  DNAJ proteins are chaperones that interact with 
HSPs, such as HSP70 (46), and the genes which encode them have been shown (32, 49, 
63-64) to both increase and decrease following disuse stimuli, as well as following 
reloading In fact, in addition to these DNAJ proteins that were upregulated in the current 
study, cluster 7 (which contained downregulated genes) also included DNAJ encoding 
genes reaching significance during reloading (Table 3.4b). Their role during these 
conditions is not clear.  
HSPB8 is a member of the superfamily of small HSPs (sHSP) and has been 
shown to exert cytoprotective and anti-apoptotic effects following insults to muscle tissue 
such as ischemic/reperfusion injury (48). Although little is known about this newly 
discovered sHSP, a loss of function mutation in the gene has been associated with the 
neurodegenerative disorder, Charcot-Marie-Tooth disease type 2Lc (48) . Conversely, 
over-expression of HSPB8 has been associated with hypertrophy in cardiac muscle cells 
(44). Although the mechanism by which HSPB8 exerts its effects is unknown, it is 
possible that in the current study, sub-clinical levels of oxidative stress resulting from 
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unloading and reloading conditions led to compensatory increases in HSPB8 mRNA 
levels. 
Mitochondrial Metabolism 
 Cluster 7 contained genes showing downregulation at both time points. The most 
significantly altered functional group in this cluster was related to mitochondrial function 
(Table 3.3), and the majority of genes in this group did not reach significance until the 
24h RL condition (Table 3.4b), though decreases in transcription of genes associated with 
aerobic metabolism and cell growth were in evidence following 48h UL. 
 Genes that encode enzymes participating in oxidative phosphorylation have been 
shown to be decreased following multiple models of disuse in animals (50) and humans 
(17).  The current study found that aerobic enzymes were downregulated at both 48h UL 
and 24h RL. Although genes encoding NADH dehydrogenase and coenzymeQ, have 
been previously shown to be downregulated with disuse in animals and in humans, this is 
the first study to show these alterations (Table 3.4b) as early as 48h following the 
initiation of the disuse stimulus in humans. Following prolonged disuse, muscle fatigue is 
increased and a shift from slow to fast twitch fibers has been reported preceded by 
decreases in oxidative phosphorylation (75). In the current study, the oxidative 
phosphorylation pathway was the top ranked downregulated pathway via IPA (Table 
3.5). Furthermore, not only did these genes continue to show downregulation following 
24h RL, but the number of oxidative phosphorylation genes showing significant 
downregulation increased at this time point (Table 3.4b, Table 3.5). The alterations in 
expression of mitochondrial metabolism genes following 48h UL not only failed to 
reverse upon reloading (24h RL), but the downregulation extended to additional genes in 
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the category. Although the cause for this is unknown, it is important to note because it 
illustrates that effects of inactivity may continue even after short-term disuse ceases. 
Furthermore, the current study found decreases in transcription of enzymes 
participating in the citric acid cycle. For example, dihydrolipoamide s-acetyltransferase 
(DLAT), which codes for a subunit of the pyruvate dehydrogenase complex (PDC) in the 
inner mitochondrial membrane was downregulated following 24h RL (Table 3.4b). This 
enzyme converts pyruvate into acetyl co-A, the rate limiting step in carbohydrate 
oxidation. Following 4wk of immobilization in humans (81), the activity of this complex 
was significantly decreased compared to control. Furthermore, genes encoding 
components of this complex were downregulated in atrophy models associated with four 
disease states (cancer cachexia, diabetes, fasting, and uremia (50)). It has been proposed 
that decreases in carbohydrate oxidation are regulated by the same pathway regulating 
protein degradation (AKT-FOXO pathway) (23) as FOXO transcribes PDC inhibitors 
(15), though these inhibitors were not upregulated in the current study. In fact, protein 
phosphatase 2C magnesium-dependent catalytic subunit (PPM2C), which codes for a 
protein that believed to activate the PDC, was downregulated (Table 3.4b). It is unclear 
how this pattern of PPM2C expression contributes to regulation of carbohydrate 
oxidation following disuse and reloading.   
While the majority of downregulated genes related to mitochondrial metabolism 
did not reach statistical significance until 24h RL, there were genes related to oxidative 
phosphorylation downregulated immediately following 48h UL. Two genes that encode 
for key components of the electron transport chain (i.e., COQ3 and NDUFS4) were 
downregulated, as was Monoamine Oxidase B (MAOB), a deanimating enzyme. 
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Decreases in mRNA transcription or deficiency of protein products of these genes have 
been associated with muscle abnormalities such as mitochondrial myopathy (47), 
Duchene muscular dystrophy (65), and Leigh-like syndrome (16). This suggests that UL 
disuse may involve changes in metabolic transcription associated with (if not 
compromised) decreased muscle function. These changes could be set in motion as early 
as 48h post-UL; following 24RL, these transcripts remained decreased (compared to 
baseline) showing that the downregulation of these genes were not immediately reversed. 
Extracellular Matrix Remodeling 
 An interesting finding in this study was that a component of COL4 (encoding for 
collagen protein) was upregulated via microarray and qRT-PCR (Table 3.6), in contrast 
to previous studies that consistently found downregulation of collagen proteins with 
disuse, including previous work in our laboratory (80). COL4 genes encode for multiple 
subunits of the most abundant ECM collagen protein, and it has been suggested that a 
decrease in this collagen and others following disuse lead to both a decrease in the 
integrity of the ECM (80) as well as an increase in the intracellular signaling that 
regulates protein degradation (4-5). In the current study, the increase in transcripts of 
COL4A3, which encodes for a subunit of COL4, may, ironically, be related to proteolysis 
of the ECM, apoptosis, and decreases in protein synthesis. Tumstatin is a protein derived 
from COL4A3 that has been shown to function as an inhibitor of endothelial cell 
proliferation and a promoter of apoptosis (59). The mechanism by which tumstatin exerts 
its effects is mediated by the AKT/mTOR pathway and leads to protein synthesis 
inhibition (55). COL4A3 has been consistently detected in skeletal muscle tissue, 
although the effects of increased tumstatin in this tissue have not been studied. However, 
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function of this α4 fragment is dependent on cleavage of the subunit from COL4 protein 
and then proteolysis of COL4, thus potentially leading to its increased COL4A3 
transcription in the current study. Finally, while previous work in our laboratory has 
shown that COL4A3 is increased with 48h immobilization in humans (80), investigation 
of muscle biopsies following 48h spinal cord injury has shown 2-fold downregulation of 
this transcript (Urso, et al.) in agreement with the UL results. Therefore, it is possible that 
transcription of this gene is not only regulated by disuse, but may differ among disuse 
models. 
Conclusions 
Microarray technology and high through-put software tools have allowed us to 
examine not only the global patterns of gene expression associated with short-term UL 
and RL, but also the biological significance of these changes.  The results of this study 
suggest that alterations in gene expression associated with atrophy-related functions such 
as protein degradation and oxidative stress following UL as previously found in the 
literature (17, 40, 61), may occur as early as 48h following the introduction of the UL 
stimulus, though increased magnitude or duration of that stimulus may be necessary in 
order for translation of protein products to occur. Furthermore, while increases in 
proteolytic gene expression found in this study suggest that there are similarities between 
expression patterns following 48h UL and IM, differences likely exist between the two 
disuse models as evidenced by decreases in collagen found with UL.  Prior to this study, 
HMOX1 had emerged as a potential regulator following UL in animals (37, 41, 50, 73), 
and the current study extends this important finding to humans.  Finally, the gene 
expression patterns with UL were not readily reversed upon RE, suggesting that 
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molecular responses to short-term periods of skeletal muscle inactivity in humans may 
persist even after activity resumes. Future studies could employ these high through-put 
technologies to examine the effects of targeted interventions on expression of genes in 
pathways and functional groups identified in the current study and shed light on how 
atrophy could be prevented or attenuated in the earliest stages of disuse. 
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Table 3.1: Subject demographics (n=7). 
 Mean±S.D. 
Age (y) 
 
22.1±3.7 
Height (m) 
 
1.4±0.1 
Weight (kg) 78.2±3.1 
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Table 3.2 qRT-PCR primers. 
Gene 
Symbol Forward Primer Reverse Primer 
Atrogin1 5’-TCA CAG CTC ACA TCC CTG AG-3’ 5’-TCA CAG CTC ACA TCC CTG AG-3’ 
COL4A3 5'-GTT CTC TGT GGC AAA GCA GCA ACT-3' 5'-ACA ATC ACC GTA GTG ACA GTG CCT-3' 
HMOX1 5’-ATT GCC AGT GCC ACC AAG TTC AAG-3' 5'-ACG CAG TCT TGG CCT CTT CTA TCA-3' 
MuRF1 5’-TGA GCC AGA AGT TTG ACA CG-3’ 5’-TGA TGA GTT GCT TGG CAG TC-3’ 
GAPDH 5'-CAT TGC CCT CAA CGA CCA CTT TGT-3' 5'-TCT CTC TCT TCC TCT TGT GCT CTT GC-3' 
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Table 3.3. Over-represented functional annotations for clusters 1 and 7.  
Count=# of genes in category; fold enrichment=magnitude of over-representation in data 
set; adjusted p-value= Benjamini and Hochberg multiple testing correction.  
Functional annotations are listed in order of p-value. 
Functional Annotation Category Count 
Fold 
Enrichment 
Adjusted 
p-value 
Cluster 1    
Ubiquitin Conjugation 23 3.3 2.00E-05 
Post-translational Modification 64 1.8 3.00E-04 
mRNA Metabolism 21 3.1 6.70E-03 
    
Cluster 7    
Mitochondrion 56 5.3 9.80E-23 
Catalytic Activity 87 1.5 1.20E-02 
Generation of precursor metabolites and energy 21 3.1 3.90E-02 
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Table 3.4a. Cluster 1 Up-regulated genes associated with ubiquitin conjugation 
UL=unloading; RL=reloading; aE2 ligase, bE3 ligase, cubiquitin protease; all fold-
changes significantly different from baseline, p<0.05; NS = Not significant. 
Affymetrix 
Accession 
Gene 
Symbol Gene Title 
48h 
UL 
24h  
RL 
213295_at CYLD cylindromatosis (turban tumor syndrome) 1.3 1.3 
209943_at FBXL4b F-box and leucine-rich repeat protein 4 1.4 1.3 
225345_s_at FBXO32b F-box protein 32 (Atrogin1) 1.7 1.6 
203068_at KLHL21 kelch-like 21 (Drosophila) 1.3 1.5 
242712_x_at RANBP2 RAN binding protein 2 1.2 1.4 
228980_at RFFLb Rififylin (ring finger) NS 1.5 
230599_at RNF19b Ring finger protein 19 (dorfin) 1.1 1.3 
205596_s_at SMURF2b SMAD specific E3 ubiquitin protein ligase 2 NS 1.3 
209142_s_at UBE2D2a ubiquitin-conjugating enzyme E2D 1  NS 1.6 
224747_at UBE2E2 a ubiquitin-conjugating enzyme E2E 1  NS 1.3 
236107_at UBE2G1 a ubiquitin-conjugating enzyme E2G 1  1.2 1.2 
221654_s_at USP3 c ubiquitin specific peptidase 3 1.2 1.3 
226505_x_at USP32 c  ubiquitin specific peptidase 32 1.2 1.3 
233595_at USP34 c ubiquitin specific peptidase 34 NS 1.3 
208648_at VCP valosin-containing protein NS 1.3 
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Table 3.4b. Cluster 7 Down-regulated genes associated with mitochondrial function. 
Expression (fold-change) relative to baseline. All reported fold-changes significant at 
p<0.05. UL=unloading; RL=reloading; NS=Not significant. 
Affymetrix 
Accession  
Gene  
Symbol Gene Title 
48h 
UL 
24h 
RL 
204824_at ENDOG endonuclease G NS -1.2 
224509_s_at RTN4IP1 reticulon 4 interacting protein 1 (aka NIMP)  -1.3 -1.4 
211662_s_at VDAC2 voltage-dependent anion channel 2 NS -1.2 
   
213379_at COQ2 coenzyme Q2 homolog, prenyltransferase (yeast) NS -1.2 
223515_s_at COQ3 coenzyme Q3 homolog, methyltransferase (S. cerevisiae) -1.3 -1.4 
225747_at COQ10A coenzyme Q10 homolog A (S. cerevisiae) NS -1.4 
203858_s_at COX10 COX10 homolog, cytochrome c oxidase assembly protein NS -1.2 
202447_at DECR1 2,4-dienoyl CoA reductase 1, mitochondrial NS -1.2 
239161_at FDX1 ferredoxin 1 NS -1.4 
204041_at MAOB monoamine oxidase B -1.2 -1.4 
203745_at HCCS holocytochrome c synthase (cytochrome c heme-lyase) -1.2 -1.3 
209303_at NDUFS4 NADH dehydrogenase (ubiquinone) Fe-S protein 4 -1.2 -1.2 
218160_at NDUFA8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8 NS -1.3 
208969_at NDUFA9 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9 NS -1.2 
219195_at PPARGC1A  
peroxisome proliferative activated receptor, gamma, coactivator 1 
alpha   NS -1.4 
   
226154_at DNM1L dynamin 1-like NS -1.2 
218246_at MUL1 mitochondrial ubiquitin ligase activator of NFKB 1 NS -1.2 
   
215792_s_at DNAJC11 DnaJ (Hsp40) homolog, subfamily C, member 11 NS -1.2 
225358_at DNAJC19 DnaJ (Hsp40) homolog, subfamily C, member 19 NS -1.2 
211538_s_at HSPA2 heat shock 70kDa protein 2 NS -1.2 
  TCA Cycle 
222572_at PPM2C protein phosphatase 2C, magnesium-dependent, catalytic subunit NS -1.5 
213149_at DLAT dihydrolipoamide S-acetyltransferase NS -1.3 
   
  Transporter Activity 
203339_at SLC25A12 solute carrier family 25 (mitochondrial carrier, Aralar), member 12 NS -1.2 
227012_at SLC25A40 solute carrier family 25, member 40 NS -1.3 
226059_at TOMM40L 
translocase of outer mitochondrial membrane 40 homolog (yeast)-
like NS -1.6 
   
  Miscellaneous and Unknown 
221069_s_at CCDC44 coiled-coil domain containing 44 NS -1.2 
224415_s_at HINT2 histidine triad nucleotide binding protein 2 NS -1.3 
223154_at MRPL1 mitochondrial ribosomal protein L1 NS -1.2 
56197_at PLSCR3 phospholipid scramblase 3 NS -1.2 
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Table 3.5. Ingenuity canonical pathways associated with clusters 1 (upregulated) and 
cluster 7 (downregulated) genes. Pathways listed in order of p-value. UL=unloading; 
RL=reloading.   
Canonical Pathways p-value 48h UL Genes 24h RL Genes 
CLUSTER 1 (Upregulated) 
Protein Ubiquitination 7.28E-04 PSMD11, UBE2G1, USP3, 
USP32, USP53 
B2M, SMURF2, UBE2G1, UBE4A, 
USP3, USP6, USP32, USP34, USP38, 
USP53 
 
NRF2-mediate Oxidative Stress 
Response 
5.37E-03 ACTG1, HMOX1, HSPB8 
 
 
CREBBP, DNAJB14, DNAJC16, 
FTL, HMOX1, HSPB8, PRKCI, VCP 
 
VDR/RXR Activation 1.60E-02 CEBPB, YY1 
 
NCOA3, PRKCI, SP1 
 
TGF-β Signaling 1.77E-02 SMAD4, TGIF1 
 
CREBBP, SMAD4, SMURF2, SOS1 
 
Estrogen Receptor Signaling 1.94E-02 TAF12 CDK7, CREBBP, HNRNPD, 
NCOA3, SOS1,  
TAF12 
Mechanism of Viral Exit from 
Host Cell 
2.77E-02 ACTG1 PRKCI, SH3GLB1 
IL-10 Signaling 3.05E-02 ARG2, HMOX1,  ARG2, HMOX1, MAP4K4, SP1 
Wnt/β-Catenin Signaling 3.07E-02 GJA1, SOX4, SOX13, CREBBP, CSNK1A1, FZD5, GJA1, 
TGFBR3 
Il-8 Signaling 4.09E-02 ANGPT2, HMOX1, IRAK3, 
RHOQ 
BCL2, HMOX1, MAP4K4, PRKC1, 
RHOQ 
Glucocorticoid Signaling 4.49E-02 CEBPB, SMAD4, TAF12,  BCL2, CDK7, CREBBP, NCOA3, 
NFATC3, SMAD4, SOS1, TAF12 
Oxidative Phosphorylation 5.17E-04 ATP5G3, NDUFS4 COX10, COX7A2, NDUFA8, 
NDUFA9, NDUFC1, UCRC 
 
CLUSTER 7 (Downregulated)  
Ubiquinone Biosynthesis 1.88E-04 COQ3, NDUFS4 NDUFA8, NDUFA9, NDUFC1 
Citrate Cycle 3.48E-04 ATP5G3 DLST, IDH1, MDH1 
Mitochondrial Dysfunction 2.07E-03 MAOB, NDUFS4 COX10, COX7A2, NDUFA8, 
NDUFA9 
Arginine and Proline 
Metabolism 
7.29E-03 MAOB CKB, GOT1 
TR/RXR Activation 1.52E-02 NCOR2, PPARGC1A, SLC16A3 NCOA4 
Tyrosine Metabolism 2.30E-02 MAOB GOT1, TYRP1 
Pyruvate Metabolism 3.53E-02  ACSL3, DLAT, MDH1 
Xenobiotic Metabolism 
Signaling 
3.60E-02 MAOB, NCOR2, PPARGC1A CUL3, NDST1, PP2R3A 
PXR/RXR Activation 3.68E-02 ALAS1, PPARGC1A ALAS1, PPARA 
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Table 3.6. qRT PCR results. All fold-changes relative to baseline significant at p<0.05. 
UL=unloading; RL = reloading; NS=not significant. 
 
Microarray qRT-PCR 
48h UL 24h RL 48h UL 24h RL 
Atrogin1 
 
1.7 
 
1.6 
 
1.4 
(p=0.01) 
NS 
 
COL4A3 
 
1.7 
 
1.4 
 
1.8 
(p<0.01) 
NS 
 
HMOX1 
 
15.4 
 
6.5 
 
12.7 
(p=0.01) 
NS 
 
MURF1 
 
NS 
 
1.5 
 
NS 
 
NS 
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Figure 3.1. Gene clustering. Unloading and reloading normalized to baseline. Yellow=no change, 
Red=upregulated, Blue=downregulated. Clusters are numbered 1 – 8. 
MAS5-PCL-2P...
Time Point 0h 
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Time Point 72h 
1
2 3
4
6 75 8
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Figure 3.2a. HMOX protein levels via Western blot. 
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Figure 3.2b. HMOX protein by individual subject. C= control; UL=48h unloading. 
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CHAPTER IV 
GLOBAL GENE EXPRESSION ANALYSIS OF HUMAN SKELETAL MUSCLE 
TWO DAYS POST-IMMOBILIZATION, -UNLOADING,  
AND -SPINAL CORD INJURY  
Abstract 
PURPOSE: Prolonged skeletal muscle disuse with immobilization (IM), spinal cord 
injury (SCI) and unloading (UL), results in decreased muscle size and function. 
Identifying universal mechanisms associated with early stages of disuse may lead to the 
development of interventions to attenuate these deleterious effects. The purpose of this 
study was to identify molecular markers following 48h of disuse (IM, SCI, and UL) 
common to these three conditions. METHODS: Microarray technology was used to 
measure global gene expression in biopsy samples collected 48h following IM, SCI, and 
UL from the vastus lateralis of male volunteers. Enriched functions were identified 
within the datasets using the Database for Annotations, Visualization and Integrated 
Discovery (DAVID), and significant canonical pathways and gene networks were 
identified using Ingenuity Pathway Analysis (IPA). RESULTS: Between 636 and 1602 
transcripts were differentially expressed within each dataset, with all three models of 
disuse sharing 32 commonly expressed genes. Functions of of these shared genes 
included transcription, protein degradation, chaperone/protein-folding, and 
metallotheioniens, among others. When the functional and pathway analysis was 
expanded to include all differentially expressed genes in each dataset, further expression 
pattern similarities among the disuse models were discovered including the enrichment of 
the protein degradation functional group and the oxidative stress response pathway. 
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CONCLUSIONS: Although only a small subset of differentially expressed genes were 
common to skeletal muscle response to 48h IM, SCI, and UL, functions of protein 
degradation and oxidative stress were statistically over-represented in all the models, 
suggesting that these molecular mechanisms are likely key regulators in the early stages 
of disuse, regardless of the specific stimulus. 
Introduction 
Disuse muscle atrophy occurs in response to immobilization (IM) (37, 63), 
unloading (UL) (2, 5-6), bed rest (7-8, 53), spaceflight (2, 60-61), and spinal cord injury 
(SCI) (13, 31, 57, 62). Although studies in humans have documented the effects of disuse 
on skeletal muscle structure and function (5-6, 9, 18-20, 26, 31, 33, 36, 38, 51, 57), the 
underlying mechanisms regulating these changes are not well understood. Investigations 
of multiple forms of disuse in animals have shown that there is a coordinated alteration in 
expression of genes encoding for proteins that function in the initiation of the muscle 
atrophy process. Mechanisms identified in these studies have included increases in gene 
expression related to protein degradation and stress response as well as decreases in gene 
expression related to transcription and translation, energy metabolism, and extracellular 
matrix proteins (44).  
Of the few studies that have been undertaken in humans (14, 37, 63), our 
laboratory (62-63) reported that differential gene expression is evident as early as 48h 
following disuse via IM and SCI; these results suggested that the molecular changes 
ultimately leading to atrophy associated with later time points (e.g., weeks and months), 
may be initiated in the first few days—before measurable decreases in size or strength 
have manifested.  However, while gene expression and related protein products of 
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individual molecules have been investigated following 48h IM and SCI (62-63), the 
global gene expression patterns in these disuse models have not been studied or 
compared to one another. Recent data collected in our laboratory following 48h UL 
afforded me the unique opportunity to compare gene expression profiles of these three 
common models of disuse by analyzing microarray datasets from the UL experiment to 
those of 48h IM and SCI (data from the latter two studies have been published elsewhere 
(62-63)). 
Molecular signaling leading to disuse atrophy is likely a complex sequence of 
events that involve numerous interrelated pathways. Systems biology is an emerging 
discipline that focuses on the relationships between multiple cellular components (25). 
Microarray technology provides the means to measure expression levels of thousands of 
genes at once, and analysis tools have been developed to analyze the expression patterns 
of these high through-put experiments. The Database for Annotation, Visualization and 
Integrated Discovery (DAVID) and Ingenuity Pathway Analysis (IPA) use results from 
microarray experiments to identify functions and pathways as well as to construct 
potential gene networks associated with the gene expression patterns revealed via 
microarray.  
Employing this technology to interpret gene expression results may lead to a 
better understanding of functions and pathways universal to IM, SCI, and UL in humans. 
Furthermore, studying global gene expression patterns at the early time-point of 48h of 
disuse (before any measurable atrophy has occurred) may lead to the identification of 
molecules and pathways for therapeutic targets to prevent or attenuate disuse-associated 
atrophy.  
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Methods 
Subjects 
Seven (n=7) sedentary men completed the UL study. Mean (±S.D.) age, height, 
and weight were 22.1 (3.7) yr, 1.4 (0.1) m, and 78.2 (3.1) kg, respectively. Those with 
bleeding problems, known allergies to Lidocaine, orthopedic problems, or use of 
medications that could increase bleeding (such as aspirin) were excluded from the study, 
as were individuals who are taking muscle building supplements or restricting caloric 
intake. All subjects signed an informed consent form approved by the University of 
Massachusetts and Hartford Hospital Review Boards and completed a medical history 
questionnaire and physical activity questionnaire before being enrolled in the study to 
insure they met the inclusion/exclusion criteria. In addition, each potential subject was 
carefully screened to ensure that he was aware of the inconvenience inherent in the 
unloading protocol, understood the potential discomfort from the biopsy procedure, and 
the felt confident that he could comply with all study requirements. Subjects (n=5) for the 
IM study were recruited using similar inclusion/exclusion criteria (63) while subjects 
(n=10) for the SCI study were recruited within 48h of their injury and were over the age 
of 18 (62).  
Disuse Protocols 
 Lower limb unloading (UL) was achieved using the ULLS model which required 
that subjects wear a shoe with a 10-cm sole (Kintec Footlabs, Surrey, BC) on the right 
foot. The left foot did not have contact with the ground; therefore, the left lower limb was 
unloaded for the duration of the 48h UL protocol. All ambulatory activity was performed 
on crutches with only the right foot having contact with the ground. Although the UL leg 
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was free to move, no load was placed on it, and any physical activity requiring use of the 
left quadriceps muscles was restricted. Berg et al. (5) and others (3, 16, 32) have used this 
ULLS model up to 6 wk. Compliance during the UL phase of the current study was 
confirmed through the use of activity monitors (Model #7164 Computer Science and 
Applications, Inc., Shalimar FL) worn on both ankles, which showed a 29% - 35% 
reduction in acceleration in the unloaded leg compared to the loaded leg. IM and SCI 
protocols are published elsewhere (62-63). In brief, the IM protocol was similar to the UL 
protocol with the exception that immobilization was achieved through the use of a long-
leg cast which was secured with fiberglass casting tape to ensure compliance.  
Data Collection 
Biopsies were collected at baseline and 48h post-disuse (in the case of the UL and 
IM conditions). All biopsy procedures for these two conditions were conducted at 
Hartford Hospital and were taken at the same time of day to reduce circadian influences. 
Subjects were fed a standardized meal 3h prior to each biopsy because meal patterns alter 
the activity of certain genes related to muscle atrophy and hypertrophy (21). In the case 
of the SCI condition, biopsies were collected 48h post-SCI. Percutaneous needle muscle 
biopsies were obtained using a Bergstrom 5-mm biopsy needle (Depuy, Warsaw, IN) in a 
sterile field. First, skin was lightly anesthetized with 2% lidocaine hydrochloride solution. 
Next, a small (5-6mm) incision was made through the skin and muscle fascia, and the 
biopsy needle was inserted. Up to 150mg of tissue was removed and divided into 3 
aliquots (up to 50mg each). Biopsy samples were immediately snap-frozen in liquid 
nitrogen upon excision. All samples were stored at -80 C until analysis.  
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Gene Expression Profiling 
The microarray data for this study were acquired from previous studies in our 
laboratory, the results of which have been published elsewhere (62-63), and from Study I 
of this dissertation. Affymetrix Human Genome U133 Plus 2.0 microarrays for analysis 
of over 47,000 transcripts were used for this study. The procedures including total RNA 
isolation, cDNA synthesis, cRNA labeling, microarray hybridization and image acquiring 
was done as described previously (15). Briefly, total RNA isolated with TRIzol reagent 
and purified with RNeasy MinElute Cleanup Kit (Qiagen, Valencia, CA).  Three 
microgram of total RNA from each sample were converted into double-stranded cDNA 
then cRNA using one-cycle target labeling and control reagents and protocol 
(Affymetrix, Santa Clara, CA). After purification using GeneChip® Sample Cleanup 
Module (Affymetrix, Santa Clara, CA), biotin-labeled cRNA was then fragmented 
randomly prior to hybridizing to the microarrays. Each array was washed and stained on 
the Affymetrix Fluidics Station 450, and then probe arrays were scanned via the 
GeneChip® Scanner 3000.  The quality control criteria developed at Children’s National 
Medical Center Microarray Center for each array were followed (1, 15). 
Absolute analysis of Affymetrix "raw" data was conducted using Affymetrix 
MAS5.0 and DNA-Chip Analyzer software (dCHIP) (46, 49). The data were then 
imported into the GeneSpring 7.0 (Silicon Genetics, Redwood City, CA) for data filtering 
and statistical analysis. First, genes with 2 “present calls” (~10% of the total arrays) were 
selected for statistical analysis.   Probe sets showing significant (p < 0.05) expression 
changes (using Welch’s t-test) in both MAS5.0 and dCHIP were retained for hierarchical 
clustering, functional and pathway analysis. 
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Each subject served as his own control (in the case of IM and UL conditions). In the case 
of SCI, baseline biopsies from the IM and UL conditions were pooled and served as the 
control for the 48h SCI condition. 
Identification of Functional Classifications and Groups 
 The datasets (IM, SCI, and UL) were compared to identify those genes that were 
differentially expressed in all three. The resulting list of gene identifiers were input into 
the DAVID online interface (http://david.abcc.ncifcrf.gov/), and the functional annotation 
tool was employed to classify genes on the list by function.  
DAVID analysis was also expanded to identify enriched functional groups for 
each individual dataset using DAVID as described in Huang et al  (35). In brief, complete 
lists of Affymetrix probe set IDs for each dataset were uploaded into the DAVID online 
interface, and the functional annotation tool was employed to filter functional groups 
associated with the each list. Filtering criteria included: 1) adjusted p-value (Benjamini & 
Hochberg) of p<0.05 and 2) enrichment score of ≥ 1.5. 
Identification of Canonical Pathways 
Ingenuity software (Ingenuity Systems, Inc., Redwood City, CA) identified the 
pathways from the IPA library of canonical pathways that were significant within each 
dataset (IM, SCI, UL). The significance of the association between the dataset and the 
canonical pathway was measured in two ways: 1) A ratio of the number of genes from the 
dataset that map to the pathway divided by the total number of genes that map to the 
canonical pathway is displayed; and 2) Fischer’s exact test was used to calculate a p-
value determining the probability that the association between the genes in the dataset 
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and the canonical pathway is explained by chance alone. Canonical pathways with a p-
value < 0.05 were reported.  
Gene Network Generation 
Custom gene networks were generated within IPA for each dataset. To build gene 
networks, the Ingenuity software mapped each Affymetrix probeset to its corresponding 
gene object in the Ingenuity Pathways Knowledge Base. These genes were overlaid onto 
a global molecular network developed from information contained in the Ingenuity 
Pathways Knowledge Base. Networks of these genes were then algorithmically generated 
based on their connectivity and ranked by network score. The network score was based 
on the hypergeometric distribution and was calculated with the right-tailed Fisher's Exact 
Test that returned a p-value determining the probability that the interconnectivity of the 
genes in the network are due to chance alone. The score is the negative log of the p-value.  
Results 
Microarray Analysis 
Microarray findings for the three models of disuse (IM, SCI, UL) included in this 
analysis showed that there were 3303 differentially expressed transcripts representing 
2393 genes. Figure 4.1 illustrates the distribution of these genes among the datasets. 
Among the three, 48h SCI resulted in the greatest number of altered transcripts compared 
to control, followed by 48h IM, and then 48h UL.  Whereas 60 – 74% of differentially 
expressed genes in each dataset were stimulus-specific, the remaining 26 – 40% of the 
genes in each list were shared by multiple models of disuse.  
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Expression Shared by IM, SCI, and UL Models of Disuse 
Thirty-two genes were differentially expressed in all three disuse models (Figure 
4.1). Of these shared genes, 26 had known biological functions (Table 4.1). Twenty genes 
were upregulated following all three models of disuse and were classified under functions 
such as transcription, protein degradation, stress response, and ECM, among others. Six 
genes were downregulated following all three models of disuse. Of these, 3 were related 
to chaperone/protein folding, whereas the remaining 3 were related to transcription.  
Biological Functions and Pathways within Individual Models of Disuse 
 Table 4.2 lists functional groups associated with the individual disuse conditions. 
Protein degradation-related functional groups (e.g., ubiquitin conjugation, ubiquitin-
protein ligase activity, and proteasome) were enriched in all three individual models of 
disuse. In addition to shared functions, unique functional themes were found. Gene 
expression changes related to oxidative phosphorylation and mitochondrion were 
observed following 48h SCI; stress response reached significance following 48h UL; and 
heatshock proteins and chaperone reached significance following 48h IM. Functional 
analysis via DAVID showed that, while common global expression patterns related to 
protein degradation were evident, changes in oxidative phosphorylation and stress 
response, may have varied depending on the disuse stimulus. 
 The only significantly altered (p<0.05) canonical pathway shared by all three 
models of disuse was the NRF2-mediated oxidative stress response pathway.  This is of 
particular interest because oxidative stress has been proposed as an early trigger of the 
atrophy program in skeletal muscle following disuse (54). In brief, cellular stress results 
in translocation of transcription factor NRF2 to the nucleus where it activates genes that 
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encode antioxidant proteins (to neutralize reactive molecules), chaperones and co-
chaperones (to repair damaged proteins), and detoxifying enzymes (to metabolize 
harmful chemicals). In this way, the muscle cell works to combat the oxidative damage 
that can lead to deleterious effects such as contractile protein degradation, and thus, 
decreased muscle size. 
 The altered gene expression (compared to control) in the NRF2-mediated 
Oxidative Stress Pathway for all three conditions is represented in Table 4.3. While all 
three models of disuse resulted in downregulation of co-chaperone genes in the pathway 
(i.e., DNAJ), expression profiles for the three datasets still showed differing patterns of 
expression. Aside from the downregulated expression of three DNAJ transcripts, the 
remaining altered components of the pathway in the UL dataset were upregulated; the 
majority of those genes are purported to serve a protective role in the cell. Of particular 
interest is heme oxygenase-1 (HMOX1) because of the 15.4-fold increase observed in 
the, otherwise, subtly altered UL expression profile. HMOX1 encodes for an enzyme that 
is proposed to have direct and/or indirect antioxidant effects in skeletal muscle (4); 
increases in transcripts for this protein have been shown in multiple models of disuse (44, 
59). Although HMOX1 was not found to be differentially expressed following 48h IM 
(4.1-fold increase, p=0.12), there was a trend towards a significance increase following 
48h SCI (3.4-fold, p=0.07). Evidence from the UL expression profile suggests that while 
there were decreases in pathway products related to chaperone activity, the majority of 
expression in this canonical pathway following 48h UL was upregulated and consistent 
with increased antioxidant activity. 
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The expression profile for the SCI disuse model showed the greatest number of 
differentially expressed genes of the three datasets for this pathway; in addition to 6 
downregulated DNAJs, decreases in mRNA levels for 8 genes encoding for antioxidant 
glutathione S-transferase (GST) proteins were observed. Even so, there were increases in 
expression of cytoprotective genes following 48h SCI in this pathway including FTL, 
glutathione reductase (GSR), and superoxidase dismutase-2 (SOD). GSR codes for 
glutathione reductase, an enzyme that helps maintain the antioxidant capacity of the cell 
(40); and SOD is a potent oxidant scavenger (52). Regardless of the downregulation of 
certain components of the NRF2 pathway following 48h SCI, there is evidence of 
increased antioxidant gene transcription in this model of disuse. 
Conversely, the expression profile for the IM disuse model showed expression for 
the majority of differentially expressed genes in the NRF2 pathway were downregulated. 
In addition to the shared expression pattern of downregulated DNAJ chaperone genes, 
other protein-folding genes were down-regulated (e.g., STIP1 and GST member gene, 
GSTM4). Furthermore, as was the case with the SCI expression profile, both NRF2-
activity enhancer, ATF4 (an NRF2 nuclear enhancer), and NRF2 encoding gene NFE2L2 
were downregulated. Decreased activity of NRF2 could lead to decreases in antioxidant 
transcription. While there were genes upregulated in this pathway for the IM model of 
disuse, they were primarily related to protein degradation at the proteasome (USP14) and 
the transport of lysosomal enzymes to the lysosome (PIK3C3). Therefore, unlike the UL 
and SCI models of disuse, the IM model does not appear to result in a substantial increase 
in antioxidant gene expression via the NRF2-medated Oxidative Stress Response 
Pathway. 
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Finally, two additional findings related to this pathway are worthy of note: the 
SCI and IM expression profiles both showed a decrease in MAP2K expression MAP2K 
expression is associated with activation of the p38 MAPK pathway which leads to 
increases in apoptosis (47). Decreases in MAP2K serve a protective mechanism by 
downregulating MAPK activation. 
Ingenuity network generation revealed that the top networks for all three 
conditions contained downregulated chaperone genes (e.g., those encoding heat shock 
proteins and DNAJ co-chaperones) (Figures 4.2a – c).   
DAVID analysis was employed to discover genes within each dataset that were 
categorized under the functional term “chaperone” (Table 4.4). As found in the smaller 
subset of shared genes, mRNA levels of transcripts in the chaperone functional category 
within each of the datasets were largely decreased, thus showing that down-regulation of 
chaperone and protein-folding activity was likely associated with cellular response to all 
three disuse stimuli.  
Of particular interest were HSPA1A and HSPA8, which are genes that encode a 
member of Hsp70 and Hsp70 cognate protein (Hsc70), respectively. Hsp70 responds to 
oxidative stress  but has been shown to decrease with disuse muscle atrophy (43). This is 
relevant because Hsp70 downregulation may make skeletal muscle more vulnerable to 
the oxidative stress associated with disuse. Hsc70 interacts with the stress-inducible 
Hsp70-member proteins as a co-chaperone; furthermore, under resting conditions, this 
constitutively expressed chaperone participates in the maintenance of cellular 
homeostasis and in the folding of nascent proteins including myosin (58). Also of 
importance in these findings, was the preponderance of downregulated DNAJ and BAG 
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genes in all three datasets because these genes function as co-chaperones, regulating 
Hsp70 and Hsc70 activity (39). These results suggest that a complex network of 
downregulated chaperone and protein-folding genes associated with the IM, SCI, and UL 
models of disuse contributed to protein degradation signaling activity.  
Discussion 
The global analyses in the current study revealed that, following 48h of disuse, 
there were 636 – 1602 differentially expressed transcripts in IM, SCI, and UL datasets, 
but only 32 genes were shared by all three. Hosack et al. (23) have shown that, when 
comparing the microarray datasets of multiple studies, it is common for there to be very 
little overlap in differential expression of individual transcripts. In fact, a recent meta-
analysis of expression profiles drawn primarily from studies in rats and mice (12) found 
no shared expression patterns of individual transcripts, yet common biological functions. 
Given these previous findings, we discovered a relatively robust percentage of shared 
altered expression among the three disuse models in this study (32 genes). This was 
likely due to the following factors: 1) muscle samples from all three studies were 
processed for storage and shipping by members of our laboratory; 2) mRNA isolation, 
cRNA synthesis, and microarray analysis were all conducted in the same genomics 
facility (Center for Genetic Medicine, Children’s National Medical, Washington, D.C.) 
using the same genechip technology and the same parameters for statistical analysis; and 
3) the inclusion criteria for the IM and UL studies were the same, as were the procedures 
in place for subject preparation and biopsy (including biopsy excision by the same 
physician).    
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The global gene expression analysis revealed that all three models of disuse 
shared common functions and pathways within the individual datasets. The chelation 
group (comprised of upregulated metallotheioneine isoforms) was enriched in all three 
conditions. Chaperone-coding genes were found in the highest ranked IPA networks for 
both UL and IM as well as the seventh highest ranked network in the SCI condition. 
Furthermore,  the NRF2-mediated Oxidative Stress Response Pathway was the only 
canonical pathway identified as statistically significant in all three models. 
Metallothioneines 
Metallothioneins (MTs; MT1F, MT1E, MT1X, MT1 pseudogene 2, and MT2A) 
were consistently upregulated following 48h IM, UL, and SCI. This is in agreement with 
findings in animal models (44) of skeletal muscle atrophy including denervation, spinal 
cord dissection, fasting, 2004), and uremia (44), as well as in a cell culture model of 
atrophy (55). Metallothioneins are small molecular weight metal-binding proteins that 
have been found to increase following oxidative stress and to scavenge reactive oxygen 
species (ROS) (17). Because oxidative stress has been implicated as a contributor in the 
initiation of disuse atrophy, it has been proposed that the increase in MT expression 
consistently observed across multiple models of disuse may confer a protective effect 
following atrophy stimuli (63). The current study confirmed that increases in MT mRNA 
may also be a consistent early response to multiple disuse stimuli in humans. However, 
although increases in MT protein products were observed following 5d SCI (62) 
increases in protein products were not found following 48h SCI or 48h IM in humans 
(63). This suggests that while MT mRNA levels may rise regardless of disuse stimulus, 
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perhaps MT translation is regulated by duration and/or intensity of the stimulus and 
controlled at the post-transcriptional level. 
Protein Chaperones 
Protein chaperones were largely decreased following 48h IM, SCI, and UL (Table 
4.4), Downregulated genes encoding for heat shock protein chaperones has been 
observed in rats following short-term (12h and 25h) hindlimb unloading (10, 29, 59) 
however this is the first time that downregulation of these genes has been observed with 
disuse in humans.  Chaperones are molecules that function to protect proteins from 
degradation by stabilizing nascent proteins during folding and damaged proteins during 
refolding (43). HSP70 (a subunit of which is encoded by HSPA1A) and its co-chaperone 
HSC70 (encoded by HSPA8) have been identified as key proteins in oxidative stress 
response in muscle and may aid in the folding of the contractile protein myosin (24, 58). 
While it has been argued that skeletal muscle atrophy is driven by the upregulation of 
protein degradation (24), attention has also been paid to the contribution of decreased 
protein synthesis (22). Downregulation of protein folding genes, as observed in the 
current study, may serve to attenuate the rate of protein synthesis. 
The protein complex HSP70/HSC70 associates with nascent polypeptides and 
newly translated proteins. While HSC70 aids with protein folding (29), HSP70 regulates 
the rate of elongation, and thus protein synthesis (42). Ku et al. observed that following 
hind-limb unloading in rats, elongation-dependent protein synthesis rate was slowed, and 
in a subsequent study (42) established that HSP70 and HSC70 association with nascent 
polypeptides were decreased following 12h and 24h unloading. Perhaps, in the current 
study, decreases in HSPA1A and HSPA8 gene expression not only rendered the skeletal 
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muscle more vulnerable to oxidative stress, but also led to decreases in elongation, and 
thus protein synthesis. Oxidative damage and decreased protein synthesis 48h post-disuse 
stimulus may both be early precursors to the atrophy associated with longer durations of 
IM, SCI, and UL in humans. 
These shared chaperone coding genes, took part in the highest rated IPA network 
(Figure 4.2a) for the 124-member subset of shared genes among the three models of 
disuse. This network featured HSP-coding genes and genes that code for chaperones 
which regulate these HSPs such as HSPE1 and DNAJA4.  HSPE1 codes for HSP10, a 
heat-shock protein that prevents the ubquitination of IGF-1 and the IGF-1 receptor in 
cardiac myocytes, and may perform the same function in skeletal muscle. As IGF-1 is a 
key signaling molecule in the AKT-mTOR pathway leading to protein synthesis, 
decreases in HSP10 protein may lead to decreased IGF-1 signaling and, therefore, a 
cellular environment that favors AKT-FOXO signaling and protein degradation.  DNAJ 
genes code for HSP40 proteins that interact with and mediate HSP70 activity. 
Importantly, the network also included key components of degradation-related pathways 
such as NFKβ, ERK, and p38 MAPK, the activity of which have been shown to lead to 
skeletal muscle atrophy.  
Increases in chaperone proteins have been associated with decreases in the 
activity of these pathways. For example, Senf et al. (56) found that by overexpressing 
HSP70 in rat soleus muscle, NFKβ expression was decreased and atrophy was attenuated. 
Furthermore, chaperone proteins have been shown to inhibit ERK, and ERK inhibition 
has been shown to blunt hypertrophy (reviewed in (27)). Finally, p38 MAPK has been 
shown to be an important signaling molecule in the molecular events leading to atrogin1 
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transcription, with activation of p38 via phosphorylation leading to atrogin1 upregulation. 
HSP70 has been shown to decrease p38 activation (48).  
 Although only 32 genes were shared by IM, SCI, and UL. DAVID and IPA 
analysis revealed that a larger group of genes within each dataset were related to 
functions common, if not to all three, at least to two of the models of disuse. This is 
consistent with previous meta-analyses that found few, if any, commonly expressed 
genes, yet still found significantly shared biological functions among datasets (34).  
Protein Degradation 
Within each of the models of disuse, functional groups related to protein 
degradation were enriched with the vast majority of genes within each dataset 
upregulated. Although measurable atrophy has not been detected following durations as 
short as 48h disuse, the upregulation of protein degradation genes support the hypotheses 
that the atrophy program may be put in motion as early as 48h after the onset of the 
disuse stimulus (63).  
Notably, transcription of FBXO32 (which codes for the atrogin1 protein) was 
increased following 48h of disuse in each of the three models. atrogin1 is an E3 ligase 
that is a key component of the ubiquitin proteasome pathway, and it has been previously 
shown to be differentially expressed with disuse atrophy. For example, 24h following the 
initiation of immobilization and unloading in rat muscle, atrogin1 and the related E3 
ligase MuRF1 were upregulated (11) . Furthermore, atrogin1 knockout mice dispayed 
attenuated atrophy following unloading (11), and C2C12  myotubes transfected with 
atrogin1 were measurably thinner than controls (11). Taken together, these findings 
suggest that atrogin1 is likely an important early regulator of skeletal muscle atrophy and 
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that it (or its protein targets) may represent candidates for early intervention following 
disuse via drug-mediated modification to attenuate atrophy in humans.  
Findings from human studies have not been in agreement regarding atrogin1. 
While both 20d of bed rest (53) and 2wk of leg immobilization (37) led to a significant 
1.6-fold increase in atrogin1 gene expression (37), findings in our laboratory have been 
equivocal. While analysis of biopsies from the UL (Reich et al., unpublished) and SCI 
(62) protocol measured with the more sensitive quantitative real-time polymerase chain 
reaction (qRT-PCR) confirmed increases in atrogin1, analysis of biopsies from the IM 
samples (63) found no significant differences (63).  Furthermore, protein quantification 
via Western blot found no significant differences in protein products for atrogin1 
following 48h UL (unpublished), IM (63), or SCI (64). However, it has been suggested 
that atrogin1 expression is controlled at the translational level, and that the level of 
expression is dependent on the magnitude and duration of the disuse stimulus (45). 
Therefore, it is possible that 48h of disuse, regardless of stimulus (IM, SCI, or UL) is not 
adequate duration in humans to lead to decreases in protein content. 
Stress Response 
 IPA analysis revealed that the NRF2-mediated Stress Response Pathway was the 
only pathway found to be significant in all three models of atrophy (Table 4.6). Oxidative 
stress has been identified as a likely contributor to the cellular response to disuse, 
ultimately leading to atrophy if the disuse stimulus persists (54). Oxidative may lead to 
increases in calpain cleavage of acto-myosin complexes (30), NFKβ activity (65), and E3 
ligases such as atrogin1 (54). Upregulated stress response genes in this pathway 
following 48h SCI and UL such as HMOX1 in UL, GSR, and SOD in SCI, is evidence 
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that oxidative stress is likely a component of the molecular changes following disuse (41, 
44). However, the downregulation of many member genes in the NRF2-mediated Stress 
Response Pathway such as DNAJ co-chaperone genes suggests that this stress response 
may be impaired following disuse. The hypothesis is supported by previous work of 
McClug et al. (50) who found redox imbalance associated with disuse in mouse 
diaphragm following unloading.  
It is unclear as to why the IM model of disuse did not exhibit increases in 
cytoprotective stress response genes as seen with SCI and UL, but rather only increases 
in genes related to protein degradation (Table 4.6). One difference between the IM model 
and the latter two was that with IM, subjects were prevented from moving the knee joint, 
but were not restricted from standing on the leg; conversely, no weight-bearing activity 
was permitted in the experimental leg in the UL or SCI models of disuse. Little is known 
about this stress response pathway and mechanotransduction. However, Fluck et al. (28) 
showed that there are differences in structure and function at the cellular level when 
comparing high-contractile/low-loading conditions to low-contractile/high-loading 
conditions such that mitochondrial metabolism is uncompromised in the former 
condition, but not the latter. Since many of the stress response components of this 
pathway localize to the mitochondria, it is possible that differences in how stress response 
contributes to molecular changes following IM (compared to SCI and UL) are related to 
differences at the mitochondrial level. In fact, differences in mitochondrial function are 
further evidenced in the current study with regard to mitochondrial metabolism; the 
mitochondrion functional group was significantly enriched following both SCI (2.4-fold, 
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p<0.05) and UL (2.1-fold, p<0.05), but not following IM. The majority of these genes 
were downregulated and related to aerobic metabolism.  
Conclusions 
 
Recent development of technologies such as microarray analysis not only allowed 
us to measure the differential gene expression of thousands of genes within each dataset, 
but also high through-put tools such as DAVID and IPA provided us with the ability to 
interpret these expression patterns within the context of known biological functions. 
Although the molecular signatures for immobilization, spinal cord injury, and unloading 
are unique, there are clearly common molecular changes among all three models, 
particularly those associated with oxidative stress response such as metallothioneins and 
protein chaperones, as well as the expected function of protein degradation. In addition to 
the shared enriched function of protein degradation, stress response is an attractive area 
for further study in the search for potential gene targets as oxidative stress has already 
been posited as an early upstream regulator of skeletal muscle atrophy.  
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Table 4.1. Shared changes in gene expression among all three conditions. IM=immobilization, SCI=spinal cord injury, UL=unloading, 
FC=fold-change relative to control (baseline for IM and UL, control subjects for SCI). 
 
Chaperone/Protein Folding     
IM  SCI  UL 
FC p-value FC p-value FC p-value 
209406_at BAG2 BCL2-associated athanogene 2 -1.24 3.63E-02 -1.14 4.61E-02 -1.16 1.35E-02 
225061_at DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 -2.50 2.96E-03 -3.20 1.29E-02 -1.76 4.65E-03 
200799_at, 200800_s_at HSPA1A heat shock 70kda protein 1a -1.76 4.91E-02 -1.81 3.54E-02 -1.35 4.93E-02 
    
Protein Degradation/Ubiquitin Proteasome Pathway 
200655_s_at, 211985_s_at CALM1 calmodulin 1 (phosphorylase kinase, delta) 1.36 1.23E-02 1.66 5.39E-03 1.35 1.77E-02 
225328_at, 241763_s_at FBXO32 F-box protein 32 (Atrogin1) 1.79 1.70E-02 4.72 4.15E-03 1.55 2.64E-02 
      
Metallothioneins     
212859_x_at MT1E metallothionein 1E 1.91 3.62E-02 5.21 3.26E-03 2.14 2.83E-02 
217165_x_at MT1F metallothionein 1F 2.31 2.18E-02 10.51 2.30E-03 2.26 2.00E-03 
211456_x_at MT1P2 metallothionein 1 pseudogene 2 1.87 3.78E-02 10.04 2.30E-03 2.00 3.70E-02 
204326_x_at MT1X metallothionein 1X 1.68 4.51E-02 4.51 2.50E-03 1.54 1.03E-02 
208581_x_at MT1X metallothionein 1X 1.80 4.50E-02 5.65 2.37E-03 1.71 1.51E-02 
212185_x_at MT2A metallothionein 2A 1.98 1.90E-02 7.56 5.61E-04 1.88 1.58E-02 
      
mRNA 
Transcription/Processing     
204113_at, 209489_at CUGBP1 CUG triplet repeat, RNA binding protein 1 -1.31 4.00E-02 1.87 5.39E-03 1.22 1.20E-02 
225310_at RBMX RNA binding motif protein, X-linked 1.43 4.30E-02 1.68 8.27E-03 1.38 4.46E-02 
226682_at RORA RAR-related orphan receptor A 1.45 2.48E-02 2.61 2.69E-03 1.48 2.33E-02 
201586_s_at, 214016_s_at SFPQ splicing factor proline/glutamine-rich 1.43 1.39E-02 1.56 1.07E-03 1.41 7.09E-03 
38918_at SOX13 SRY (sex determining region Y)-box 13 1.38 2.51E-02 1.52 1.04E-02 1.32 2.27E-03 
Metabolism     
203746_s_at, 203745_at HCCS holocytochrome c synthase  -1.36 1.25E-02 -1.75 1.13E-03 -1.17 3.38E-02 
202464_s_at PFKFB3 fructose-2,6-biphosphatase 3 3.30 2.37E-02 10.65 3.62E-04 2.70 2.20E-02 
Continued
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Table 4.1 Continued
IM  SCI UL 
Extracellular Matrix     FC p-value FC p-value FC p-value 
222693_at, 225032_at, 242029_at FNDC3B fibronectin type III domain containing 3B 1.79 1.30E-03 1.64 4.20E-02 -1.69 1.50E-02 
205498_at GHR growth hormone receptor 1.33 2.81E-02 1.55 1.43E-02 1.26 4.52E-02 
Protein Transport/Binding     
226633_at RAB8B RAB8B, member RAS oncogene family 1.45 2.24E-02 2.71 4.03E-02 1.36 4.14E-02 
1553177_at SH2D1B SH2 domain containing 1B 2.11 7.69E-03 4.45 4.64E-02 1.26 4.90E-02 
Striated Muscle Contraction 
208430_s_at, 205741_s_at DTNA dystrobrevin, alpha -1.68 2.28E-02 -2.00 1.48E-02 -1.15 4.02E-03 
Cell Cycle     
202769_at CCNG2 cyclin G2 2.08 8.03E-03 2.80 1.90E-02 1.72 2.08E-02 
Immune Response 
222484_s_at CXCL14 chemokine (C-X-C motif) ligand 14 2.53 1.78E-03 2.43 8.89E-03 1.62 3.52E-04 
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Table 4.2. Over-represented functional groups associated with each disuse condition. 
Count =# of genes in each category; Fold enrichment=magnitude of over-representation 
in dataset. Adjusted p-value=Benjamani and Hockberg multiple testing correction. 
Functional annotations are listed in order of fold enrichment. 
 
Functional Groups Count p-value 
Fold 
Enrichment 
Adjusted 
p-value 
heat shock 5 4.88E-04 11.61 3.20E-02 
chaperone 25 2.06E-07 3.44 2.75E-05 
acetylation 70 1.65E-09 2.17 3.51E-07 
mrna processing 25 8.95E-04 2.09 4.66E-02 
ubl conjugation 38 6.15E-04 1.81 3.58E-02 
SCI Functional Groups Count p-value 
Enrichment 
Score 
Adjusted 
p-value 
chelation 6 7.47E-05 11.24 4.96E-03 
tricarboxylic acid cycle 8 1.40E-04 6.42 8.27E-03 
oxidative phosphorylation 11 5.27E-05 4.88 4.01E-03 
proteasome 18 9.14E-08 4.82 1.08E-05 
mitochondrion 128 7.90E-30 3.01 8.42E-27 
acetylation 102 3.29E-22 2.87 1.17E-19 
oxidoreductase 77 1.67E-11 2.29 3.56E-09 
repressor 36 2.96E-04 1.91 1.42E-02 
ubl conjugation 40 0.00103 1.72 3.58E-02 
UL Functional Groups Count p-value 
Enrichment 
Score 
Adjusted 
p-value 
rna-binding 25 6.84E-04 2.15 5.00E-02 
acetylation 33 3.89E-05 2.22 0.00E+00 
ubl conjugation 28 1.67E-06 2.89 0.00E+00 
mrna processing 16 4.33E-04 2.91 3.00E-02 
stress response 9 3.23E-04 5.19 3.00E-02 
chelation 6 1.05E-06 26.91 0.00E+00 
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Table 4.3. Gene expression in NRF2-mediated Oxidative Stress Response Pathway. The only 
canonical pathway that was significantly altered in all three groups was NRF2-mediated 
Oxidative Stress Response.  The genes below are from this canonical pathway. Superscripts 
denote genes associated with the following molecular complexes/families: aActin, bERK1/2, cGST, 
dHSP22/40/90, eMkk3/6, fPI3K, gPkc, hRas 
 
IM SCI UL 
Gene FC Gene FC Gene FC 
Up 
DNAJC9d 1.3  ABCC1 1.7  ACTG1a 1.2 
 FKBP5 1.6  AOX1 7.8  BACH1 1.2 
MAPK6 2.2  DNAJC9d 1.6 GCLM 1.3 
MAPK7 1.6 FKBP5 3.5 GSTM1c 1.3 
 PIK3C3f 1.5  FTL 1.9  HMOX1 15.4 
TXNRD1 1.3  GSR 2.2  HSPB8d 1.2 
 USP14 1.4  MAFF 6.0  MAFF 1.9 
 MAPK1b 2.1 
 MGST1c 10.6 
 PIK3R1f  5.6 
 PIK3R3f 2.0 
 PRKCIg 1.2 
 SOD2 9.2 
Down 
ACTB a -1.3 AKR7A2 -1.2 DNAJA1d -1.3 
ATF4 -1.5 DNAJA4 d -2.6 ACTB a -1.8 
CCT7, -1.3 DNAJB1 d -2.4 ACTG1 a -1.8 
DNAJA4d -3.0 DNAJB4 d -1.8  
DNAJB5d -1.4 DNAJB5 d -2.0  
DNAJB6d -1.3 DNAJC19 d -1.4  
DNAJC5d -1.5 GSTA4c -1.6  
GSTM4c -1.4 GSTK1c -1.9  
JUND -1.6 GSTM1c -2.4  
MAP2K3e -1.3 GSTM2c -2.4  
MAP2K7e -3.2 GSTM4c -1.6  
NFE2L2 -1.4 GSTO1c -1.2  
RRASh -1.5 HERPUD1 -1.6  
RRAS2h -1.7 MAF -2.0  
STIP1 -1.5 MAP2K3e -2.7  
MGST2c -1.6  
MGST3c -1.6  
PIK3C2Bf -3.2 
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Table 4.4. Chaperone genes differentially expressed among three models of disuse.  
IM = immobilizations; SCI =spinal cord injury; UL = unloading. ↓ = downregulated up to -
2-fold; ↓↓= downregulated up to -5-fold; ↑ = upregulated up to 2-fold; All are significant p<0.05 
except for those denoted *trend, p<0.07. 
Gene  Gene Title IM SCI UL 
Heat Shock Proteins 
HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 ↓ ↓ 
HSP90AB1 heat shock protein 90kDa alpha (cytosolic), class B member 1 ↓  
HSP90B1 heat shock protein 90kDa beta (Grp94), member 1 ↓  
HSPA1A  heat shock 70kDa protein 1A  ↓ ↓ ↓ 
HSPA8 heat shock 70kDa protein 8 ↓  
HSPB8 heat shock 22kDa protein 8  ↑ 
HSPD1 heat shock 60kDa protein 1 (chaperonin) ↓  
HSPE1 heat shock 10kDa protein 1 (chaperonin 10) ↓ ↓ 
DNAJ co-chaperones 
BAG1 BCL2-associated athanogene ↓  
BAG2 BCL2-associated athanogene 2 ↓  
DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1  ↓ ↓ 
DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 ↓↓ ↓↓ ↓ 
DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1   
DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1 ↓ ↓↓  
DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4  ↓ ↓ 
DNAJB5 DnaJ (Hsp40) homolog, subfamily B, member 5 ↓ ↓ ↓ 
DNAJB6 DnaJ (Hsp40) homolog, subfamily B, member 6 ↓  
DNAJC19 DnaJ (Hsp40) homolog, subfamily C, member 19  ↓  
DNAJC5 DnaJ (Hsp40) homolog, subfamily C, member 5 ↓  
DNAJC9 DnaJ (Hsp40) homolog, subfamily C, member 9 ↓  
FKBP5 FK506 binding protein 5 ↓ ↑  
Chaperonin-Containing TCP1 
CCT2 chaperonin containing TCP1, subunit 2 (beta) ↓ ↑  
CCT3 chaperonin containing TCP1, subunit 3 (gamma)  ↓ 
CCT4 chaperonin containing TCP1, subunit 4 (delta) ↓ ↓ 
CCT5 chaperonin containing TCP1, subunit 5 (epsilon) ↓ ↑  
CCT6A chaperonin containing TCP1, subunit 6A (zeta 1) ↓  
CCT7 chaperonin containing TCP1, subunit 7 (eta) ↓  
CLPX ClpX caseinolytic peptidase X homolog (E. coli) ↓  
Miscellaneous 
ABCE1 ATP-binding cassette, sub-family E (OABP), member 1  ↑  
AHSA1 AHA1, activator of heat shock 90kDa protein ATPase homolog 1 (yeast) ↓ ↓ ↓* 
ASF1A ASF1 anti-silencing function 1 homolog A (S. cerevisiae)    
CALR calreticulin ↓  ↓* 
MKKS McKusick-Kaufman syndrome  ↓  
PFDN5 prefoldin subunit 5 ↓   
PIP5K3 phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase, type III ↓   
SEC63 SEC63 homolog (S. cerevisiae)  ↑  
TIMM8A translocase of inner mitochondrial membrane 8 homolog A (yeast)  ↓ ↓ 
TIMM8B translocase of inner mitochondrial membrane 8 homolog B (yeast)    
TXNDC4 thioredoxin domain containing 4 (endoplasmic reticulum) ↓ ↑  
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Figure 4.1. Distribution of differentially expressed genes among disuse models. It is 
important to note that in each dataset, there are cases in which multiple probe-sets 
represent the same gene. The totals in this diagram represent unique genes rather than 
unique probe-sets. IM = immobilization, SCI = spinal cord injury, UL = unloading.  
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Figure 4.2a. Chaperone-related network associated with immobilization. Network 
score=31 (log of p-value). Green represents downregulated genes. Red represents 
upregulated genes. 
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Figure 4.2b. Chaperone-related network associated with spinal cord injury. Network 
score= 34 (log of p-value). Green represents downregulated genes. Red represents 
upregulated genes. 
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Figure 4.2c. Chaperone-related network associated with unloading. Network score=50 
(log of p-value). Green represents downregulated genes. Red represents upregulated 
genes. 
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CHAPTER V 
THE EFFECT OF HEMIN TREATMENT ON E3 LIGASE GENE EXPRESION AND 
MITOCHONDRIAL DEHYDROGENASE ACTIVITY FOLLOWING AN 
OXIDATIVE STRESS STIMULUS IN C2C12 MYOTUBES 
Abstract 
PURPOSE: Our laboratory and others have shown that gene expression of heme 
oxygenase-1 (HMOX1) is upregulated with limb unloading in humans and rodents. It has 
been suggested that this increase is a protective mechanism against atrophy-related 
oxidative stress at the onset of muscle disuse. The purpose of this study was to measure 
the effects of hemin-induced changes in HMOX1 transcription on the expression of 
atrophy-related genes (atrogin1 and MuRF1) and mitochondrial dehydrogenase activity 
in C2C12 mouse muscle cells following an oxidative stress stimulus. METHODS: C2C12 
myoblasts were incubated in growth medium (Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% Fetal Bovine Serum), and at ~80% confluency, were 
transferred to differentiation medium (DMEM supplemented with 2% horse serum). At 
5d post-differentiation, cultures were treated with hemin (20uM, 50uM, and 100uM 
doses) to induce HMOX1 expression. At 5.5d post-differentiation, cultures were treated 
with 100uM hydrogen peroxide (H2O2) to induce oxidative stress. RNA was isolated 3h 
and 6h post-H2O2 treatment, after which mRNA levels of HMOX1, atrogin1, and MuRF1 
were measured via qRT-PCR. Mitochondrial dehydrogenase (DHO) activity was 
measured via XTT assay. RESULTS: mRNA levels of atrogin1 and MuRF1 decreased 
with hemin treatment (p<0.05). There was a trend towards a negative correlation between 
HMOX1 gene expression and atrogin1 gene expression (r=-0.38, p=0.06); furthermore, 
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atrogin1 and MuRF1 gene expression was strongly correlated (r=0.92, p<0.05). XTT 
assays revealed that 50uM and 100uM dose concentrations of hemin resulted in greater 
mitochondrial DHO activity following the H2O2 treatment than 20uM dose 
concentrations or control cells. CONCLUSIONS: Hemin pretreatment of C2C12 cells 
resulted in decreases in E3 ligase gene expression, as well as increased mitochondrial 
DHO following an oxidative stress stimulus, suggesting that HMOX1 may be a 
promising gene target to protect against oxidative stress associated muscle loss such as 
that observed following disuse. 
Introduction 
Extended periods of skeletal muscle disuse lead to atrophy, as seen with limb 
unloading (1, 6-7), immobilization (26, 62), bed rest (6, 8, 46), spaceflight (1, 59-60), 
spinal cord injury (12, 23, 51, 61), and mechanical ventilation (17-18, 34). This disuse 
results in increases in protein degradation characterized by upregulation of genes 
associated with the ubiquitin proteasome pathway (UPP), such as E3 ligases atrogin1 and 
MuRF1 (10-11, 14), as well as decrease in protein synthesis (14). It has been posited that 
oxidative stress exerted by reactive oxygen species (ROS), and other reactive molecules 
such as reactive nitrogen species (RNS) and reactive iron, may play an important role in 
the regulation of the atrophy process (4, 18, 21, 28-30, 32, 38, 41, 44, 63). Increases in 
intracellular oxidant production have been found both in vitro (56) and in animal models 
(18, 27, 30, 47, 55) of atrophy. Furthermore, increases in stress proteins have been 
observed in muscle after disuse including heme oxygenase-1 (HMOX1) (21, 24, 55). A 
recent microarray study in our laboratory (50) found that both atrogin1 and HMOX1 gene 
expression was upregulated  during unloading and spinal cord injury.  
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 In the atrophy process, increases in reactive molecules may contribute to the 
induction of UPP activity. In C2C12  myotubes, atrogin1, MuRF1, and components of the 
26S proteasome (the molecular machinery that degrades ubiquitinated proteins) have 
been found to be increased with H2O2 -mediated oxidative stress (36). Since changes in 
the UPP occur as early as 2d following an atrophy stimulus in humans (50, 61-62), it may 
be possible to attenuate the rapid muscle wasting that follows by blunting the 
upregulation of E3 ligases even before measurable atrophy has begun. Antioxidant 
proteins upregulate in response to disuse stimuli (43-44, 62), but, clearly, not to levels 
that can restore redox balance and prevent proteolysis. Treatment with exogenous 
antioxidants such as trolox (9), cysteine (25), and vitamin E (3) have shown promise in 
that they have been demonstrated to attenuate atrophy when introduced in super-
physiological levels. 
HMOX1 is an inducible enzyme that participates in heme catabolism (48). 
Although studies have found pro-oxidant properties for the HMOX1 protein in some 
tissues (13, 31), it is primarily considered to have antioxidant effects; it leads to the 
production of bilirubin, a potent antioxidant (48, 66) that is associated with the induction 
of ferritin, a reactive iron scavenger. While HMOX1 has been shown to be increased at 
the onset of skeletal muscle disuse, its role during the atrophy process is not well 
understood. In a recent study, super-physiological HMOX1 induction via exogenous 
hemin treatment restored redox balance in mouse diaphragm during mechanical 
ventilation (22).  It is not known whether induction of HMOX1 can attenuate the 
expression of E3 ligases atrogin1 or MuRF1. However, if HMOX1 were to prove to 
participate in the regulation of one or both of these “atrogenes,” it could be a promising 
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gene target for future therapies. Hemin, a substrate of HMOX1 (and an inducer of the 
HMOX1 gene) has been shown to reduce proteolysis in a variety of cell types including 
rat reticulocytes (19). Hemin is already available as a drug (Panhematin) used to treat the 
blood disorder, porphyra, under a physicians care in a hospital setting. 
 As proof of concept to pave the way for further studies in animals and humans, I 
initiated a series of in vitro experiments to investigate the effects of hemin-induced super-
physiological levels of HMOX1 gene expression on E3 ligase gene expression and cell 
viability following an oxidative stress stimulus. The C2C12 mouse muscle immortal cell 
line is often used as an in vitro model for skeletal muscle because these cells differentiate 
into multinucleated myotubes that exhibit similar phenotypes and gene expression 
patterns as mammalian skeletal muscle cells in vivo. Hydrogen peroxide (H2O2) treatment 
of C2C12 cells has been used as a model of skeletal muscle oxidative stress (54), and H2O2 
treatment has been shown to increase HMOX1(42), atrogin1, and MuRF1 (36) in C2C12 
myotubes. The purpose of the present study was to investigate the effects of pre-treatment 
of C2C12 myotubes with hemin on cell viability and expression of HMOX1, atrogin1, and 
MuRF1 following H2O2 treatment.  
Methods 
Cell Culture 
C2C12 myoblasts were maintained in growth media (Dulbecco’s modified Eagles’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (GIBCO Invitrogen, 
Carlsbad, CA)) and penicillin/streptomycin in 10% CO2 at 37°C. They were seeded in 
either 6-well plates (for gene expression experiments) or 96-well plates (for cell viability 
assays) at ~50% density. At ~80% confluency, they were switched to differentiation 
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media (DMEM supplemented with 2% horse serum (GIBCO Invitrogen, Carlsbad, CA). 
At 2d post-differentiation and 4d post-differentiation, cells were re-fed with 
differentiation media supplemented with 20uM cytosine arabinoside to enrich the cultures 
for myotubes. Cells seeded in 96-well plates were washed with PBS prior to the addition 
of phenol-red free DMEM supplemented with 2% horse serum and sodium pyruvate. 
Phenol-red free media was used so as to enhance sensitivity of the cell viability assay. 
Hemin pre-treatment 
At 5d post-differentiation, cells were treated with cell culture grade hemin. A 
stock solution was first prepared by dissolving hemin in 0.1N NaOH solution: 20, 50, and 
100uM hemin solutions were prepared by serial dilution in sterile-filtered double-distilled 
H2O, with final dilutions in differentiation media. pH was then adjusted to 7.2 (consistent 
with the pH of the non-hemin supplemented differentiation media) and sterile filtered. 
Cells treated with this hemin-supplemented media in10% CO2 for 18h. This treatment 
duration was chosen based on results of published in vitro hemin experiments, which 
showed that HMOX1 was expressed 14 – 18h post-hemin treatment. Selected wells were 
treated with NaOH-supplemented, but hemin-free, differentiation media (hemin vehicle 
solution) to serve as controls. Preliminary experiments were performed to confirm that 
there were no significant differences between the hemin-vehicle solution and regular 
differentiation media. 
H2O2 treatment 
Following 18h hemin pre-treatment, cells were treated with cell culture grade 
H2O2 (Sigma-Aldrich, St. Louis, MO). A stock solution of 30% w/w H2O2 was used for 
all experiments. H2O2 solutions were prepared by serial dilution in sterile-filtered double-
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distilled H2O2, with final dilutions in differentiation media. For cells destined for gene 
expression experiments, final concentrations of H2O2 were 100uM, consistent with 
previous literature (36), and not intended to induce cell death. For cells destined for cell 
viability assays, final concentrations of H2O2 were 100uM, 500uM, 1000uM, and 2mM, 
with intended cell viability ranging from 100 – 40%, as demonstrated in previous 
literature (42). Hemin-supplemented media was removed, cells were washed with PBS 
(so as to remove any residual hemin), and immediately replaced with H2O2-supplemented 
media. Cells were then cultured in 10% CO2 for a period of 3h or 6h. Selected wells were 
treated with H2O2-free differentiation media to serve as controls. Each experiment was 
run multiple times to ensure validity. 
RNA isolation and cDNA synthesis 
Following H2O2 treatment, media was removed from experimental and control 
cells, washed with PBS, treated with trypsin, and lysed directly in the culture dishes. One 
ml of TRIZOL reagent (Invitrogen, Carlsbad, CA) was added per well, and cell lysate 
was passed several times through a pipette, collected, and stored at -80°C until analysis. 
Total mRNA was isolated using TRIZOL reagent (following manufacturer’s instructions) 
and quantified via spectrophotometry (Nanodrop, Wilmington, DE). Equal amounts of 
total RNA was synthesized into cDNA using a First-Strand cDNA Synthesis kit 
(Fermentas, Hanover, MD). ABgene Absolute qPCR SYBR Green Master Mix 
(ABggene, Surrey, UK) with ROX dye was used for all PCR protocols. Forward and 
reverse primers (Integrated DNA Technologies, Coralville, IA) were designed using 
NCBI gene sequences with IDT DNA SciTools for all genes of interest (Table 5.1). 
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Gene Expression Analysis via qRT-PCR 
Reactions were run in 96-well plates with all cDNA samples from each treatment 
condition run in triplicate for each gene of interest. Thus, each plate could accommodate 
the analysis of two genes of interest and one reference standard (Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH)). For each experiment, HMOX1 expression was 
measured on one plate and atrogin1 and MuRF1 were analyzed on another. When 
possible, the qRT-PCR experiments were performed on the same day. The average 
comparative threshold (Ct) value for triplicate samples was used for data analysis.  The 
Ct values directly related to fluorescence of the respective SYBR-green probe after 40 
cycles of amplification on a MX3000p Real-Time PCR System (Stratagene, La Jolla, 
CA) available in the central Bioinformatics and Genomics Facility at the University of 
Massachusetts. At the end of each reaction, a melting curve analysis was run to identify 
possible primer dimmers. The results of the melting curve were confirmed, and 
appropriate product size was determined via 1.5% agarose gel electrophoresis with 
ethidium bromide staining. 
XTT Assays 
Following H2O2 treatment, cell viability was analyzed via the XXT assay (Roche 
USA, Nutley, NJ). The XTT reagent was prepared per manufacturer’s instructions, 50ul 
of reagent was added to each well for a final concentration of 0.3 mg/ml, and then plates 
were incubated at room temperature in 5% CO2 for 4h. During the incubation period, 
metabolically active cells cleaved yellow tetrazolium salt (XTT) to form an orange 
formazan dye, which was measured colormetrically on a fluorostar plate reader (BMG 
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Laboratories, Chapel Hill, NC) at a wavelength of 480nm. Data were normalized to a 
blank well and then expressed as percentage of non-treatment controls. 
Statistical Analysis 
Gene expression data (∆CT values) and cell viability data (optical density values 
normalized to control) were analyzed by factorial ANOVA or ANCOVA when there 
were significant differences between hemin-pre-treated and hemin-non-pretreated cells 
prior to H2O2 treatment. Tukey post-hoc tests were performed when significance was 
indicated. Differential gene expression was calculated using the -2∆∆CT method as 
described in (39) and presented as fold-change relative to control. In addition, Pearson 
correlations were performed to analyze the relationship between HMOX1, atrogin1, and 
MuRF1 gene expression. Significance was set at p<0.05. Statistics were performed using 
Systat statistical software, version 12. 
Results 
Gene Expression 
HMOX1 mRNA levels were significantly greater with H2O2 treatment, such that 
there was a mean fold-change of 3.7 in H2O2-treated cells compared to non-H2O2-treated 
cells (Figure 5.1). This confirmed that HMOX1 gene expression increased following the 
oxidative stress stimulus. Pre-treatment with 50uM and 100uM hemin resulted in 
significant increases in HMOX1 mRNA levels compared to hemin-control cells (Figure 
5.2), verifying that exogenous hemin treatment successfully induced HMOX1 gene 
expression. HMOX1 mRNA levels were higher in cells collected 3h after 18h hemin pre-
treatment compared to those collected 6h after 18h hemin pre-treatment. Finally, 
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regardless of timepoint or dose of H2O2 treatment, the patterns of HMOX1 expression 
across increasing doses of hemin were similar. 
Atrogin1 and MuRF1 mRNA levels decreased with hemin pre-treatment (Figure 
5.3). Expression levels of these two transcripts decreased in a dose-dependent manner 
and reached significance at the 100uM dose level (mean fold-change = -2.2 for both 
atrogin1 and MuRF1). There was no significant effect of H2O2 treatment on expression 
levels of either atrogin1 or MuRF1. Furthermore, there was no significant effect of time 
on mRNA levels of atrogin1.  
Correlations: As expected, atrogin1 and MuRF1 gene expression values (∆CT ) 
were strongly correlated with one another (r=0.92, p<0.05). Furthermore, there was a 
trend towards a negative correlation between HMOX1 expression and atrogin1 
expression (r=-0.38, p=0.06). However, there was no significant correlation between 
HMOX1 and MuRF1 expression (r=-0.18, p=0.43).   
XTT Assays 
Serial dilutions of H2O2 (100uM, 500uM, 1mM, 2mM) induced a dose-dependent 
decrease in XTT cleavage at the 1mM and 2mM doses (Figure 5.4); therefore, 1mM and 
2mM doses were the H2O2 doses that were included in the XTT assay analysis.  
The ANOVA found that there were significant differences in XTT cleavage in 
hemin pre-treated cells compared with hemin-control cells (independent of H2O2 
treatment), such that XTT cleavage increased with larger doses of hemin. Therefore, an 
ANCOVA was then performed that co-varied for H2O2-control XTT cleavage (Figure 
5.5). There was no significant effect of time, so the following results show pooled data 
from both the 3h and 6h time points. 
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Significant main effects of hemin dose and H2O2 dose were observed as well as 
interactions between the two variables (Figure 5.6). As expected, XTT cleavage 
decreased in H2O2-treated cells compared to H2O2-control cells in a dose-dependent 
manner. Following H2O2 treatment, XTT cleavage in hemin pre-treated cells was greater 
compared to hemin-control cells, and these differences were dose-dependent with greater 
doses of hemin resulting in greater XTT cleavage. Furthermore, the 50uM and 100uM 
dose concentrations of hemin pre-treatment resulted in greater XTT cleavage than non-
pre-treated cells. Because levels of XTT cleavage reflect relative differences in metabolic 
activity, the results may be interpreted in a number of ways including increased cell 
viability (survival) or increased mitosis as a result of hemin treatment. 
Discussion 
Taken together, the results of the XTT and the gene expression experiments found 
that hemin treatment was associated with increased HMOX1 expression, decreased 
atrogin1 and MuRF1 expression, and increased XTT cleavage.  
Gene Expression 
Effects of Hemin Treatment on HMOX1, Atrogin1, and MuRF1 Expression 
In the current study, HMOX1 expression was greater in cells treated with H2O2 
than those that were not (Figure 5.1). This is consistent with results data-mined from the 
National Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database, 
a public domain microarray data repository hosted by the National Institutes of Health 
(NIH). In a dataset contributed to GEO (Kandarian et al., http://www.ncbi.nlm.nih.gov), 
C2C12 myotubes were treated with serial dilutions of H2O2 (10uM, 100uM, 1mM) for 2h, 
and microarray experiments were performed. The results showed increased HMOX1 at 
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the 100uM and 1mM dose levels compared to control cells. The results from the current 
study and the GEO-submitted study both lend support for the characterization of HMOX1 
as a stress protein that responds to oxidative stress in skeletal muscle (2, 47)  
HMOX1 has both pro-oxidant and anti-oxidant functions across various tissues in 
the body. For example, in vascular cells, HMOX1 has been found to cause endothelial 
injury (13), and in brain cells, to exacerbate early injury after intracerebral hemorrhage 
(65). The majority of the examples in the literature however provide evidence for the 
cytoprotective role of HMOX1. Overexpression of HMOX1 has been found to protect 
neuronal cells against the deleterious effects of ischemic stroke (15), to decrease 
inflammation during lung injury (57), and to protect liver cells from ischemic/reperfusion 
injury (40). Furthermore, inhibition of HMOX1 has been found to lead to increased 
oxidative stress during sepsis in diaphragm muscle (5). Therefore, it is likely that the 
increased expression of HMOX1 following H2O2 treatment in the current study was 
cytoprotective. 
 Hemin treatment successfully increased HMOX1 gene expression in C2C12 
myotubes (Figure 5.2), L6G8 rat myoblasts (64), and other cell lines from tissues such as 
kidney (49) and heart (20). Our findings also showed that 100uM hemin was associated 
with decreased expression of atrogin1 and MuRF1, E3 ligases that attach ubiquitin to 
contractile proteins actin and myosin, tagging them for degradation by the proteasome 
(10-11). Increased gene expression of these ligases is associated with disuse atrophy in 
vivo (26, 33), and experiments in atrogin1 and MuRF1 knockout mice have shown 
attenuations in atrophy following disuse (11). Because hemin treatment was associated 
with decreased expression of the genes encoding these molecules, the findings in the 
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current study suggest that over-expression of HMOX1 could contribute to molecular 
events that reduce the proteolysis of contractile proteins.  Furthermore, the trend towards 
a negative correlation between HMOX1 and atrogin1 expression (r=-.38, p<0.05) 
suggests that this may be achieved in a dose-dependent manner.  
The mechanism by which HMOX1 contributed to the negative regulation of 
atrogin1 or MuRF1 expression was beyond the scope of this study. However, it can be 
speculated that HMOX1 functions to help maintain redox balance under conditions of 
increased oxidative stress. This is particularly compelling because oxidative stress has 
been shown to be a component of molecular events associated with the early stages of 
skeletal muscle disuse (29-30, 32-33, 38, 41, 43, 45, 47, 52) and has been identified as a 
likely trigger for proteolysis (reviewed in (47)). It has been hypothesized that increased 
reactive molecules (e.g., ROS, RNS, and reactive iron) mediates Ca2+ disturbances 
leading to activation of caplains, which in turn release contractile proteins from 
actomysin complexes so that they may be degraded by the proteosome (45). It is probable 
that physiological levels of HMOX1 are no match for the magnitude of oxidative stress 
that accompanies disuse. However, in a recent study, treatment with hemin restored redox 
balance in murine diaphragm muscle during mechanical unloading (43). Therefore, it is 
possible that super-physiological levels of the enzyme could intervene to help maintain 
redox homeostasis during a disuse stimulus, thereby blunting molecular events upstream 
of proteolysis. 
Effects of H2O2 Treatment on HMOX1, Atrogin1, and MuRF1 Gene Expression 
100uM concentrations of H2O2 were chosen for the gene expression experiments 
in this study because this level of oxidative stress does not induce cell death (42), yet, has 
153 
 
been shown to lead to increased  mRNA levels of atrogin1 (at 4h posts-H2O2 treatment) 
and MuRF1 (at 6h post- H2O2 treatment) in C2C12 cells (36). The gene expression results 
of the current study were inconsistent with these previous findings in that there was no 
effect of 100uM H2O2 on atrogin1 or MuRF1 expression. I had expected that there would 
be an interaction between hemin pre-treatment and H2O2 treatment such that H2O2-
induced oxidative stress would lead to increases in E3 ligases, whereas hemin pre-
treatment would attenuate these effects.  However, the response of these genes to H2O2 in 
C2C12 cells is limited to the findings of one group of investigators (36-37)  
XTT Assays 
Hemin pre-treatment resulted in up to a 20% increase in XTT cleavage above 
control, with 100uM hemin pre-treatment resulting in the greatest increases (Figure 5.6). 
As XTT cleavage is a marker of mitochondrial dehydrogenase activity (and therefore an 
indirect marker of cell number/area), there are a number of interpretations of these 
results. One interpretation of these findings is that hemin pre-treatment led to HMOX1-
induced cell proliferation. Although the cultures were enriched for non-dividing 
myotubes, there were still (potentially mitotic) myoblasts in the cultures. However, 
studies in smooth muscle (16, 58) have demonstrated that HMOX1 inhibits cell 
proliferation. An alternative interpretation of these findings in the current study is that 
increases in HMOX1 protected against apoptosis associated with normal cell turnover (5 
and 6d post-differentiation). In murine fibroblasts, it has been shown that HMOX1 can 
inhibit apoptosis induced by tumor necrosis factor-α (35).  
Serial dilutions of H2O2 treatment showed that decreases in XTT cleavage were 
induced at 1mM (~80% of control) and 2mM doses (~40% of control) (Figure 5.4), 
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consistent with previous literature (42). 100uM hemin pre-treatment attenuated the 
decreases in mitochondrial DHO induced by 1mM hemin (Figure 5.6). This was the same 
level of hemin pre-treatment that showed significant decreases in atrogin1 and MuRF1 
expression in the related gene expression experiments. Perhaps hemin treatment led to 
decreases in UPP activity via downregulation of E3 ligase mRNA transcription, which in 
turn could have prevented decreases in myotube size (53).  
The XXT assay measures mitochondrial enzyme activity which is correlated with 
the number of mitochondria, by extension in the case of mononucleated cells, the number 
of living cells. Because myotubes can decrease in size (and organelle content) without 
undergoing apoptosis, it may be more appropriate to interpret XTT results in this study as 
a possible measurement of not only cell survival, but of cell size. And indeed, although 
cell size was not measured in this study, it has been observed in our laboratory that 
myotubes do decrease in size with H2O2 treatment (O’fallon, K., unpublished 
observation). Although Ara-C was used in this study to enrich the culture for terminal 
myotubes, there were still myoblasts in the culture capable of proliferation. Therefore, 
future studies could explore this question further by employing bromodeoxyuridine 
(BrdU), which involves the incorporation of a tag into the DNA of dividing cells and 
detection of this tag through immunocytochemistry. In this way, proliferation could be 
quantitatively measured so as to assess whether hemin-associated increases in XTT 
cleavage is proliferation-dependent or possibly cell size-dependent (as hypothesized in 
the current study). 
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Conclusions 
Overall, the results of this study suggest that there may be an inverse relationship 
between HMOX1 expression and proteolytic gene expression, though these findings are 
preliminary. If therapeutic interventions could be found to blunt the expression or activity 
of these E3s during the early stages of atrophy, it is possible that atrophy could also be 
attenuated. The association between HMOX1 overexpression and E3 ligase mRNA levels 
provides evidence to support HMOX1 as a promising gene target to attenuate atrophy. 
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Table 5.1. qRT-PCR primers. 
Gene 
Symbol Forward Primer Reverse Primer 
Atrogin1 5’-AGG CTT CTA ATT GGA TGG CTG GGA-3’ 5’-CCC GCA GTT TCA AGC CAA TGC TTA -3’ 
HMOX1 5’-TAG CCC ACT CCC TGT GTT TCC TTT-3' 5'-TGC TGG TTT CAA AGT TCA GGC CAC-3' 
MuRF1 5’-TCC GAG TGG GTT TGG AGA CAA AGA -3’ 5’-AGG CTT GGT AAA CAT CTC CAG GCA -3’ 
GAPDH 5'-AAC TTT GGC ATT GTG GAA GG -3' 5'-ACA CAT TGG GGG TAG GAA CA -3' 
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Figure  5.1.  HMOX1 gene expression (Mean±SEM) increased following 100uM H2O2 
treatment. *significantly different from control, p<0.05. 
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Figure 5.2. HMOX1 gene expression (Mean±SEM)  increases with hemin treatment in a 
dose dependent manner. *significantly different from control and from 20uM hemin 
treatment. 
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Figure 5.3. Atrogin1 and MuRF1 gene expression decreased with 100uM hemin 
treatment. *Significantly different from 20uM and from control, p<0.05. 
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Figure 5.4. XTT Cleavage decreased with H2O2 treatment. *significantly different from 
control, p<0.05. #significantly different from all other H2O2 treatment levels. 
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Figure 5.5 Hemin treatment increased cell XTT cleavage. *significantly different 
compared to control and to 20uM hemin treatment, p>0.05. 
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Figure 5.6. 100uM Hemin prevented/reversed effects of 1mM H2O2 treatment. 
*significantly different from control, p<0.05; # trend towards a difference from hemin-
control (0uM Hemin), p<0.07; † significantly different from H2O2 control (0uM H2O2), 
p<0.05. 
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CHAPTER VI 
 
SUMMARY 
Introduction 
The molecular mechanisms leading to disuse muscle atrophy are likely complex 
and involve alterations in molecular signaling of multiple pathways. While it is well 
known that prolonged disuse, regardless of stimulus (e.g., immobilization, spinal cord 
injury, limb unloading, bed rest, etc.) results in muscle atrophy and loss of muscle 
strength, the alterations in gene expression leading to these phenotypic changes are not 
well understood. It has been hypothesized (1) that genes most sensitive to disuse and 
reuse may be key regulators in the initiation of the cascade of events leading to the 
phenotypic changes that occur with prolonged disuse; therefore studying the molecular 
events in the early stages of disuse (before measurable atrophy occurs) may provide 
valuable insight into the molecular triggers that begin the process eventually leading 
these deleterious effects. The experiments and analyses described in this dissertation 
allowed me explore the following questions: 1) What are the effects of short-term loading 
and unloading on global gene expression in humans?; 2) Are these patterns similar to 
those observed in the early stages of other disuse models such as immobilization and 
spinal cord injury?; And 3) Can the information gained from these experiments allow me 
to form hypotheses to reverse or attenuate expression of candidate genes in vitro? In this 
Chapter I will summarize the results from these experiments.  
Study I 
 Few studies have examined gene expression in humans following a disuse 
stimulus. Microarray data has been collected in our laboratory following 48h 
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immobilization and spinal cord injury, and results from these studies have been published 
elsewhere (4-5); however, to date, global gene expression has not been investigated in 
skeletal muscle unloading in humans at this early time point, nor have studies been 
undertaken to measure changes in gene expression following short-term disuse and reuse 
in order to identify genes most sensitive to changes in skeletal muscle activity. Therefore, 
the specific aim of Study I was to investigate global gene expression changes following 
short-term unloading and reloading in human skeletal muscle.  
Hypothesis 1: 48h of unloading via unilateral lower limb suspension (ULLS) will 
produce patterns of gene expression that include changes in molecular contributors to 
protein degradation and cellular stress response as well previously unidentified factors in 
skeletal muscle unloading. 
Hypothesis 2: 24h of reloading subsequent to a 48h unloading will result in 
reversal of molecular changes observed following the unloading period. 
In agreement with hypothesis 1, global gene expression patterns showed enriched 
functions of protein ubiquitination as well the NRF2-medated Oxidative Stress Response 
Pathway. Decreases in cellular functions related to mitochondrial metabolism were 
enriched, as well. qRT-PCR analysis confirmed increases in mRNA for UPP-related E3 
ligase Atrogin1 (but not accompanying increases in protein products) and stress response 
gene HMOX1 (which showed a trend towards increases in protein products at 48h 
unloading). In contrast to previous work in our laboratory (5) which found decreases in 
collagen gene expression with 48h immobilization, this study revealed that COL4A3 (a 
component of COL4) was decreased with unloading. In disagreement with hypothesis 2, 
gene expression patterns following unloading generally persisted following reloading. 
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 Overall, the results of Study I suggest that alterations in gene expression 
associated with atrophy-related functions such as protein degradation and oxidative stress 
may occur very soon after the introduction of a disuse stimulus such as unloading, though 
increased magnitude or duration of that stimulus may be necessary in order for translation 
of protein products to occur.  While increases in proteolytic gene expression found in this 
study suggest that there are similarities between expression patterns following unloading 
and immobilization, differences likely exist between the two disuse models as evidenced 
by decreases in collagen found with unloading. Furthermore, the gene expression patterns 
with unloading were not readily reversed upon reloading suggesting that molecular 
responses to short-term periods of skeletal muscle inactivity may persist even after 
activity resumes. 
Author Contribution to the Study 
 This study was conceived by me with guidance from Dr. Clarkson. I was 
responsible for attaining human subjects approval, recruiting subjects, and managing the 
ULLS protocol. Dr. Paul Thompson (Hartford Hospital, Hartford, CT) and his laboratory 
group assisted with biopsy collections. Dr. Yi-wen Chen (Children’s National Medical 
Center, Washington, DC) performed the microarray analyses and initial statistical 
analysis of the microarray data to identify differential gene expression. I performed all 
subsequent analysis of the microarray data including identification of functional groups 
via DAVID and canonical pathways via IPA. I then performed all tasks associated with 
gene expression confirmation including RNA extraction, cDNA synthesis, and qRT-PCR, 
and statistical analysis. I also performed confirmational DNA gel analysis to confirm 
proper size of qRT-PCR products with the aid of Jimmy Webb. I conducted all tasks 
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associated with Western blotting including protein extraction, quantitation, 
quantification, blotting, and film development, as well as blot analysis and related 
statistics. I will be primarily responsible for writing the resulting manuscript with 
expected significant editing contributions from all co-authors. 
Study II 
 
Evidence from Study I and previous work in our laboratory (4-5) has provided 
strong evidence to suggest molecular alterations leading to skeletal muscle atrophy may 
occur as early as within 48h of the onset of disuse (i.e., immobilization, spinal cord 
injury, disuse), prior to the observation of measurable atrophy or strength-loss. Further 
elucidation of global gene expression at this early time point across disuse stimuli may be 
valuable in identifying gene targets for further research to develop therapies or 
pharmaceutical interventions to prevent or attenuate atrophy. Of particular value may be 
the discovery of an intersection between these three models of disuse in key early 
molecular regulators of atrophy. With the completion of Study I, I had access to the 
complete microarray datasets reflecting differential gene expression following 48h 
immobilization, spinal cord injury, and unloading. Therefore, the specific aim of Study II 
was to investigate global gene expression patterns related to disuse in biopsies collected 
following 48h immobilization, spinal cord injury, and unloading.  
Hypothesis 1: 48h following immobilization, spinal cord injury, and unloading 
global gene expression patterns will reveal a subset of functions and pathways common 
to all three models of disuse.  
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Hypothesis 2: 48h following immobilization, spinal cord injury, and unloading 
global gene expression patterns will reveal a subset of functions  and pathways unique to 
each model of disuse. 
 In agreement with hypothesis 1, common molecular changes among all three 
models of disuse were observed, particularly those associated with oxidative stress 
response such as metallotheioniens and protein chaperones, as well as the expected 
function of protein degradation. Also, in agreement with hypothesis 2, differences 
between the disuse models were in evidence. For example, while cellular stress response 
the only common canonical pathway to all three models, the expression patterns within 
the pathway differed. Furthermore, changes related to the oxidative phosphorylation may 
differ between disuse stimuli. Overall, the results of Study II suggest that common 
functions are, indeed, at play following 48h immobilization, spinal cord injury, and 
unloading; in addition to the shared enriched function of protein degradation, stress 
response is an attractive area for further study in the search for potential gene targets as 
oxidative stress has already been posited as an early upstream regulator of skeletal 
muscle atrophy. 
Author Contribution to the Study 
 This study was conceived by me with guidance from Dr. Clarkson. The “raw” 
microarray data for the UL model of disuse were acquired from Study I of this 
dissertation while the “raw” microarray data for the IM and SCI models of disuse were 
acquired from previous work in the muscle biology and imaging laboratory by Maria 
Urso, under the guidance of Dr. Clarkson and in collaboration with Dr. Thompson 
(Hartford Hospital, Hartford, CT), Dr. Patrick Lee (Baystate Medical Center, Springfield, 
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MA), and Dr. Eric Hoffman (Children’s National Medical Center, Washington, DC). Dr. 
Yi-Wen Chen (Children’s National Medical Center, Washington, DC.) performed initial 
microarray and statistical analysis to identify differential gene expression and gene 
clustering. I performed all subsequent analysis of the microarray data including 
identification of functional groups via DAVID and canonical pathways and gene 
networks via IPA. I will be primarily responsible for writing the resulting manuscript 
with expected significant editing contributions from all co-authors. 
Study III 
Studies I and II provided valuable information regarding the early molecular 
changes that may portend skeletal muscle atrophy if a disuse stimulus persists. Of 
particular note were oxidative stress response genes including HMOX1, which has been 
shown to restore redox balance in vivo (2). Since oxidative stress is likely an upstream 
mediator of skeletal muscle atrophy (3), preventing its effects may be a promising tool in 
fighting skeletal muscle atrophy. Therefore, HMOX1 may be an attractive gene target for 
future therapies to attenuate atrophy, though its association with proteolysis was 
unknown. Therefore, the exploratory aim of Study III was to develop hypotheses based 
on the findings of the two previous dissertation studies and to devise a proof of concept 
experiment to test these hypotheses in vitro.  
Hypothesis 1: H2O2 treatment will lead to an increase in HMOX1, Atrogin1, and 
MuRF1 gene expression compared to control. 
Hypothesis 2:  Hemin treatment will lead to increases in HMOX1 and decreases 
in Atrogin1 and MuRF1 gene expression compared to control. 
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Hypothesis 3: Hemin treatment will increase mitochondrial dehydrogenase 
activity in the face of oxidative stress. 
In agreement with hypothesis 1, H2O2 led to an increase in HMOX1. However, 
there were no accompanying increases in Atrogin1 or MuRF1 expression, possibly 
because the oxidative stress stimulus (100uM) for the gene expression experiments was 
mild. In agreement with hypothesis 2, hemin treatment did lead to increases in HMOX1 
and decreases in Atrogin1 and MuRF1. Finally, in agreement with hypothesis 3, hemin 
treatment increased mitochondrial dehydrogenase that was decreased at higher levels 
(1mM) of H2O2 treatment. Overall, the results of Study III suggest that there may be an 
inverse relationship between HMOX1 expression and proteolytic gene expression, though 
these findings are preliminary. If therapeutic interventions could be found to blunt the 
expression or activity of these E3s during the early stages of atrophy, it is possible that 
atrophy could also be attenuated. The association between HMOX1 overexpression and 
E3 ligase mRNA levels provides evidence to support HMOX1 as a promising gene target 
to attenuate atrophy. 
Author Contribution to the Study 
 This study was conceived by me with guidance from Drs Clarkson and Schwartz. 
I conducted all experiments with the exception of three qRT-PCR plates which where run 
by Rob Hyldahl. Confirmational DNA gel analysis to confirm proper size of qRT-PCR 
products were performed by Jimmy Webb. I will be primarily responsible for writing the 
resulting manuscript with expected significant editing contributions from all co-authors. 
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APPENDIX B 
 
MEDICAL HISTORY QUESTIONAIRE 
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APPENDIX C 
 
RAW DATA STUDY I 
 
Table C1. qRT-PCR Atrogin1 
Sample  Ct  
GOI- 
GAPDH 
∆CT 
Cont 
∆CT 
UL 
∆CT 
RL 
∆∆CT 
UL-Cont 
∆∆CT 
RL-Cont 
Fold∆ 
UL-Cont 
(AVG) 
Fold∆ 
RL-Cont 
(AVG) 
1 Control ATR 19.50 5.12 5.12 4.46 4.26 -0.66 -0.86 Fold∆ 1.43 1.29 
1 48h UL ATR 19.14 4.46 SD 0.31 0.44 
1 24h RL ATR 18.42 4.26 SE 0.12 0.18 
2 Control ATR 19.27 5.46 5.46 5.66 5.34 0.19 -0.12 p-value 0.01 0.30 
2 48h UL ATR 19.59 5.66 
2 24h RL ATR 19.90 5.34 
3 Control ATR 22.76 6.41 6.41 5.85 7.20 -0.56 0.79 
3 48h UL ATR 24.95 5.85 
3 24h RL ATR 22.07 7.20 
4 Control ATR 19.43 4.68 4.68 4.04 4.03 -0.64 -0.65 
4 48h UL ATR 18.55 4.04 
4 24h RL ATR 18.24 4.03 
5 Control ATR 18.72 4.75 4.75 4.57 -0.17 
5 48h UL ATR 18.53 4.57 
5 24h RL ATR no ct 
6 Control ATR 19.25 4.83 4.83 4.07 4.63 -0.75 -0.20 
6 48h UL ATR 18.85 4.07 
6 24h RL ATR 19.29 4.63 
7 Control ATR 19.55 5.66 5.66 4.88 5.05 -0.78 -0.62 
7 48h UL ATR 19.59 4.88 
7 24h RL ATR 18.79 5.05 
1 Control GAP 14.38 
1 48h UL GAP 14.68 
1 24h RL GAP 14.16 
2 Control GAP 13.81 
2 48h UL GAP 13.93 
2 24h RL GAP 14.56 
3 Control GAP 16.34 
3 48h UL GAP 19.10 
3 24h RL GAP 14.87 
4 Control GAP 14.74 
4 48h UL GAP 14.51 
4 24h RL GAP 14.20 
5 Control GAP 13.97 
5 48h UL GAP 13.95 
5 24h RL GAP no ct 
6 Control GAP 14.42 
6 48h UL GAP 14.78 
6 24h RL GAP 14.66 
7 Control GAP 13.88 
7 48h UL GAP 14.71 
7 24h RL GAP 13.74 
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Table C2. qRT-PCR COL4A3 
Sample Ct 
GOI- 
GAPDH 
∆CT 
Cont 
∆CT 
UL 
∆CT 
RL 
∆∆CT 
UL-Cont 
∆∆CT 
RL-Cont 
Fold∆ 
UL-Cont 
(AVG) 
Fold∆ 
RL-Cont 
(AVG) 
1 Control COL 21.75 7.62 7.62 6.05 6.96 -1.57 -0.66 Fold∆ 1.78 2.34 
1 48h UL COL 20.48 6.05 SD 0.54 2.65 
1 24h RL COL 20.86 6.96 SE 0.20 1.08 
2 Control COL 21.24 7.96 7.96 7.39 8.04 -0.57 0.08 p-value 0.001 0.34 
 48h UL COL 20.96 7.39 
2 24h RL COL 22.22 8.04 
3 Control COL 22.62 6.44 7.15 6.44 4.23 -0.71 -2.92 
3 48h UL COL 23.12 4.23 
3 24h RL COL 21.36 6.47 
4 Control COL 21.09 6.24 6.24 5.5 6.31 -0.74 0.07 
4 48h UL COL 19.61 5.5 
4 24h RL COL 20.42 6.31 
5 Control COL 20.66 6.99 6.99 6.19 -0.8 
5 48h UL COL 19.66 6.19 
5 24h RL COL No Ct 
6 Control COL 20.9 6.66 6.66 6.25 7.52 -0.41 0.86 
6 48h UL COL 20.56 6.25 
6 24h RL COL 21.86 7.52 
7 Control COL 21.97 8.43 8.43 7.7 7.15 -0.73 -1.28 
7 48h UL COL 21.98 7.7 
7 24h RL COL 20.86 7.15 
1 Control GAP 14.13 
1 48h UL GAP 14.43 
1 24h RL GAP 13.9 
2 Control GAP 13.28 
2 48h UL GAP 13.57 
2 24h RL GAP 14.18 
3 Control GAP 16.18 
3 48h UL GAP 18.89 
3 24h RL GAP 14.89 
4 Control GAP 14.85 
4 48h UL GAP 14.11 
4 24h RL GAP 14.11 
5 Control GAP 13.67 
5 48h UL GAP 13.47 
5 24h RL GAP No Ct 
6 Control GAP 14.24 
6 48h UL GAP 14.31 
6 24h RL GAP 14.34 
7 Control GAP 13.54 
7 48h UL GAP 14.28 
7 24h RL GAP 13.71 
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Table C3. qRT-PCR HMOX1 
Sample Ct 
GOI- 
GAPDH 
∆CT 
Cont 
∆CT 
UL 
∆CT 
RL 
∆∆CT 
UL-Cont 
∆∆CT 
RL-Cont 
Fold∆ 
UL-Cont 
(AVG) 
Fold∆ 
RL-Cont 
(AVG) 
 
1 Control HMX 25.58 10.34 10.34 7.68 10.47 -2.66 0.13 Fold∆ 12.69 1.10  
1 48h UL HMX 22.95 7.68 SD 14.86 0.53 
 
1 24h RL HMX 25.71 10.47 SE 5.25 0.20 
 
2 Control HMX 24.70 9.38 9.38 7.77 8.70 -1.61 -0.68 p-value 0.01 0.09 
 
2 48h UL HMX 23.20 7.77  
 
2 24h RL HMX 24.30 8.70  
 
3 Control HMX 25.60 10.39 10.39 9.98 9.90 -0.41 -0.49 
  
3 48h UL HMX 24.90 9.98 
  
3 24h RL HMX 25.00 9.90 
  
4 Control HMX 25.70 10.40 10.40 7.97 9.70 -2.43 -0.70 
  
4 48h UL HMX 23.10 7.97 
  
4 24h RL HMX 25.10 9.70 
  
5 Control HMX 26.20 10.58 10.58 5.69 -4.89 
  
5 48h UL HMX 21.00 5.69 
  
5  24h RL HMX no ct 
  
6 Control HMX 25.77 10.90 10.90 10.10 7.15 -0.79 -3.75 
  
6 48h UL HMX 25.28 10.10 
  
6  24h RL HMX 22.90 7.15 
  
7 Control HMX 26.08 11.52 11.52 6.15 9.90 -5.37 3.75 
  
7 48h UL HMX 21.82 6.15 
  
7 24h RL HMX 24.70 9.90 
  
1 Control GAP 15.24 
  
1 48h UL GAP 15.27 
  
1 24h RL GAP 15.24 
  
2 Control GAP 15.32 
  
2 48h UL GAP 15.43 
  
2 24h RL GAP 15.60 
  
3 Control GAP 15.21 
  
3 48h UL GAP 14.92 
  
3 24h RL GAP 15.10 
  
4 Control GAP 15.3 
  
4 48h UL GAP 15.13 
  
4 24h RL GAP 15.4 
  
5 Control GAP 15.62 
  
5 48h UL GAP 15.31 
  
5 24h RL GAP no ct 
  
6 Control GAP 14.87 
  
6 48h UL GAP 15.18 
  
6 24h RL GAP 15.75 
  
7 Control GAP 14.55 
  
7 48h UL GAP 15.67 
  
7 24h RL GAP 14.80 
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Table C4. qRT-PCR MuRF1 
Sample Ct 
GOI- 
GAPDH 
∆CT 
Cont 
∆CT 
UL 
∆CT 
RL 
∆∆CT 
UL-Cont 
∆∆CT 
RL-Cont 
Fold∆ 
UL-Cont 
(AVG) 
Fold∆ 
RL-Cont 
(AVG) 
1 Control MUR 27.68 7.49 7.49 5.62 5.92 -1.87 -1.57 Fold∆ 1.53 1.90 
1 48h UL MUR 20.19 5.62 SD 0.97 0.86 
1 24h RL MUR 19.95 5.92 SE 0.40 0.39 
2 Control MUR 19.70 6.66 6.66 6.91 6.14 0.25 -0.53 p-value 0.44 0.12 
2 48h UL MUR 21.34 6.91 
2 24h RL MUR 20.00 6.14 
3 Control MUR 23.02 6.82 6.82 8.24 7.75 1.42 0.92 
3 48h UL MUR 27.01 8.24 
3 24h RL MUR 22.42 7.75 
4 Control MUR 19.74 5.87 5.87 5.60 4.59 -0.27 -1.28 
4 48h UL MUR 20.16 5.60 
4 24h RL MUR 18.93 4.59 
5 Control MUR 20.68 6.98 6.98 6.13 -0.85 
5 48h UL MUR 20.61 6.13 
5 24h RL MUR no ct 
6 Control MUR 19.75 6.16 6.16 5.83 4.71 -0.34 -1.45 
6 48h UL MUR 20.07 5.83 
6 24h RL MUR 18.86 4.71 
7 Control MUR 20.20 6.53 6.53 5.85 6.10 -0.68 -0.43 
7 48h UL MUR 20.14 5.85 
7 24h RL MUR 19.75 6.10 
1 Control GAP 20.20 
1 48h UL GAP 14.58 
1 24h RL GAP 14.02 
2 Control GAP 13.04 
2 48h UL GAP 14.43 
2 24h RL GAP 13.86 
3 Control GAP 16.19 
3 48h UL GAP 18.77 
3 24h RL GAP 14.67 
4 Control GAP 13.87 
4 48h UL GAP 14.56 
4 24h RL GAP 14.34 
5 Control GAP 13.70 
5 48h UL GAP 14.47 
5 24h RL GAP no ct 
6 Control GAP 13.59 
6 48h UL GAP 14.24 
6 24h RL GAP 14.15 
7 Control GAP 13.67 
7 48h UL GAP 14.28 
7 24h RL GAP 13.65 
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APPENDIX D 
 
RAW DATA STUDY III 
 
Table D.1. C2C12 XTT Raw Data 
TIME (HR)  HEMIN (uL)  H2O2 (ul) XTT
3  0  0 1.021
3  0  0 1.148
3  0  0 1.058
3  0  0 1.055
3  0  0 0.981
3  0  0 1.026
3  0  0 0.952
3  0  0 0.747
3  100  0 1.345
3  100  0 1.29
3  100  0 1.259
3  100  0 1.354
3  100  0 1.386
3  100  0 1.235
3  100  0 1.259
3  100  0 1.095
3  0  100 1.151
3  0  100 1.175
3  0  100 1.34
3  0  100 1.091
3  0  100 1.035
3  0  100 1.033
3  0  100 0.904
3  0  100 0.801
3  100  100 1.205
3  100  100 1.498
3  100  100 1.494
3  100  100 1.483
3  100  100 1.347
3  100  100 1.348
3  100  100 1.532
3  100  100 1.017
3  0  500 1.203
3  0  500 1.323
3  0  500 1.233
3  0  500 1.151
3  0  500 1.04
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3  0  500 1.03
3  0  500 1.125
3  0  500 0.886
3  100  500 1.493
3  100  500 1.765
3  100  500 1.477
3  100  500 1.338
3  100  500 1.295
3  100  500 1.292
3  100  500 1.264
3  100  500 1.107
3  0  1000 0.912
3  0  1000 1.144
3  0  1000 0.999
3  0  1000 0.913
3  0  1000 0.904
3  0  1000 0.784
3  0  1000 0.908
3  0  1000 0.738
3  100  1000 1.081
3  100  1000 1.189
3  100  1000 1.128
3  100  1000 1.227
3  100  1000 1.07
3  100  1000 0.957
3  100  1000 0.98
3  100  1000 0.854
3  0  2000 0.483
3  0  2000 0.473
3  0  2000 0.593
3  0  2000 0.389
3  0  2000 0.343
3  0  2000 0.313
3  0  2000 0.35
3  0  2000 0.4
3  100  2000 0.512
3  100  2000 0.554
3  100  2000 0.5
3  100  2000 0.405
3  100  2000 0.352
3  100  2000 0.34
3  100  2000 0.379
3  100  2000 0.398
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3  0  0 1.358433735
3  0  0 0.96746988
3  0  0 0.877710843
3  0  0 1.019879518
3  0  0 1.068072289
3  0  0 0.898795181
3  0  0 0.993975904
3  0  0 0.804216867
3  20  0 1.342771084
3  20  0 1.31686747
3  20  0 0.942168675
3  20  0 0.909036145
3  20  0 1.028313253
3  20  0 1.010240964
3  20  0 0.931325301
3  20  0 0.836144578
3  0  100 1.334939759
3  0  100 0.925301205
3  0  100 0.989759036
3  0  100 1.139156627
3  0  100 1.204216867
3  0  100 0.935542169
3  0  100 0.925301205
3  0  100 0.724096386
3  20  100 1.389759036
3  20  100 1.31626506
3  20  100 1.31686747
3  20  100 1.294578313
3  20  100 1.263855422
3  20  100 1.187349398
3  20  100 1.18373494
3  20  100 0.936144578
3  0  500 1.439156627
3  0  500 1.055421687
3  0  500 1.101204819
3  0  500 1.301807229
3  0  500 1.209638554
3  0  500 1.040361446
3  0  500 1.03373494
3  0  500 0.837951807
3  20  500 1.460843373
3  20  500 1.362650602
3  20  500 1.280120482
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3  20  500 1.509638554
3  20  500 1.310240964
3  20  500 1.191566265
3  20  500 1.187951807
3  20  500 1.03313253
3  0  1000 0.676506024
3  0  1000 0.752409639
3  0  1000 0.707228916
3  0  1000 0.737951807
3  0  1000 0.901807229
3  0  1000 0.578313253
3  0  1000 0.673493976
3  0  1000 0.503012048
3  20  1000 0.753012048
3  20  1000 0.797590361
3  20  1000 0.610843373
3  20  1000 0.769277108
3  20  1000 0.807831325
3  20  1000 0.503614458
3  20  1000 0.528313253
3  20  1000 0.51746988
3  0  2000 0.465060241
3  0  2000 0.385542169
3  0  2000 0.305421687
3  0  2000 0.377710843
3  0  2000 0.242168675
3  0  2000 0.278313253
3  0  2000 0.252409639
3  0  2000 0.193373494
3  20  2000 0.463855422
3  20  2000 0.437951807
3  20  2000 0.348795181
3  20  2000 0.304216867
3  20  2000 0.243975904
3  20  2000 0.262048193
3  20  2000 0.211445783
3  20  2000 0.204819277
3  0  0 1.361538462
3  0  0 1.11958042
3  0  0 1.058041958
3  0  0 0.843356643
3  0  0 0.848951049
3  0  0 0.888811189
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3  0  0 1.097202797
3  0  0 0.786713287
3  50  0 1.682517483
3  50  0 1.302097902
3  50  0 1.106993007
3  50  0 1.208391608
3  50  0 0.906993007
3  50  0 1.023776224
3  50  0 1.05034965
3  50  0 1.260839161
3  0  100 1.70979021
3  0  100 1.496503497
3  0  100 1.13986014
3  0  100 1.33986014
3  0  100 1.076923077
3  0  100 1.133566434
3  0  100 1.245454545
3  0  100 1.106993007
3  50  100 1.683916084
3  50  100 1.579020979
3  50  100 1.33986014
3  50  100 1.500699301
3  50  100 1.421678322
3  50  100 1.303496503
3  50  100 1.393706294
3  50  100 1.230769231
3  0  500 1.675524476
3  0  500 1.486013986
3  0  500 1.323776224
3  0  500 1.49020979
3  0  500 1.469230769
3  0  500 1.237762238
3  0  500 1.431468531
3  0  500 1.067832168
3  50  500 1.897202797
3  50  500 1.864335664
3  50  500 1.742657343
3  50  500 1.783916084
3  50  500 1.559440559
3  50  500 1.593006993
3  50  500 1.565734266
3  50  500 1.152447552
3  0  1000 1.179020979
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3  0  1000 1.218181818
3  0  1000 1.092307692
3  0  1000 1.011888112
3  0  1000 0.948951049
3  0  1000 1.116083916
3  0  1000 0.906293706
3  0  1000 0.637062937
3  50  1000 1.144055944
3  50  1000 1.144055944
3  50  1000 1.207692308
3  50  1000 1.217482517
3  50  1000 1.088811189
3  50  1000 0.967832168
3  50  1000 0.959440559
3  50  1000 0.862937063
3  0  2000 0.574825175
3  0  2000 0.51958042
3  0  2000 0.474825175
3  0  2000 0.439160839
3  0  2000 0.295804196
3  0  2000 0.315384615
3  0  2000 0.309090909
3  0  2000 0.336363636
3  50  2000 0.637062937
3  50  2000 0.555944056
3  50  2000 0.597202797
3  50  2000 0.434965035
3  50  2000 0.400699301
3  50  2000 0.328671329
3  50  2000 0.379020979
3  50  2000 0.348951049
6  0  0 1.125
6  0  0 0.989
6  0  0 1.003
6  0  0 1.074
6  0  0 0.889
6  0  0 0.878
6  0  0 1.03
6  0  0 1.005
6  100  0 1.293
6  100  0 1.398
6  100  0 1.362
6  100  0 1.264
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6  100  0 1.172
6  100  0 1.112
6  100  0 1.091
6  100  0 1.07
6  0  100 1.112
6  0  100 1.15
6  0  100 1.129
6  0  100 1.125
6  0  100 0.997
6  0  100 0.911
6  0  100 0.94
6  0  100 0.871
6  100  100 1.346
6  100  100 1.314
6  100  100 1.289
6  100  100 1.297
6  100  100 1.18
6  100  100 1.208
6  100  100 1.16
6  100  100 1.18
6  0  500 1.236
6  0  500 1.124
6  0  500 1.115
6  0  500 0.958
6  0  500 0.867
6  0  500 1.042
6  0  500 0.844
6  0  500 0.905
6  100  500 1.515
6  100  500 1.437
6  100  500 1.247
6  100  500 1.377
6  100  500 1.367
6  100  500 1.379
6  100  500 1.409
6  100  500 1.219
6  0  1000 1.129
6  0  1000 1.073
6  0  1000 0.998
6  0  1000 1.119
6  0  1000 1.01
6  0  1000 0.948
6  0  1000 1.074
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6  0  1000 0.932
6  100  1000 1.446
6  100  1000 1.376
6  100  1000 1.2
6  100  1000 1.266
6  100  1000 1.1
6  100  1000 1.13
6  100  1000 1.151
6  100  1000 1.02
6  0  2000 0.599
6  0  2000 0.662
6  0  2000 0.958
6  0  2000 0.677
6  0  2000 0.507
6  0  2000 0.574
6  0  2000 0.597
6  0  2000 0.458
6  100  2000 0.497
6  100  2000 0.635
6  100  2000 0.45
6  100  2000 0.653
6  100  2000 0.522
6  100  2000 0.531
6  100  2000 0.525
6  100  2000 0.483
6  0  0 0.95
6  0  0 1.27
6  0  0 0.97
6  0  0 0.94
6  0  0 0.98
6  0  0 0.96
6  0  0 0.99
6  0  0 0.93
6  20  0 1.22
6  20  0 1.37
6  20  0 1.17
6  20  0 1.14
6  20  0 1.16
6  20  0 1.09
6  20  0 1.1
6  20  0 1.05
6  0  100 1.14
6  0  100 1.26
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6  0  100 1
6  0  100 1.03
6  0  100 1.01
6  0  100 1.07
6  0  100 1.11
6  0  100 1.07
6  20  100 1.19
6  20  100 1.25
6  20  100 1.19
6  20  100 1.14
6  20  100 1.12
6  20  100 1.21
6  20  100 1.23
6  20  100 1.15
6  0  500 1.35
6  0  500 1.45
6  0  500 1.3
6  0  500 1.43
6  0  500 1.25
6  0  500 1.38
6  0  500 1.32
6  0  500 1.21
6  20  500 1.48
6  20  500 1.53
6  20  500 1.36
6  20  500 1.42
6  20  500 1.38
6  20  500 1.37
6  20  500 1.31
6  20  500 1.34
6  0  1000 0.76
6  0  1000 0.36
6  0  1000 0.6
6  0  1000 0.44
6  0  1000 0.57
6  0  1000 0.43
6  0  1000 0.43
6  0  1000 0.41
6  20  1000 0.66
6  20  1000 0.64
6  20  1000 0.41
6  20  1000 0.52
6  20  1000 0.42
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6  20  1000 0.48
6  20  1000 0.46
6  20  1000 0.3
6  0  2000 0.48
6  0  2000 0.4
6  0  2000 0.3
6  0  2000 0.43
6  0  2000 0.35
6  0  2000 0.27
6  0  2000 0.29
6  0  2000 0.31
6  20  2000 0.48
6  20  2000 0.43
6  20  2000 0.4
6  20  2000 0.42
6  20  2000 0.29
6  20  2000 0.34
6  20  2000 0.3
6  20  2000 0.29
6  0  0 1.209
6  0  0 1.09
6  0  0 0.966
6  0  0 0.937
6  0  0 0.994
6  0  0 0.882
6  0  0 0.922
6  0  0 1
6  50  0 1.91
6  50  0 1.132
6  50  0 1.189
6  50  0 1.246
6  50  0 1.006
6  50  0 1.094
6  50  0 1.154
6  50  0 1.247
6  0  100 1.724
6  0  100 1.104
6  0  100 1.024
6  0  100 1.024
6  0  100 0.998
6  0  100 1.007
6  0  100 0.898
6  0  100 1.111
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6  50  100 1.769
6  50  100 1.251
6  50  100 1.205
6  50  100 1.298
6  50  100 1.18
6  50  100 1.197
6  50  100 1.116
6  50  100 1.288
6  0  500 1.396
6  0  500 1.138
6  0  500 1.154
6  0  500 1.171
6  0  500 1.016
6  0  500 1.177
6  0  500 1.055
6  0  500 1.158
6  50  500 1.6
6  50  500 1.426
6  50  500 1.283
6  50  500 1.229
6  50  500 1.243
6  50  500 1.202
6  50  500 1.18
6  50  500 1.309
6  0  1000 0.941
6  0  1000 0.884
6  0  1000 0.77
6  0  1000 0.877
6  0  1000 0.879
6  0  1000 0.88
6  0  1000 0.814
6  0  1000 0.863
6  50  1000 0.905
6  50  1000 0.954
6  50  1000 0.874
6  50  1000 0.888
6  50  1000 1.026
6  50  1000 0.889
6  50  1000 0.869
6  50  1000 0.915
6  0  2000 0.339
6  0  2000 0.284
6  0  2000 0.249
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6  0  2000 0.245
6  0  2000 0.259
6  0  2000 0.232
6  0  2000 0.213
6  0  2000 0.26
6  50  2000 0.311
6  50  2000 0.34
6  50  2000 0.254
6  50  2000 0.25
6  50  2000 0.167
6  50  2000 0.233
6  50  2000 0.253
6  50  2000 0.258
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    Table D2. C2C2 Gene Expression Raw Data 
  
Experiment 
Time 
(h) 
Hemin 
(uM) 
H2O2 
(uM) 
HMOX 
dCT 
ATR 
dCT 
MURF 
dCT 
HMOX‐
ddCT‐
hemin‐
control 
ATR‐
ddCT‐
Hemin 
Control 
MuRF‐
ddCT‐
Hemin 
Control 
HMOX‐
dCT‐
H2O2 
Control 
ATR‐
ddCT‐
H2O2 
Control 
MURF‐
ddCT‐
Hemin 
Control 
HMOX‐
hemin 
Control 
FC 
Atrogin‐
Hemin  
Control 
FC 
MuRF
Hemin  
Control 
FC 
1  3  Control  Control  3.03  3.58  3.46  0.00  0.00  0.00  0.00  0.00  0.00  1.00  1.00  1.00 
1  3  20  Control  0.45  4.40  3.65  ‐2.58  0.82  0.19  0.00  0.00  0.00  5.99  0.57  0.87 
1  3  50  Control  ‐1.43  4.04  3.66  ‐4.46  0.46  0.20  0.00  0.00  0.00  22.01  0.73  0.87 
1  3  100  Control  ‐3.72  5.06  4.60  ‐6.75  1.48  1.15  0.00  0.00  0.00  107.26  0.36  0.45 
1  3  Control  100  1.14  2.67  2.90  0.00  0.00  0.00  ‐1.89  ‐0.91  ‐0.55  1.00  1.00  1.00 
1  3  20  100  ‐0.21  3.59  3.85  ‐1.35  0.93  0.94  ‐0.65  ‐0.80  0.20  2.54  0.53  0.52 
1  3  50  100  ‐4.64  .  3.29  ‐5.78  0.39  ‐3.21  ‐0.37  54.95  0.77 
1  3  100  100  ‐4.04  3.86  4.43  ‐5.18  1.19  1.53  ‐0.33  ‐1.20  ‐0.17  36.25  0.44  0.35 
2  3  Control  Control  5.01  4.14  3.37  0.00  0.00  0.00  0.00  0.00  0.00  1.00  1.00  1.00 
2  3  20  Control  2.25  4.45  3.98  ‐2.76  0.31  0.62  0.00  0.00  0.00  6.77  0.81  0.65 
2  3  50  Control  0.00  4.71  3.47  ‐5.01  0.57  0.10  0.00  0.00  0.00  32.15  0.68  0.93 
2  3  100  Control  ‐1.57  5.34  4.38  ‐6.58  1.20  1.02  0.00  0.00  0.00  95.67  0.43  0.49 
2  3  Control  100  2.99  3.15  2.92  0.00  0.00  0.00  ‐2.02  ‐0.99  ‐0.45  1.00  1.00  1.00 
2  3  20  100  1.26  4.06  4.27  ‐1.73  0.90  1.35  ‐0.99  ‐0.39  0.28  3.32  0.54  0.39 
2  3  50  100  ‐3.89  .  2.79  ‐6.88  ‐0.13  ‐3.89  ‐0.69  117.78  1.10 
2  3  100  100  ‐2.24  4.82  3.99  ‐5.23  1.67  1.08  ‐0.67  ‐0.53  ‐0.39  37.44  0.32  0.47 
3  3  Control  Control  2.74  5.22  5.08  0.00  0.00  0.00  0.00  0.00  0.00  1.00  1.00  1.00 
3  3  20  Control  0.25  5.25  5.54  ‐2.50  0.02  0.46  0.00  0.00  0.00  5.64  0.98  0.73 
3  3  50  Control  ‐0.83  5.64  6.19  ‐3.57  0.42  1.11  0.00  0.00  0.00  11.89  0.75  0.46 
3  3  100  Control  ‐1.62  5.82  5.44  ‐4.36  0.60  0.36  0.00  0.00  0.00  20.53  0.66  0.78 
3  3  Control  100  2.96  5.59  5.13  0.00  0.00  0.00  0.22  0.36  0.05  1.00  1.00  1.00 
3  3  20  100  0.78  5.90  5.93  ‐2.18  0.31  0.80  0.53  0.65  0.39  4.53  0.81  0.57 
3  3  50  100  ‐0.35  5.64  5.78  ‐3.31  0.05  0.65  0.48  0.00  ‐0.40  9.94  0.96  0.64 
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  3  3  100  100  ‐2.07  5.41  5.32  ‐5.03  ‐0.18  0.19  ‐0.45  ‐0.41  ‐0.12  32.60  1.13  0.88 
4  6  Control  Control  3.92  4.31  4.36  0.00  0.00  0.00  0.00  0.00  0.00  1.00  1.00  1.00 
4  6  20  Control  2.56  4.64  4.67  ‐1.36  0.33  0.31  0.00  0.00  0.00  2.57  0.80  0.81 
4  6  50  Control  0.53  4.46  4.47  ‐3.40  0.15  0.12  0.00  0.00  0.00  10.53  0.90  0.92 
4  6  100  Control  ‐2.37  6.16  5.87  ‐6.29  1.85  1.51  0.00  0.00  0.00  78.34  0.28  0.35 
4  6  Control  100  0.48  3.98  3.89  0.00  0.00  0.00  ‐3.45  ‐0.33  ‐0.47  1.00  1.00  1.00 
4  6  20  100  ‐1.00  4.24  4.23  ‐1.48  0.25  0.34  ‐3.56  ‐0.40  ‐0.45  2.78  0.84  0.79 
4  6  50  100  ‐1.31  4.59  4.70  ‐1.79  0.61  0.81  ‐1.84  0.13  0.22  3.46  0.66  0.57 
4  6  100  100  ‐3.06  5.72  5.89  ‐3.54  1.73  2.00  ‐0.69  ‐0.44  0.02  11.60  0.30  0.25 
5  6  Control  Control  .  4.68  4.42  0.00  0.00  0.00  0.00  1.00  1.00 
5  6  20  Control  .  4.61  4.54  ‐0.07  0.12  0.00  0.00  1.05  0.92 
5  6  50  Control  .  4.71  4.62  0.03  0.21  0.00  0.00  0.98  0.87 
5  6  100  Control  .  6.11  6.02  1.43  1.60  0.00  0.00  0.37  0.33 
5  6  Control  100  .  4.24  3.82  ‐0.44  ‐0.60  1.00  1.00 
5  6  20  100  .  6.70  7.05  2.46  3.24  2.09  2.52  0.18  0.11 
5  6  50  100  .  5.31  5.11  1.06  1.29  0.60  0.49  0.48  0.41 
5  6  100  100  .  6.75  6.76  2.51  2.94  0.65  0.74  0.18  0.13 
6  6  Control  Control  5.09  .  .  0.00  0.00  1.00 
6  6  20  Control  3.99  .  .  ‐1.10  0.00  2.15 
6  6  50  Control  2.31  .  .  ‐2.78  0.00  6.88 
6  6  100  Control  0.55  .  .  ‐4.55  0.00  23.37 
6  6  Control  100  5.07  .  .  ‐0.02  1.00 
6  6  20  100  3.72  .  .  ‐1.36  ‐0.27  2.56 
6  6  50  100  2.18  .  .  ‐2.89  ‐0.13  7.43 
6  6  100  100  0.54  .  .  ‐4.53  ‐0.01  23.16 
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